NEW YORK STATE

MEDICAID PROGRAM

PHYSICIAN – PROCEDURE CODES

SECTION 2 – MEDICINE, DRUGS and

DRUG ADMINISTRATION
Table of Contents

GENERAL RULES AND INFORMATION ................................................................. 3
MMIS MODIFIERS ......................................................................................... 13
EVALUATION AND MANAGEMENT SERVICES .............................................. 15
LABORATORY SERVICES PERFORMED IN A PHYSICIAN’S OFFICE ............... 38
DRUGS AND DRUG ADMINISTRATION ......................................................... 39
IMMUNIZATIONS ......................................................................................... 39
DRUGS ADMINISTERED OTHER THAN ORAL METHOD .................................. 43
HYDRATION, THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC .............. 53
CHEMOTHERAPY DRUGS ........................................................................... 57
MEDICINE ................................................................................................. 61
PSYCHIATRY ............................................................................................... 61
DIALYSIS ..................................................................................................... 64
GASTROENTEROLOGY ................................................................................. 67
OPHTHALMOLOGY ....................................................................................... 68
SPECIAL OTORHINOLARYNGOLOGIC SERVICES ......................................... 73
CARDIOVASCULAR ...................................................................................... 76
NONINVASIVE VASCULAR DIAGNOSTIC STUDIES ..................................... 87
PULMONARY ............................................................................................... 89
ALLERGY AND CLINICAL IMMUNOLOGY ...................................................... 90
NEUROLOGY AND NEUROMUSCULAR PROCEDURES ................................. 92
CENTRAL NERVOUS SYSTEM ASSESSMENTS/TESTS .................................... 97
PHOTODYNAMIC THERAPY ......................................................................... 98
SPECIAL DERMATOLOGICAL PROCEDURES ............................................ 98
OSTEOPATHIC MANIPULATIVE TREATMENT ............................................. 99
SPECIAL SERVICES .................................................................................... 99
MODERATE (CONSCIOUS) SEDATION ....................................................... 103
OTHER SERVICES AND PROCEDURES ..................................................... 104
GENERAL RULES AND INFORMATION

1. PRIMARY CARE: Primary care is first contact care, the type furnished to individuals when they enter the health care system. Primary care is comprehensive in that it deals with a wide range of health problems, diagnosis and modes of treatment. Primary care is continuous in that an ongoing relationship is established with the primary care practitioner who monitors and provides the necessary follow-up care and is coordinated by linking patients with more varied specialized services when needed. Consultations and care provided on referral from another practitioner is not considered primary care.

2. CLASSIFICATION OF EVALUATION AND MANAGEMENT (E/M) SERVICES: The Federal Health Care Finance Administration has mandated that all state Medicaid programs utilize the new Evaluation and Management coding as published in the American Medical Association's Physicians' Current Procedural Terminology.

For the first time, a major section has been devoted entirely to E/M services. The new codes are more than a clarification of the old definitions; they represent a new way of classifying the work of practitioners. In particular, they involve far more clinical detail than the old visit codes. For this reason, it is important to treat the new codes as a new system and not make a one-for-one substitution of a new code number for a code number previously used to report a level of service defined as "brief", "limited", "intermediate", etc.

The E/M section is divided into broad categories such as office visits, hospital visits and consultations. Most of the categories are further divided into two or more subcategories of E/M services. For example, there are two subcategories of office visits (new patient and established patient) and there are two subcategories of hospital visits (initial and subsequent). The subcategories of E/M services are further classified into levels of E/M services that are identified by specific codes. This classification is important because the nature of practitioner work varies by type of service, place of service, and the patient's status.

The basic format of the levels of E/M services is the same for most categories. First, a unique code number is listed. Second, the place and/or type of service is specified, eg, office consultation. Third, the content of the service is defined, eg, comprehensive history and comprehensive examination. (See levels of E/M services following for details on the content of E/M services.) Fourth, the nature of the presenting problem(s) usually associated with a given level is described. Fifth, the time typically required to provide the service is specified.

3. DEFINITIONS OF COMMONLY USED E/M TERMS: Certain key words and phrases are used throughout the E/M section. The following definitions are intended to reduce the potential for differing interpretations and to increase the consistency of reporting.

NEW AND ESTABLISHED PATIENT: Solely for the purpose of distinguishing between new and established patients, professional services are those face-to-face services rendered by a physician and reported by a specific code. A new patient is one who has not received any professional services from the practitioner or practitioners working in the same specialty within the same group within the past three years. An established patient is one who has received professional services from the practitioner within the past three years.
In the instance where a practitioner is on call for or covering for another practitioner, the patient's encounter will be classified as it would have been by the practitioner who is not available. No distinction is made between new and established patients in the emergency department. E/M services in the emergency department category may be reported for any new or established patient who presents for treatment in the emergency department.

CHIEF COMPLAINT: A concise statement describing the symptom, problem, condition, diagnosis or other factor that is the reason for the encounter, usually stated in the patient's words.

CONCURRENT CARE: is the provision of similar services, eg, hospital visits, to the same patient by more than one practitioner on the same day. When concurrent care is provided, no special reporting is required. Modifier -75 has been deleted.

COUNSELING: Counseling is a discussion with a patient and/or family concerning one or more of the following areas:

- diagnostic results, impressions, and/or recommended diagnostic studies;
- prognosis;
- risks and benefits of management (treatment) options;
- instructions for management (treatment) and/or follow-up;
- importance of compliance with chosen management (treatment) options;
- risk factor reduction; and
- patient and family education.

HISTORY OF PRESENT ILLNESS: A chronological description of the development of the patient’s present illness from the first sign and/or symptom to the present. This includes a description of location, quality, severity, timing, context, modifying factors and associated signs and symptoms significantly related to the presenting problem(s).

NATURE OF PRESENTING PROBLEM: A presenting problem is a disease, condition, illness, injury, symptom, sign, finding, complaint, or other reason for encounter, with or without a diagnosis being established at the time of the encounter. The E/M codes recognize five types of presenting problems that are defined as follows:

- Minimal – A problem that may not require the presence of the practitioner, but service is provided under the practitioner’s supervision.
- Self-limited or Minor – A problem that runs a definite and prescribed course, is transient in nature and is not likely to permanently alter health status OR has a good prognosis with management/compliance.
- Low severity – A problem where the risk of morbidity without treatment is low; there is little to no risk of mortality without treatment; full recovery without functional impairment is expected.
- Moderate severity – A problem where the risk of morbidity without treatment is moderate; there is moderate risk of mortality without treatment; uncertain prognosis OR increased probability of prolonged functional impairment.
- High severity – A problem where the risk of morbidity without treatment is high to extreme; there is a moderate to high risk of mortality without treatment OR high probability of severe, prolonged functional impairment.

PAST HISTORY: A review of the patient’s past experiences with illnesses, injuries, and treatments that includes significant information about:

- prior major illnesses and injuries;
- prior operations;
• prior hospitalizations;
• current medications;
• allergies (e.g., drug, food);
• age appropriate immunization status;
• age appropriate feeding/dietary status.

**FAMILY HISTORY**: A review of medical events in the patient’s family that includes significant information about:

• the health status or cause of death of parents, siblings, and children;
• specific diseases related to problems identified in the Chief Complaint or History of the Present Illness, and/or System Review;
• diseases of family members which may be hereditary or place the patient at risk.

**SOCIAL HISTORY**: an age appropriate review of past and current activities that include significant information about:

• marital status and/or living arrangements;
• current employment;
• occupational history;
• use of drugs, alcohol, and tobacco;
• level of education;
• sexual history;
• other relevant social factors.

**SYSTEM REVIEW (REVIEW OF SYSTEMS)**: An inventory of body systems obtained through a series of questions seeking to identify signs and/or symptoms which the patient may be experiencing or has experienced. The following elements of a system review have been identified:

• Constitutional symptoms (fever, weight loss, etc.)
• Eyes
• Ears, Nose, Mouth, Throat
• Cardiovascular
• Respiratory
• Gastrointestinal
• Genitourinary
• Musculoskeletal
• Integumentary (skin and/or breast)
• Neurological
• Psychiatric
• Endocrine
• Hematologic/Lymphatic
• Allergic/Immunologic

The review of systems helps define the problem, clarify the differential diagnoses, identify needed testing, or serves as baseline data on other systems that might be affected by any possible management options.
TIME: The inclusion of time in the definitions of levels of E/M services has been implicit in prior editions. The inclusion of time as an explicit factor beginning in 1992 is done to assist practitioners in selecting the most appropriate level of E/M services. Beginning with CPT 2021, except for time alone may be used to select the appropriate code level for the office or other outpatient E/M service codes (99202, 99203, 99204, 99205, 99212, 99214, 99215). Different categories of services use time differently. It is important to review the instructions for each category.

Time is not a descriptive component for the emergency department levels of E/M services because emergency department services are typically provided on a variable intensity basis, often involving multiple encounters with several patients over an extended period of time. Therefore, it is often difficult for practitioners to provide accurate estimates of the time spent face-to-face with the patient.

Time may be used to select a code level in office or other outpatient services whether or not counseling and/or coordination of care dominates the service. Time may only be used for selecting the level of the other E/M services when counseling and/or coordination of care dominates the service.

When time is used for reporting E/M services codes, the time defined in the service descriptors is used for selecting the level of the appropriate service. The E/M services for which these guidelines apply require a face-to-face encounter with the physician or other qualified health care professional. For office or other outpatient services, if the physician’s or other qualified health care professional’s time is spent in the supervision of clinical staff who perform the face-to-face services of the encounter, use 99211.

When prolonged time occurs, the appropriate prolonged services code may be reported. The appropriate time should be documented in the medical record when it is used as the basis for code selection.

Face-to-face time (outpatient consultations [99241, 99242, 99243, 99244, 99245], domiciliary, rest home, or custodial services [99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337], home services [99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350], cognitive assessment and care plan services [99483]): For coding purposes, face-to-face time for these services is defined as only that time spent face-to-face with patient and/or family. This includes the time spent preforming such tasks as obtaining a history, examination, and counseling the patient.

Unit/floor time (hospital observation services [99218, 99219, 99220, 99224, 99225, 99226, 99234, 99235, 99236], hospital inpatient services [99221, 99222, 99223, 99231, 99232, 99233], inpatient consultations [99251, 99252, 99253, 99254, 99255], nursing facility services [99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99318]): For coding purposes, time for these services is defined as unit/floor time, which includes the time present on the patient’s hospital unit and at bedside rendering services for that patient. This includes the time to establish and/or
review the patient’s chart, examine the patient, write notes, and communicate with other professionals and the patient’s family.

**Total time on the date of the encounter (office or other outpatient services [99202,99203,99204, 99205, 99212, 99213, 99214, 99215]):** For coding purposes, time for these services is the total time on the date of encounter. It includes both the face-to-face and non-face-to-face time personally spent by the physician and/or other qualified health care professional(s) on the day of the encounter (includes time in activities that require the physician or other qualified health care professional and does not include time in activities normally performed by clinical staff).

Physician/other qualified health care professional time includes the following activities when preformed:

- Preparing to see the patient (e.g., review of tests)
- Obtaining and/or reviewing separately obtained history
- Performing a medically appropriate examination and/or evaluation
- Counseling and educating the patient/family/caregiver
- Ordering medications, tests, or procedures
- Referring and communicating with other health care professional (when not separately reported)
- Documenting clinical information in the electronic or other health record
- Independently interpreting results (not separately reported) and communicating results to the patient/family/caregiver
- Care coordination (not separately reported)

4A. **LEVELS OF E/M SERVICES:** Within each category or subcategory of E/M service, there are three to five levels of E/M services available for reporting purposes. Levels of E/M services are not interchangeable among the different categories or subcategories of service. For example, the first level of E/M services in the subcategory of office visit, new patient, does not have the same definition as the first level of E/M services in the subcategory of office visit, established patient.

The levels of E/M services include examinations, evaluations, treatments, conferences with or concerning patients, preventive health supervision, and similar medical services such as the determination of the need and/or location for appropriate care. Medical screening includes the history, examination, and medical decision-making required to determine the need and/or location for appropriate care and treatment of the patient (e.g., office and other outpatient setting, emergency department, nursing facility, etc.). The levels of E/M services encompass the wide variations in skill, effort, time, responsibility and medical knowledge required for the prevention or diagnosis and treatment of illness or injury and the promotion of optimal health.

The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history; examination, medical decision making, counseling; coordination of care; nature of presenting problem, and time.

The first three of these components (history, examination and medical decision making) are considered the key components in selecting a level of E/M services.
The next three components (counseling, coordination of care, and the nature of the presenting problem) are considered **contributory** factors in the majority of encounters. Although the first two of these contributory factors are important E/M services, it is not required that these services be provided at every patient encounter. The final component, time, has already been discussed in detail.

The actual performance of diagnostic tests/studies for which specific codes are available is **not** included in the levels of E/M services. Practitioner performance of diagnostic tests/studies for which specific codes are available should be reported separately, in addition to the appropriate E/M code.

**4B. INSTRUCTIONS FOR SELECTING A LEVEL OF E/M SERVICE:**

i. **IDENTIFY THE CATEGORY AND SUBCATEGORY OF SERVICE:** Select from the categories and subcategories of codes available for reporting E/M services.

ii. **REVIEW THE REPORTING INSTRUCTIONS FOR THE SELECTED CATEGORY OR SUBCATEGORY:** Most of the categories and many of the subcategories of service have special guidelines or instructions unique to that category or subcategory. Where these are indicated, e.g., “Hospital Care”, special instructions will be presented preceding the levels of E/M services.

iii. **REVIEW THE LEVEL OF E/M SERVICE DESCRIPTORS AND EXAMPLES IN THE SELETED CATEGORY OR SUBCATEGORY:** The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history, examination, medical decision making, counseling, coordination of care, nature of presenting problem, and time.

The first three of these components (i.e., history, examination and medical decision making) should be considered the key components in selecting the level of E/M services. An exception to this rule is in the case of visits which consist predominantly of counseling or coordination of care (see viii.c.).

The nature of the presenting problem and time are provided in some levels to assist the practitioner in determining the appropriate level of E/M service.

iv. **DETERMINE THE EXTENT OF HISTORY OBTAINED:** The levels of E/M services recognize four types of history that are defined as follows:

   • Problem Focused – chief complaint, brief history of present illness or problem.
   • Expanded Problem Focused – chief complaint; brief history of present illness; problem pertinent system review.
   • Detailed – chief complaint; extended history of present illness; problem pertinent system review extended to include review of a limited number of additional systems; pertinent past, family and/or social history directly related to the patient’s problems.
   • Comprehensive – chief complaint; extended history of present illness; review of systems which is directly related to the problem(s) identified in the history of the present illness plus a review of all additional body systems; **complete** past, family and social history.
The comprehensive history obtained as part of the preventive medicine evaluation and management service is not problem-oriented and does not involve a chief complaint of present illness. It does, however, include a comprehensive system review and comprehensive or interval past, family and social history as well as a comprehensive assessment/history of pertinent risk factors.

v. DETERMINE THE EXTENT OF EXAMINATION PERFORMED: The levels of E/M services recognize four types of examination that are defined as follows:

- **Problem Focused** – a limited examination of the affected body area or organ system.
- **Expanded Problem Focused** – a limited examination of the affected body area or organ system and other symptomatic or related organ system(s).
- **Detailed** – an extended examination of the affected body area(s) and other symptomatic or related organ system(s).
- **Comprehensive** – a general multi-system examination or a complete examination of a single organ system. **NOTE:** The comprehensive examination performed as part of the preventive medicine evaluation and management service is multi-system, but its extent is based on age and risk factors identified.

For the purpose of these definitions, the following body areas are recognized: head, including the face; neck; chest, including breasts and axilla; abdomen; genitalia, groin, buttocks; back and each extremity.

For the purposes of these definitions, the following organ systems are recognized: eyes, ears, nose, mouth and throat; cardiovascular; respiratory; gastrointestinal; genitourinary; musculoskeletal; skin, neurologic; psychiatric; hematologic/lymphatic/immunologic.

vi. DETERMINE THE COMPLEXITY OF MEDICAL DECISION MAKING: Medical decision making refers to the complexity of establishing a diagnosis and/or selecting a management option as measured by:

- the number of possible diagnoses and/or the number of management options that must be considered;
- the amount and/or complexity of medical records, diagnostic tests, and/or other information that must be obtained, reviewed and analyzed; and
- the risk of significant complications, morbidity and/or mortality, as well as co-morbidities, associated with the patient’s presenting problem(s), the diagnostic procedure(s) and/or the possible management options.

Four types of medical decision making are recognized: straightforward; low complexity; moderate complexity, and, high complexity. To qualify for a given type of decision making, two of the three elements in the table following must be met or exceeded:

<table>
<thead>
<tr>
<th>Number of diagnoses or management options</th>
<th>Amount and/or complexity of data to be reviewed</th>
<th>Risk of complications and/or morbidity or mortality</th>
<th>Type of decision making</th>
</tr>
</thead>
<tbody>
<tr>
<td>minimal</td>
<td>minimal or none</td>
<td>minimal</td>
<td>straightforward</td>
</tr>
<tr>
<td>limited</td>
<td>limited</td>
<td>low</td>
<td>low complexity</td>
</tr>
<tr>
<td>multiple</td>
<td>moderate</td>
<td>moderate</td>
<td>moderate complexity</td>
</tr>
<tr>
<td>extensive</td>
<td>extensive</td>
<td>high</td>
<td>high complexity</td>
</tr>
</tbody>
</table>
Co-morbidities/underlying disease, in and of themselves, are not considered in selecting a level of E/M services unless their presence significantly increases the complexity of the medical decision making.

vii. SELECT THE APPROPRIATE LEVEL OF E/M SERVICES BASED ON THE FOLLOWING:

a. For the following categories/subcategories, ALL OF THE KEY COMPONENTS (i.e., history, examination, and medical decision making), must meet or exceed the stated requirements to qualify for a particular level of E/M service: initial observation care; initial hospital care; observation or inpatient hospital care (including admission and discharge services); office, or other outpatient consultations, inpatient consultation; emergency department services; initial nursing facility care; domiciliary care, new patient; and home, new patient.

b. For the following categories/subcategories, TWO OF THE THREE KEY COMPONENTS (i.e., history, examination, and medical decision making) must meet or exceed the stated requirements to qualify for a particular level of E/M services: subsequent observation care; subsequent hospital care; subsequent nursing facility care domiciliary care, established patient; and home services, established patient.

c. In the case where counseling and or coordination of care dominates (more than 50%) the practitioner/patient and/or family encounter (face-to-face time in the office or other outpatient setting or floor/unit time in the hospital), then time is considered the key or controlling factor to qualify for a particular level of E/M services. The extent of counseling and/or coordination of care must be documented in the medical record.

NOTE: CLINICAL EXAMPLES: Clinical examples of the codes for E/M services are provided to assist practitioners in understanding the meaning of the descriptors and selecting the correct code. The same problem, when seen by physicians in different specialties, may involve different amounts of work. Therefore, the appropriate level of encounter should be reported using the descriptor rather than the examples.

5. BY REPORT: A service that is rarely provided, unusual, variable, or new may require a special report in determining medical appropriateness of the service. Pertinent information should include an adequate definition or description of the nature, extent, and need for the procedure, and the time, effort, and equipment necessary to provide the service. Additional items which may be included are: complexity of symptoms, final diagnosis, pertinent physical findings (such as size, locations, and number of lesion(s), if appropriate), diagnostic and therapeutic procedures (including major supplementary surgical procedures, if appropriate), concurrent problems, and follow-up care.

When the value of a procedure is to be determined "By Report" (BR), information concerning the nature, extent and need for the procedure or service, the time, the skill and the equipment necessary, is to be furnished. Appropriate documentation (eg, operative report, procedure description, and/or itemized invoices) should accompany all claims submitted. Itemized invoices must document acquisition cost, the line item cost from a manufacturer or wholesaler net of any rebates, discounts or other valuable considerations.
6. **CRITICAL CARE**: Represents extraordinary care by the attending physician in personal attendance in the care of a medical emergency, both directing and personally administering specific corrective measures after initial examination had determined the nature of the ailment. See codes 99291, 99292. **NOTE: Report Required for 99292.**

7. **EVALUATION AND MANAGEMENT SERVICES (outpatient or inpatient)**: Evaluation and management fees do not apply to preoperative consultations or follow-up visits as designated in accordance with the surgical fees listed in the SURGERY section of the State Medical Fee Schedule.
   For additional information on the appropriate circumstances governing the billing of the hospital visit procedure codes see PHYSICIAN SERVICES PROVIDED IN HOSPITALS.

8. **FAMILY PLANNING CARE**: In accordance with approval received by the State Director of the Budget, effective July 1, 1973 in the Medicaid Program, all family planning services are to be reported on claims using appropriate MMIS code numbers listed in this fee schedule in combination with modifier '-FP'.
   This reporting procedure will assure to New York State the higher level of federal reimbursement which is available when family planning services are provided to Medicaid patients (90% instead of 50% for other medical care). It will also provide the means to document conformity with mandated federal requirements on provision of family planning services.

9. **INJECTIONS**: are usually given in conjunction with a medical service. When an injection is the only service performed, a minimal service may be listed in addition to the injection.

10. **SEPARATE PROCEDURE**: Certain of the listed procedures are commonly carried out as an integral part of a total service, and as such do not warrant a separate charge. When such a procedure is carried out as a separate entity, not immediately related to other services, the indicated value for “Separate Procedure” is applicable.

11. **SEPARATE SERVICE**: If a significantly separately identifiable Evaluation and Management services (eg, office service, preventative medicine services) is performed, the appropriate E/M code should be reported in addition to the vaccine and toxoid codes.

12. **MATERIALS SUPPLIED BY PHYSICIAN**: Supplies and materials provided by the physician, eg, sterile trays/drugs, over and above those usually included with the procedure(s), office visit or other services rendered may be listed separately. List drugs, trays, supplies and materials provided. Identify as 99070 or specific supply code.
   **Payment for supplies and materials** furnished by practitioners to their patients is based on the acquisition cost to the practitioner. For all items furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the item provided.
13. **PAYMENT FOR DRUGS (including vaccines and immune globulins):** furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

**NOTE:** The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert acquisition cost per dose in amount charged field on claim form. For codes listed as BR in the Fee Schedule, also attach an itemized invoice to claim form.

14. **PAYMENT IN FULL:** Fees paid in accordance with the allowances in the Physician Fee Schedule shall be considered full payment for services rendered. No additional charge shall be made by a physician.

15. **PRIOR APPROVAL:** Payment for those listed procedures where the MMIS code number is underlined is dependent upon obtaining the approval of the Department of Health prior to performance of the procedure. If such prior approval is not obtained, no reimbursement will be made.

16. **DVS AUTHORIZATION (#):** Codes followed by # require an authorization via the dispensing validation system (DVS) before services are rendered.

17. **BILLING GUIDELINES:** For additional general billing guidelines see the current CTP manual.

18. **FEES:** The fees are listed in the Physician Medicine Fee Schedule, available at [http://www.emedny.org/ProviderManuals/Physician/index.html](http://www.emedny.org/ProviderManuals/Physician/index.html)

Listed fees are the maximum reimbursable Medicaid fees. Fees for the HIV Program and the PPAC Program can be found in the Enhanced Program fee schedule.
MMIS MODIFIERS

Note: NCCI associated modifiers are recognized for NCCI code pairs/related edits. For additional information please refer to the CMS website:
http://www.cms.hhs.gov/NationalCorrectCodInitEd/

Under certain circumstances, the procedure code identifying a specific procedure or service must be expanded by two additional characters to further define or explain the nature of the procedure.

The circumstances under which such further description is required are detailed below along with the appropriate modifiers to be added to the basic code when the particular circumstance applies. Up to four modifiers are allowed on a claim line.

-24 Unrelated Evaluation and Management Service by the Same Practitioner During a Postoperative Period: The practitioner may need to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) unrelated to the original procedure. This circumstance may be reported by adding the modifier -24 to the appropriate level of E/M service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

-25 Significant, Separately Identifiable Evaluation and Management Service by the Same Practitioner on the Day of a Procedure: (Effective 10/1/92) The practitioner may need to indicate that on the day a procedure or service identified by an MMIS code was performed, the patient's condition required a significant, separately identifiable E/M service above and beyond the usual preoperative and postoperative care associated with the procedure that was performed. The E/M service may be prompted by the symptom or condition for which the procedure and/or service was provided. As such, different diagnoses are not required for reporting of the E/M services on the same date. This circumstance may be reported by adding the modifier -25 to the appropriate level of E/M service. NOTE: This modifier is not used to report an E/M service that resulted in a decision to perform surgery. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

-26 Professional Component: Certain procedures are a combination of a physician component and a technical component. When the physician component is reported separately, the service may be identified by adding the modifier -26 to the usual procedure number. (Reimbursement will not exceed 40% of the maximum State Medical Fee Schedule amount.)

-50 Bilateral Procedure: Unless otherwise identified in the listings, bilateral medical procedures and surgical procedures requiring a separate incision that are performed at the same operative session, or bilateral x-ray examinations should be identified by the appropriate procedure code describing the first procedure. To indicate a bilateral procedure was done add modifier -50 to the procedure number. (Reimbursement will not exceed 150% of the maximum State Medical Fee Schedule amount for medicine and surgery services or 160% of the maximum State Medical Fee Schedule amount for radiology services. One claim line is to be billed representing the bilateral procedure. Amount billed should reflect total amount due.)

-77 Repeat Procedure By Another Physician (or Practitioner): The physician may need to indicate that a basic procedure or service performed by another physician had to be repeated. This situation may be reported by adding modifier -77 to the repeated service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

-79 Unrelated Procedure or Service by the Same Practitioner During the Postoperative Period: The practitioner may need to indicate that the performance of a procedure or service during the
postoperative period was unrelated to the original procedure. This circumstance may be
reported by using the modifier -79 to the related procedure. (Reimbursement will not exceed
100% of the maximum State Medical Fee Schedule amount.)

- AJ  Clinical Social Worker: To report services of a Certified Social Worker (CSW) under the direct
supervision of an employing psychiatrist, modifier “AJ” should be added to the appropriate
procedure code listed below. (Reimbursement will not exceed the indicated amount.) 90832
($13.50), 90834 ($27.00), 90846 ($7.20), 90847 ($7.20), 90849 ($7.20), 90853 ($7.20)

- AQ  Physician Providing a Service in an Unlisted Health Professional Shortage Area (HPSA)

- EP  Child/Teen Health Program (EPSDT Program): Service provided as part of the Medicaid Early
Periodic Screening, Diagnosis and Treatment (EPSDT) Program or Child/Teen Health
Program will be identified by adding the modifier -EP to the usual procedure number.
(Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

- FP  Service Provided as Part of Family Planning Program: All Family Planning Services will be
identified by adding the modifier -FP to the usual procedure code number. (Reimbursement will
not exceed 100% of the maximum State Medical Fee Schedule amount.)

- GT  Via interactive audio and video telecommunication systems: Indicates services were performed
via telemedicine. (Reimbursement will not exceed 100% of the maximum State Medical Fee
Schedule amount.)

- LT  Left Side: (Used to identify procedures performed on the left side of the body). Add modifier –
LT to the usual procedure code number. (Reimbursement will not exceed 100% of the
maximum State Medical Fee Schedule amount. One claim line should be billed.) **(Use
modifier –50 when both sides done at same operative session.)**

- RT  Right Side: (Used to identify procedures performed on the right side.) Add modifier –RT to the
usual procedure code number. (Reimbursement will not exceed 100% of the maximum State
Medical Fee Schedule amount. One claim line should be billed). **(Use modifier –50 when
both sides done at same operative session.)**

- SL  State Supplied Vaccine: (Used to identify administration of vaccine supplied by the Vaccine for
Children's Program (VFC) for children under 19 years of age). When administering vaccine
supplied by the state (VFC program), you must append modifier –SL State Supplied Vaccine
to the procedure code number representing the vaccine administered. Omission of this
modifier on claims for recipients under 19 years of age will cause your claim to deny.
(Reimbursement will not exceed $17.85, the administration fee for the VFC program.)
EVALUATION AND MANAGEMENT SERVICES
Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.

OFFICE OR OTHER OUTPATIENT SERVICES
The following codes are used to report evaluation and management services provided in the practitioner's office or in an outpatient or other ambulatory facility. A patient is considered an outpatient until inpatient admission to a health care facility occurs. When claiming for Evaluation and Management procedure codes 99202-99205 and 99211-99215 Office or Other Outpatient Services, report the place of service code that represents the location where the service was rendered in claim form field 24B Place of Service. The maximum reimbursable amount for these codes is dependent on the Place of Service reported.

Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.

For Evaluation and Management services rendered in the practitioner's private office, report place of service "11". For services rendered in a Hospital Outpatient setting report place of service "22".

For services provided by practitioners in the Emergency Department, see 99281-99285. For services provided to hospital inpatients, see Hospital Services 99221-99239.

To report services provided to a patient who is admitted to a hospital or nursing facility in the course of an encounter in the office or other ambulatory facility, see the notes for initial hospital inpatient care or comprehensive nursing facility assessments.

For observation care, see 99217-99220.

For observation or inpatient care services (including admission and discharge services), see 99234-99236.

NEW PATIENT

99202 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 15-29 minutes of total time is spent on the date of the encounter.

99203 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter.

99204 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter.

99205 Office or other outpatient visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection, 60-74 minutes of total time is spent on the date of the encounter.

ESTABLISHED PATIENT
The following codes are used to report the evaluation and management services provided to established patients who present for follow-up and/or periodic reevaluation of problems or for the evaluation and management of new problem(s) in established patients.
99211  Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional.

99212  Office or other outpatient visit for the evaluation and management of an established patient, which requires medically appropriate history and/or examination and straightforward medical decision making. When using time for code selection, 10-19 minutes of total time is spent on the date of the encounter.

99213  Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter.

99214  Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter.

99215  Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using time for code selection 40-54 minutes of total time is spent on the date of the encounter.

HOSPITAL OBSERVATION SERVICES

The following codes are used to report evaluation and management services provided to patients designated/admitted as "observation status" in a hospital. It is not necessary that the patient be located in an observation area designated by the hospital. If such an area does exist in a hospital (as a separate unit in the hospital, in the emergency department, etc.), these codes are to be utilized if the patient is placed in such an area.

Typical times have not yet been established for this category of services.
OBSERVATION CARE DISCHARGE SERVICES
Observation care discharge of a patient from "observation status" includes final examination of the patient, discussion of the hospital stay, instructions for continuing care, and preparation of discharge records. For observation or inpatient hospital care including the admission and discharge of the patient on the same date, see codes 99234-99236 as appropriate.

99217 Observation care discharge day management (This code is to be utilized by the practitioner to report all services provided to a patient on discharge from "observation status" if the discharge is on other than the initial date of outpatient hospital "observation status". To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes for Observation or Inpatient Care Services (99234-99236)).

INITIAL OBSERVATION CARE

NEW OR ESTABLISHED PATIENT
The following codes are used to report the encounter(s) by the supervising practitioner with the patient when designated as "observation status". This refers to the initiation of observation status, supervision of the care plan for observation and performance of periodic reassessments. For observation encounters by other physicians, see Inpatient Consultation codes (99251 – 99255).

To report services provided to a patient who is admitted to the hospital after receiving hospital observation care services on the same date, see the notes for initial hospital inpatient care. For a patient admitted to the hospital on a date subsequent to the date of observation status, the hospital admission would be reported with the appropriate initial hospital care codes (99221-99223). For a patient admitted and discharged from observation or inpatient status on the same date, the services should be reported with codes 99234-99236 as appropriate. Do not report observation discharge (99217) in conjunction with the hospital admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner’s office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are considered part of the initial observation care when performed on the same date. The observation care level of service reported by the supervising practitioner should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting. Evaluation and Management services on the same date provided in sites that are related to initiating "observation status" should NOT be reported separately.

These codes may not be utilized for post-operative recovery if the procedure is considered a part of the surgical "package". These codes apply to all Evaluation and Management services that are provided on the same date of initiating "observation status".

99218 Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components:
- a detailed or comprehensive history;
- a detailed or comprehensive examination; and
- medical decision making that is straightforward or of low complexity.
Usually the problem(s) requiring admission to outpatient hospital "observation status" are of low severity. Physicians typically spend 30 minutes at the bedside and on the patient’s hospital floor or unit.

**99219** Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:
- a comprehensive history;
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually the problem(s) requiring admission to outpatient hospital "observation status" are of moderate severity. Physicians typically spend 50 minutes at the bedside and on the patient’s hospital floor or unit.

**99220** Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:
- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.

Usually the problem(s) requiring admission to outpatient hospital "observation status" are of high severity. Physicians typically spend 70 minutes at the bedside and on the patient’s hospital floor or unit.

**SUBSEQUENT OBSERVATION CARE**

All levels of subsequent observation care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician.

**99224** Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- problem focused interval history;
- problem focused examination;
- medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 15 minutes at the bedside and on the patient's hospital floor or unit.

**99225** Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.

**99226** Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- a detailed interval history;
- a detailed examination;
- medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Physicians typically spend 35 minutes at the bedside and on the patient's hospital floor or unit.
**HOSPITAL INPATIENT SERVICES**

The following codes are used to report evaluation and management services provided to HOSPITAL INPATIENTS. For Hospital Observation Services, see 99218-99220. For a patient admitted and discharged from observation or inpatient status on the same date, the services should be reported with codes 99234-99236 as appropriate. For services rendered in a hospital outpatient setting, see procedure codes 99202-99215 Office or Other Outpatient Services.

**INITIAL HOSPITAL CARE**

**NEW OR ESTABLISHED PATIENT**

The following codes are used to report the first hospital inpatient encounter with the patient by the admitting practitioner. For initial inpatient encounters by practitioners other than the admitting practitioner, see initial inpatient consultation codes (99251-99255) or subsequent hospital care codes (99231-99233) as appropriate.

99221  Initial hospital care, per day, for the evaluation and management of a patient which requires these three key components:
- a detailed or comprehensive history,
- a detailed or comprehensive examination, and
- medical decision making that is straightforward or of low complexity.

Usually, the problem(s) requiring admission are of low severity. Practitioners typically spend 30 minutes at the bedside and on the patient's hospital floor or unit.

99222  Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:
- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the problem(s) requiring admission are of moderate severity. Practitioners typically spend 50 minutes at the bedside and on the patient's hospital floor or unit.

99223  Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:
- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the problem(s) requiring admission are of high severity. Practitioners typically spend 70 minutes at the bedside and on the patient’s hospital floor or unit.

**SUBSEQUENT HOSPITAL CARE**

All levels of subsequent hospital care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient’s status, (i.e., changes in history, physical condition and response to management) since the last assessment by the practitioner.

99231  Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:
- a problem focused interval history,
- a problem focused examination, and/or
• medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering or improving. Practitioners typically spend 15 minutes at the bedside and on the patient’s hospital floor or unit.

99232 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:
• an expanded problem focused interval history,
• an expanded problem focused examination, and/or
• medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Practitioners typically spend 25 minutes at the bedside and on the patient’s hospital floor or unit.

99233 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:
• a detailed interval history,
• a detailed examination, and/or
• medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Practitioners typically spend 35 minutes at the bedside and on the patient’s hospital floor or unit.

**OBSERVATION OR INPATIENT CARE SERVICES (INCLUDING ADMISSION AND DISCHARGE SERVICES)**

The following codes are used to report observation or inpatient hospital care services provided to patients admitted and discharged on the same date of service. When a patient is admitted to the hospital from observation status on the same date, the practitioner should report only the initial hospital care code. The initial hospital care code reported by the admitting practitioner should include the services related to the observation status services he/she provided on the same date of inpatient admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner's office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are considered part of the initial observation care when performed on the same date. The observation care level of service should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting when provided by the same practitioner.

99234 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
• a detailed or comprehensive history;
• a detailed or comprehensive examination; and
• medical decision making that is straightforward or of low complexity.

Usually the presenting problem(s) requiring admission are of low severity.

99235 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
• a comprehensive history;
• a comprehensive examination; and
• medical decision making of moderate complexity.

Usually the presenting problem(s) requiring admission are of moderate severity.
99236 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.
Usually the presenting problem(s) requiring admission are of high severity.

**HOSPITAL DISCHARGE SERVICES**
The hospital discharge day management codes are to be used to report the total duration of time spent by a practitioner for final hospital discharge of a patient. The codes include, as appropriate, final examination of the patient, discussion of the hospital stay, even if the time spent by the practitioner on that date is not continuous, instructions for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms. For patients admitted and discharged from observation or inpatient status on the same date, the service should be reported with codes 99234-99236 as appropriate.

99238 Hospital discharge day management; 30 minutes or less
99239 more than 30 minutes

(These codes are to be utilized by the practitioner to report all services provided to a patient on the date of discharge, if other than the initial date of inpatient status. To report services to a patient who is admitted as an inpatient, and discharge on the same date, see codes 99234-99236 for observation or inpatient hospital care including the admission and discharge of the patient on the same date. To report concurrent care services provided by a practitioner(s) other than the attending practitioner, use subsequent hospital care codes (99231-99233) on the day of discharge.)

(For Observation Care Discharge, use 99217)
(For discharge services provided to newborns admitted and discharged on the same date, use 99463)
(For Nursing Facility Care Discharge, see 99315, 99316)
(For observation or inpatient hospital care including the admission and discharge of the patient on the same date, see 99234-99236)

**CONSULTATIONS (BY SPECIALISTS)**
A consultation is a type of service provided by a physician whose opinion or advice regarding evaluation and/or management of a specific problem is requested by another physician or other appropriate source.
A physician consultant may initiate diagnostic and/or therapeutic services at the same or subsequent visit.
The request for a consultation from the attending physician or other appropriate source and the need for consultation must be documented in the patient's medical record. The consultant's opinion and any services that were ordered or performed must also be documented in the patient's medical record and communicated by written report to the requesting physician or other appropriate source.
A "consultation" initiated by a patient and/or family is not reported using the consultation codes, but may be reported using the codes for visits, as appropriate.
Any specifically identifiable procedure (i.e., identified with a specific procedure code) performed on or subsequent to the date of the initial consultation should be reported separately. If subsequent to the completion of a consultation, the consultant assumes responsibility for management of a portion or all of the patient's condition(s), the consultation codes should not be used. In the hospital setting, the consulting physician should use the appropriate initial hospital care code for the initial encounter and subsequent hospital care codes (not follow-up consultation codes). In the office setting, the appropriate established patient code should be used. There are two subcategories of consultations: office and initial inpatient consultation (other than office). See each subcategory for specific reporting instructions.

**OFFICE OR OTHER OUTPATIENT CONSULTATION**

**NEW OR ESTABLISHED PATIENT**
The following codes are used to report consultations provided in the physician's office or in an outpatient or other ambulatory facility, including hospital observation services, home services, domiciliary, rest home, custodial care, or emergency department (see consultation definition, above). When reporting procedure codes 99241-99245 with a place of service office, reimbursement will not exceed 120% of the Maximum State Medical Fee Schedule amount. Follow-up visits in the consultant's office or other outpatient facility that are initiated by the physician consultant are reported using office visit codes for established patients (99211-99215). If an additional request for an opinion or advice regarding the same or a new problem is received from the attending physician and documented in the medical record, the office consultation codes may be used again. Follow-up visits in the consultant's office that are initiated by the physician consultant are reported using office visit codes (99211-99215). If an additional request for an opinion or advice regarding the same or a new problem is received from the attending physician or other appropriate source and documented in the medical record, the office consultation codes may be used again.

99241 Office or other outpatient consultation for a new or established patient, which requires these 3 key components:
- a problem focused history,
- a problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor. Physicians typically spend 15 minutes face-to-face with the patient and/or family.

99242 Office or other outpatient consultation for a new or established patient, which requires these 3 key components:
- an expanded problem focused history,
- an expanded problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are of low severity. Physicians typically spend 30 minutes face-to-face with the patient and/or family.

99243 Office or other outpatient consultation for a new or established patient, which requires these 3 key components:
- a detailed history,
- a detailed examination, and...
• medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Physicians typically spend 40 minutes face-to-face with the patient and/or family.

99244  Office or other outpatient consultation for a new or established patient, which requires these 3 key components:
• a comprehensive history,
• a comprehensive examination, and
• medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 60 minutes face-to-face with the patient and/or family.

99245  Office or other outpatient consultation for a new or established patient, which requires these 3 key components:
• a comprehensive history,
• a comprehensive examination, and
• medical decision making of high complexity.

Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 80 minutes face-to-face with the patient and/or family.

INPATIENT CONSULTATIONS

NEW OR ESTABLISHED PATIENT
The following codes are used to report physician consultations provided to hospital inpatients, residents of nursing facility, or patients in a partial hospital setting.

99251  Inpatient consultation for a new or established patient, which requires these three key components:
• a problem focused history,
• a problem focused examination, and
• straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor. Physicians typically spend 20 minutes at the bedside and on the patient's hospital floor or unit.

99252  Inpatient consultation for a new or established patient, which requires these three key components:
• an expanded problem focused history,
• an expanded problem focused examination, and
• straightforward medical decision making.

Usually, the presenting problem(s) are of low severity. Physicians typically spend 40 minutes at the bedside and on the patient's hospital floor or unit.

99253  Inpatient consultation for a new or established patient, which requires these three key components:
• a detailed history,
• a detailed examination, and
• medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Physicians typically spend 55 minutes at the bedside and on the patient's hospital floor or unit.

99254  Inpatient consultation for a new or established patient, which requires these three key components:
• a comprehensive history,
• a comprehensive examination, and
• medical decision making of moderate complexity.
Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 80 minutes at the bedside and on the patient's hospital floor or unit.

99255  Inpatient consultation for a new or established patient, which requires these 3 key components:
• a comprehensive history;
• a comprehensive examination; and
• medical decision making of high complexity.
Usually, the presenting problem(s) are of moderate to high severity. Physicians typically spend 110 minutes at the bedside and on the patient's hospital floor or unit.

**EMERGENCY DEPARTMENT SERVICES**

**NEW OR ESTABLISHED PATIENT**
The following codes are used to report evaluation and management services provided in the emergency department. No distinction is made between new and established patients in the emergency department.

An emergency department is defined as an organized hospital-based facility for the provision of unscheduled episodic services to patients who present for immediate medical attention. The facility must be available 24 hours a day.

For critical care services provided in the Emergency Department, see critical care notes and 99291-99292.

For evaluation and management services provided to a patient in an observation area of a hospital, see 99217-99220.

For observation or inpatient care services (including admission and discharge services), see 99234-99236.

99281  Emergency department visit for the evaluation and management of a patient, which requires these three key components:
• a problem focused history,
• a problem focused examination, and
• straightforward medical decision making.
Usually, the presenting problem(s) are self-limited or minor.

99282  Emergency department visit for the evaluation and management of a patient, which requires these three key components:
• an expanded problem focused history,
• an expanded problem focused examination, and
• medical decision making of low complexity.
Usually, the presenting problem(s) are of low to moderate severity.

99283  Emergency department visit for the evaluation and management of a patient, which requires these three key components:
• an expanded problem focused history,
• an expanded problem focused examination, and
• medical decision making of moderate complexity.
Usually, the presenting problem(s) are of moderate severity.
99284  Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- a detailed history;
- a detailed examination; and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of high severity and require urgent evaluation by the physician but do not pose an immediate significant threat to life or physiologic function.

99285  Emergency department visit for the evaluation and management of a patient, which requires these three key components within the constraints imposed by the urgency of the patient’s clinical condition and/or mental status:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.

CRITICAL CARE SERVICES

Critical care is the direct delivery by a physician(s) of medical care for a critically ill or critically injured patient. A critical illness or injury acutely impairs one or more vital organ systems such that there is a high probability of imminent or life threatening deterioration in the patient’s condition. Critical care involves high complexity decision making to assess, manipulate, and support vital system function(s) to treat single or multiple vital organ system failure and/or to prevent further life threatening deterioration of the patient’s condition. Examples of vital organ system failure include, but are not limited to: central nervous system failure, circulatory failure, shock, renal, hepatic, metabolic, and/or respiratory failure. Although critical care typically requires interpretation of multiple physiologic parameters and/or application of advanced technology(s), critical care may be provided in life threatening situations when these elements are not present. Critical care may be provided on multiple days, even if no changes are made in the treatment rendered to the patient, provided that the patient’s condition continues to require the level of physician attention described above.

Providing medical care to a critically ill, injured, or post-operative patient qualifies as a critical care service only if both the illness or injury and the treatment being provided meet the above requirements.

Critical care is usually, but not always, given in a critical care area, such as the coronary care unit, intensive care unit, pediatric intensive care unit, respiratory care unit, or the emergency care facility. Inpatient critical care services provided to infants 29 days through 71 months of age are reported with pediatric critical care codes 99471-99476. The pediatric critical care codes are reported as long as the infant/young child qualifies for critical care services during the hospital stay through 71 months of age. Inpatient critical care services provided to neonates (28 days of age or less) are reported with the neonatal critical care codes 99468 and 99469. The neonatal critical care codes are reported as long as the neonate qualifies for critical care services during the hospital stay through the 28th postnatal day. The reporting of the pediatric and neonatal critical care services is not based on time or the type of unit (eg, pediatric or neonatal critical care unit) and it is not dependent upon the type of provider delivering the care. To report critical care services provided in the outpatient setting (eg, emergency department or office), for neonates and pediatric patients up through 71 months of age, see the critical care codes 99291, 99292. If the same physician provides critical care services for a
neonatal or pediatric patient in both the outpatient and inpatient settings on the same day, report only the appropriate neonatal or pediatric critical care code 99468-99472 for all critical care services provided on that day.

Also report 99291-99292 for neonatal or pediatric critical care services provided by the physician providing critical care at one facility but transferring the patient to another facility. Critical care services provided by a second physician of a different specialty not reporting a per day neonatal or pediatric critical care code can be reported with codes 99291-99292. For additional instructions on reporting these services, see the neonatal and pediatric critical care section and codes 99468-99476.

Services for a patient who is not critically ill but happens to be in a critical care unit are reported using other appropriate E/M codes.

Critical care and other E/M services may be provided to the same patient on the same date by the same individual.

For reporting by professionals, the following services are included in critical care when performed during the critical period by the physician(s) providing critical care: the interpretation of cardiac output measurements (93598), chest X rays (71045, 71046), pulse oximetry (94760, 94761, 94762), blood gases, and collection and interpretation of physiologic data (eg, ECHs, blood pressures, hematologic data); gastric intubation (43752, 43753); temporary transcutaneous pacing (92953); ventilatory management (94002–94004, 94660, 94662); and vascular access procedures (36000, 36410, 36415, 36591, 36600). Any services performed that are not included in this listing should be reported separately. Facilities may report the above services separately.

Codes 99291, 99292 should be reported for the physician’s attendance during the transport of critically ill or critically injured patients over 24 months of age to or from a facility or hospital. For physician transport services of critically ill or critically injured pediatric patients 24 months of age or less see 99466, 99467.

The critical care codes 99291 and 99292 are used to report the total duration of time spent by a physician providing critical care services to a critically ill or critically injured patient, even if the time spent by the physician on that date is not continuous. For any given period of time spent providing critical care services, the physician must devote his or her full attention to the patient and, therefore, cannot provide services to any other patient during the same period of time.

Time spent with the individual patient should be recorded in the patient’s record. The time that can be reported as critical care is the time spent engaged in work directly related to the individual patient’s care, whether that time was spent at the immediate bedside or elsewhere on the floor or unit. For example, time spent on the unit or at the nursing station on the floor reviewing test results or imaging studies, discussing the critically ill patient’s care with other medical staff or documenting critical care services in the medical record would be reported as critical care, even though it does not occur at the bedside. Also, when the patient is unable or lacks capacity to participate in discussions, time spent on the floor or unit with family members or surrogate decision makers obtaining a medical history, reviewing the patient’s condition or prognosis, or discussing treatment or limitation(s) of treatment may be reported as critical care, provided that the conversation bears directly on the management of the patient.

Time spent in activities that occur outside of the unit or off the floor (eg, telephone calls whether taken at home, in the office, or elsewhere in the hospital) may not be reported as critical care since the physician is not immediately available to the patient.

Time spent in activities that do not directly contribute to the treatment of the patient may not be reported as critical care, even if they are performed in the critical care unit (eg, participation in administrative meetings or telephone calls to discuss other patients). Time spent performing
separately reportable procedures or services should not be included in the time reported as critical care time.

Code 99291 is used to report the first 30-74 minutes of critical care on a given date. It should be used only once per date even if the time spent by the physician is not continuous on that date. Critical care of less than 30 minutes total duration on a given date should be reported with the appropriate E/M code.

Code 99292 is used to report additional block(s) of time, of up to 30 minutes each beyond the first 74 minutes.

99291 Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99292 each additional 30 minutes (Report required)
(List separately in addition to primary service)
(Use 99292 in conjunction with 99291)

NURSING FACILITY SERVICES
The following codes are used to report evaluation and management services to patients in nursing facilities (formerly called skilled nursing facilities (SNFs), intermediate care facilities (ICFs) or long-term care Facilities (LTCFs)).

INITIAL NURSING FACILITY CARE

NEW OR ESTABLISHED PATIENT
More than one comprehensive assessment may be necessary during an inpatient confinement.

99304 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:
• a detailed or comprehensive history;
• a detailed or comprehensive examination; and
• medical decision making that is straightforward or of low complexity.
Usually, the problem(s) requiring admission are of low severity. Physicians typically spend 25 minutes at the bedside and on the patient’s facility floor or unit.

99305 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:
• a comprehensive history;
• a comprehensive examination; and
• medical decision making of moderate complexity.
Usually, the problem(s) requiring admission are of moderate severity. Physicians typically spend 35 minutes at the bedside and on the patient’s facility floor or unit.

99306 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:
• a comprehensive history;
• a comprehensive examination; and
• medical decision making of high complexity.
Usually, the problem(s) requiring admission are of high severity. Physicians typically spend 45 minutes at the bedside and on the patient’s facility floor or unit.

SUBSEQUENT NURSING FACILITY CARE
NEW OR ESTABLISHED PATIENT
The following codes are used to report the services provided to residents of nursing facilities who do not require a comprehensive assessment, and/or who have not had a major, permanent change of status.

All levels of subsequent nursing facility care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient’s status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician.

99307 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- a problem focused interval history;
- a problem focused examination;
- straightforward medical decision making.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 10 minutes at the bedside and on the patient’s facility floor or unit.

99308 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of low complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 15 minutes at the bedside and on the patient’s facility floor or unit.

99309 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- a detailed interval history;
- a detailed examination;
- medical decision making of moderate complexity.

Usually, the patient has developed a significant complication or a significant new problem. Physicians typically spend 25 minutes at the bedside and on the patient’s facility floor or unit.

99310 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:
- a comprehensive interval history;
- a comprehensive examination;
- medical decision making of high complexity.

The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically spend 35 minutes at the bedside and on the patient’s facility floor or unit.

NURSING FACILITY DISCHARGE SERVICES
The nursing facility discharge day management codes are to be used to report the total duration of time spent by a practitioner for the final nursing facility discharge of patient. The codes include, as appropriate, final examination of the patient, discussion of the nursing facility stay, even if the time spent by the practitioner on that date is not continuous. Instructions are given for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms.

99315 Nursing facility discharge day management; 30 minutes or less
99316  more than 30 minutes

**DOMICILIARY, REST HOME (e.g., BOARDING HOME), OR CUSTODIAL CARE SERVICES**

The following codes are used to report evaluation and management services in a facility which provides room, board and other personal assistance services, generally on a long-term basis. The facility's services do not include a medical component. Typical times have not yet been established for this category of services.

**NEW PATIENT**

99324  Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a problem focused history,
- a problem focused examination, and
- medical decision making that is straightforward.

Usually, the presenting problem(s) are of low severity. Practitioners typically spend 20 minutes with the patient and/or family or caregiver.

99325  Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes with the patient and/or family or caregiver.

99326  Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a detailed history,
- a detailed examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high complexity. Practitioners typically spend 45 minutes with the patient and/or family or caregiver.

99327  Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

99328  Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Practitioners typically spend 75 minutes with the patient and/or family or caregiver.

**ESTABLISHED PATIENT**
99334 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
- a problem focused interval history,
- a problem focused examination, and/or
- medical decision making that is straightforward.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes with the patient and/or family or caregiver.

99335 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
- an expanded problem focused interval history,
- an expanded problem focused examination, and/or
- medical decision making of low complexity.

Usually, the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes with the patient and/or family or caregiver.

99336 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
- a detailed interval history,
- a detailed examination, and/or
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes with the patient and/or family or caregiver.

99337 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
- a comprehensive interval history,
- a comprehensive examination, and
- medical decision making of moderate to high complexity.

Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

**HOME SERVICES**
The following codes are used to report evaluation and management services provided in a private residence.

**NEW PATIENT**
99341 Home visit for the evaluation and management of a new patient, which requires these three key components:
- a problem focused history,
- a problem focused examination, and
- medical decision making that is straightforward.

Usually, the presenting problem(s) are of low severity. Practitioners typically spend 20 minute face-to-face with the patient and/or family.

99342 Home visit for the evaluation and management of a new patient, which requires these three key components:
- an expanded problem focused history,
- an expanded problem focused examination, and
• medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes face-to-face with the patient and/or family.

99343 Home visit for the evaluation and management of a new patient, which requires these three key components:
  • a detailed history,
  • a detailed examination, and
  • medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 45 minutes face-to-face with patient and/or family.

99344 Home visit for the evaluation and management of a new patient, which requires these three key components:
  • a comprehensive history,
  • a comprehensive examination; and
  • medical decision making of moderate complexity.

Usually, the patient is unstable or has developed a significant new problem requiring immediate Practitioner attention. Practitioners typically spend 75 minutes face-to-face with the patient and/or family.

99345 Home visit for the evaluation and management of a new patient, which requires these three key components:
  • a comprehensive history,
  • a comprehensive examination; and
  • medical decision making of high complexity.

ESTABLISHED PATIENT

99347 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  • a problem focused interval history;
  • a problem focused examination and
  • straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes face-to-face with the patient and/or family.

99348 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  • an expanded problem focused interval history;
  • an expanded problem focused examination;
  • medical decision making of low complexity.

Usually the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes face-to-face with the patient and/or family.

99349 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  • a detailed interval history;
  • a detailed examination;
  • medical decision making of moderate complexity.
Usually the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes face-to-face with the patient and/or family.

99350 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
- a comprehensive interval history;
- a comprehensive examination;
- medical decision making of moderate to high complexity.

Usually the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate practitioner attention. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

**PROLONGED SERVICES**

**PROLONGED PHYSICIAN SERVICE WITH DIRECT (FACE TO FACE) PATIENT CONTACT**

Codes 99354-99357 are used when a physician provides prolonged service involving direct (face-to-face) patient contact that is beyond the usual service in either the inpatient or outpatient setting, even if the time spent by the physician on that date is not continuous. This service is reported, for the total duration, in addition to other physician service, including evaluation and management services at any level. Appropriate codes should be selected for supplies provided or procedures performed in the care of the patient during this period. *(Report Required)*

Code 99354 or 99356 is used to report the first hour of prolonged service on a given date, depending on the place of service. Either code also may be used to report a total duration of prolonged service of 30-60 minutes on a given date. Either code should be used only once per date, even if the time spent by the physician is not continuous on that date. Prolonged service of less than 30 minutes total duration on a given date is not separately reported because the work involved is included in the total work of the evaluation and management codes.

Code 99355 or 99357 is used to report each additional 30 minutes beyond the first hour, depending on the place of service. Either code may also be used to report the final 15-30 minutes of prolonged service on a given date. Prolonged service of less than 15 minutes beyond the first hour or less than 15 minutes beyond the final 30 minutes is not reported separately.

99354 Prolonged service(s) in the outpatient setting requiring direct patient contact beyond the time of usual service; first hour
(List separately in addition to code for outpatient Evaluation and Management or psychotherapy service, except with office or other outpatient services [99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215]

99355 each additional 30 minutes
(List separately in addition to code for prolonged service)
(Use 99355 in conjunction with code 99354)

99356 Prolonged service in the inpatient or observation setting, requiring unit/floor time beyond the usual service; first hour
(List separately in addition to code for inpatient or observation Evaluation and Management service)
(Use 99356 in conjunction with 90837, 90847, 99218-99220, 99221-99233, 99224-99226, 99231-99233, 99234-99236, 99251-99255, 99304-99310)

99357 each additional 30 minutes
(List separately in addition to code for prolonged service)
(Use 99357 in conjunction with code 99356)

PROLONGED SERVICES WITH OR WITHOUT DIRECT PATIENT CONTACT ON THE DATE OF AN OFFICE VISIT OR OTHER OUTPATIENT SERVICE

99417  Prolonged office or other outpatient evaluation and management service(s) beyond the minimum required time of the primary procedure which has been selected using total time, requiring total time with or without direct patient contact beyond the usual service on the date of primary service, each 15 minutes of total time
(List separately in addition to codes 99205,99215 for office or other outpatient Evaluation and Management services)

PREVENTIVE MEDICINE SERVICES (Well Visits)
The following codes are used to report well visit services provided to patients.

NEW PATIENT
99381  Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)
99382  early childhood (age 1 through 4 years)
99383  late childhood (age 5 through 11 years)
99384  adolescent (age 12 through 17 years)
99385  18-39 years
99386  40-64 years
99387  65 years and older

ESTABLISHED PATIENT
99391  Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)
99392  early childhood (age 1 through 4 years)
99393  late childhood (age 5 through 11 years)
99394  adolescent (age 12 through 17 years)
99395  18 - 39 years
99396  40 - 64 years
99397  65 years and older

COUNSELING RISK FACTOR REDUCTION AND BEHAVIOR CHANGE INTERVENTION

BEHAVIOR CHANGE INTERVENTIONS, INDIVIDUAL
99406  Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes
99407  intensive, greater than 10 minutes

Non-Face-to-Face Services
**Telephone Services**

Telephone services are non-face-to-face evaluation and management (E/M) services provided to a patient using the telephone by a physician or other qualified health care professional, who may report evaluation and management services. These codes are used to report episodes of patient care initiated by an established patient or guardian of an established patient. If the telephone service ends with a decision to see the patient within 24 hours or next available urgent visit appointment, the code is not reported; rather the encounter is considered part of the preservice work of the subsequent E/M service, procedure, and visit. Likewise, if the telephone call refers to an E/M service performed and reported by that individual within the previous seven days (either requested or unsolicited patient follow-up) or within the postoperative period of the previously completed procedure, then the service(s) is considered part of that previous E/M service or procedure. (Do not report 99441-99443, if 99421, 99422, 99423 have been reported by the same provider in the previous seven days for the same problem.)

(For telephone services provided by a qualified nonphysician who may not report evaluation and management services [eg, speech-language pathologists, physical therapists, occupational therapists, social workers, dietitians], see 98966-98968

99441  Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion

99442  11-20 minutes of medical discussion

99443  21-30 minutes of medical discussion

**NEWBORN CARE SERVICES**

The following codes are used to report the services provided to newborns (birth through the first 28 days) in several different settings. Use of the normal newborn codes is limited to the initial care of the newborn in the first days after birth prior to home discharge.

Evaluation and management (E/M) services for the newborn include maternal and/or fetal and newborn history, newborn physical examination(s), ordering of diagnostic tests and treatments, meetings with the family, and documentation in the medical record.

When delivery room resuscitation services (99465) are required, report this in addition to normal newborn services evaluation and management codes.

For E/M services provided to newborns who are other than normal, see codes for hospital inpatient services (99221-99233) and neonatal intensive and critical care services (99466-99469, 99477-99480). When normal newborn services are provided by the same physician on the same date that the newborn later becomes ill and receives additional intensive or critical care services, report the appropriate E/M code with modifier 25 for these services in addition to the normal newborn code.

Procedures (eg, 54150, newborn circumcision) are not included with the normal newborn codes, and when performed, should be reported in addition to the newborn services.

When newborns are seen in follow-up after the date of discharge in the office or outpatient setting, see 99202-99215, 99381, 99391 as appropriate.

99460  Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant

99462  Subsequent hospital care, per day, for evaluation and management of normal newborn
99463 Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant admitted and discharged on the same day
(For newborn hospital discharge services provided on a date subsequent to the admission date, see 99238, 99239)

DELIVERY/BIRTHING ROOM ATTENDANCE AND RESUSCITATION SERVICES
99464 Attendance at delivery (when requested by the delivering physician or other qualified health care professional) and initial stabilization of newborn
99465 Delivery/birthing room resuscitation, provision of positive pressure ventilation and/or chest compressions in the presence of acute inadequate ventilation and/or cardiac output (99465 may be reported in conjunction with 99460, 99468, 99477)
(Procedures that are performed as a necessary part of the resuscitation [eg, intubation, vascular lines] are reported separately in addition to 99465. In order to report these procedures, they must be performed as a necessary component of the resuscitation and not as a convenience before admission to the neonatal intensive care unit)

INPATIENT NEONATAL INTENSIVE CARE SERVICES AND PEDIATRIC AND NEONATAL CRITICAL CARE SERVICES

PEdiATRIC CRiTiCAL CARE PATiENT TRANSPORT
The following codes (99466, 99467) are used to report the physical attendance and direct face-to-face care by a physician during the interfacility transport of a critically ill or critically injured pediatric patient 24 months of age or less. For the purpose of reporting codes 99466 and 99467, face-to-face care begins when the physician assumes primary responsibility of the pediatric patient at the referring hospital/facility, and ends when the receiving hospital/facility accepts responsibility for the pediatric patient's care. Only the time the physician spends in direct face-to-face contact with the patient during the transport should be reported. Pediatric patient transport services involving less than 30 minutes of face-to-face physician care should not be reported using codes 99466, 99467. Procedure(s) or service(s) performed by other members of the transporting team may not be reported by the supervising physician.
For the definition of the critically ill or critically injured pediatric patient and the list of services included in critical care, see the Neonatal and Pediatric Critical Care Services section. Any services performed, which are not listed, may be reported separately.
The direction of emergency care to transporting staff by a physician located in a hospital or other facility by two-way communication is not considered direct face-to-face care and should not be reported with codes 99466, 99467. Physician-directed emergency care through outside voice communication to transporting staff personnel is not reimbursable as a separate procedure. Emergency department services (99281-99285), initial hospital care (99221-99223), critical care (99291, 99292), initial date neonatal intensive (99477) or critical care (99468) are only reported after the patient has been admitted to the emergency department, the inpatient floor or the critical care unit of the receiving facility. If inpatient critical care services are reported in the referring facility prior to transfer to the receiving hospital, use the critical care codes (99291, 99292).
Code 99466 is used to report the first 30-74 minutes of direct face-to-face time with the transport pediatric patient and should be reported only once on a given date. Code 99467 is used to report each additional 30 minutes provided on a given date. Face-to-face services less than 30 minutes should not be reported with these codes.
99466 Critical care services delivered by a physician, face-to-face, during an interfacility transport of critically ill or critically injured pediatric patient, 24 months of age or less; first 30-74 minutes of hands on care during transport

99467 each additional 30 minutes
   (List separately in addition to primary service)
   (Use 99467 in conjunction with 99466)
   (Critical care of less than 30 minutes total duration should be reported with the appropriate E/M code)

**INPATIENT NEONATAL AND PEDIATRIC CRITICAL CARE**

99468 Initial inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or less

99469 Subsequent inpatient neonatal critical care, per day, for the evaluation and management of a critically ill neonate, 28 days of age or less

99471 Initial inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age

99472 Subsequent inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 29 days through 24 months of age

99475 Initial inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 2 through 5 years of age

99476 Subsequent inpatient pediatric critical care, per day, for the evaluation and management of a critically ill infant or young child, 2 through 5 years of age

**INITIAL AND CONTINUING INTENSIVE CARE SERVICES**

99477 Initial hospital care, per day, for the evaluation and management of the neonate, 28 days of age or less, who requires intensive observation, frequent interventions, and other intensive care services

99478 Subsequent intensive care, per day, for the evaluation and management of the recovering very low birth weight infant (present body weight less than 1500 grams) (Neonatologist or Pediatric Critical Care Specialist only)

99479 Subsequent intensive care, per day, for the evaluation and management of the recovering low birth weight infant (present body weight of 1500-2500 grams) (Neonatologist or Pediatric Critical Care Specialist only)

99480 Subsequent intensive care, per day, for the evaluation and management of the recovering infant (present body weight of 2501-5000 grams)

**LABORATORY SERVICES PERFORMED IN A PHYSICIAN'S OFFICE**

Certain laboratory procedures specified below are eligible for direct physician reimbursement when performed in the office of the physician in the course of treatment of his own patients. The physician must be registered with the federal Health Care Finance Administration (HCFA) to perform laboratory procedures as required by the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).
Procedures other than those specified must be performed by a laboratory, holding a valid clinical laboratory permit in the commensurate laboratory, specialty issued by the New York State Department of Health or, where appropriate, the New York City Department of Health. Procedure code 85025 complete blood count (CBC) may not be billed with its component codes 85007, 85013, 85018, 85041 or 85048.

81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy
81001 automated, with microscopy
81002 non-automated, without microscopy
81003 automated, without microscopy
81015 Urinalysis; microscopic only
81025 Urine pregnancy test, by visual color comparison methods
83655 Lead
85007 Blood count; blood smear, microscopic examination with manual differential WBC count (includes RBC morphology and platelet estimation)
85013 spun microhematocrit
85018 hemoglobin (Hgb)
85025 complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count
85041 red blood cell (RBC) automated
85048 leukocyte (WBC), automated
85651 Sedimentation rate, erythrocyte; non-automated
85652 automated
86701 Antibody; HIV-1
86703 HIV-1 and HIV-2, single result
87081 Culture, presumptive, pathogenic organisms, screening only (throat only)
87651 Streptococcus, group A, amplified probe technique
87806 HIV-1 antigen(s), with HIV1 and HIV-2 antibodies
87880 Infectious agent detection by immunoassay with direct optical observation; streptococcus, group A (throat only)
87426 Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]).
87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

NOTE: Medicare reimburses for these services at 100 percent. No Medicare co insurance payments may be billed for the above listed procedure codes.

DRUGS AND DRUG ADMINISTRATION

IMMUNIZATIONS
If a significantly separately identifiable Evaluation and Management service (eg, office service, preventative medicine services) is performed, the appropriate E/M code should be reported in addition to the vaccine and toxoid codes.

Immunizations are usually given in conjunction with a medical service. When an immunization is the only service performed, a minimal service may be listed in addition to the injection. Immunization procedures include reimbursement for the supply of materials and administration. Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

IMMUNE GLOBULINS
Immune globulin products listed here include broad-spectrum and anti-infective immune globulins, antitoxins, and various isoantibodies.

90291  Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use
90371  Hepatitis B immune globulin (HB Ig), human, for intramuscular use
90375  Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use
90376  Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use
90377  Rabies immune globulin, heat- and solvent/detergent-treated (RIg-HT S/D), human, for intramuscular and/or subcutaneous use
90378  Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each
90384  Rho(D) immune globulin (Rhlg), human, full-dose, for intramuscular use
90385  Rho(D) immune globulin (Rhlg), human, mini-dose, for intramuscular use
90386  Rho(D) immune globulin (RhlgIV), human, for intravenous use
90389  Tetanus immune globulin (TIg), human, for intramuscular use
90393  Vaccinia immune globulin, human, for intramuscular use
90396  Varicella-zoster immune globulin, human, for intramuscular use
90399  Unlisted immune globulin
**IMMUNIZATION ADMINISTRATION for VACCINES/TOXOIDS**

90460  Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered

90471  Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid

90472  each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

90473  Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)

90474  each additional vaccine (single or combination vaccine/toxoid) (list separately in addition to code for primary procedure)

**VACCINES, TOXOIDS**

For dates of service on or after 7/1/03 when immunization materials are supplied by the Vaccine for Children Program (VFC), bill using the procedure code that represents the immunization(s) administered and append modifier –SL State Supplied Vaccine to receive the VFC administration fee. See Modifier Section for further information.

For administration of vaccines supplied by VFC, including influenza and pneumococcal administration, providers are required to bill vaccine administration code 90460. Providers must bill the specific vaccine code with the “SL” modifier on the claim (payment for “SL” will be $0.00). If an administration code is billed without a vaccine code with “SL”, the claim will be denied. For reimbursement purposes, the administration of the components of a combination vaccine will continue to be considered as one vaccine administration. More than one vaccine administration is reimbursable under 90460 on a single date of service.

NCCI editing will allow payment for an office visit (E&M and preventative medicine codes) and a vaccine administration service billed on the same day of service if the office visit meets a higher complexity level of care than a service represented by CPT code 99211. For payment to be made for both services, the office visit must be billed with Modifier-25. Providers must maintain documentation in the medical record to support use of an appropriate modifier.

**NOTE:** The maximum fees for immunization injection codes are adjusted periodically by the State to reflect the current acquisition cost of the antigen. For immunizations not supplied by the VFC Program insert acquisition cost per dose in amount charged field on claim form. For codes listed **BR/Report required**, also attach itemized invoice to claim form.

To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported with modifier -SL. Multiple codes for a particular vaccine are provided in CPT when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.

Separate codes are available for combination vaccines (eg, DTP-Hib, DtaP-Hib, HepB-Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the Unlisted procedure code should be reported, until a new code becomes available.

90585  Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use

90586  Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use

90632  Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
<table>
<thead>
<tr>
<th>Code</th>
<th>Vaccine Description</th>
<th>Dosage</th>
<th>Schedule</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>90633</td>
<td>Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90636</td>
<td>Hepatitis A and hepatitis B vaccine (HEPA– HEPB), adult dose, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90647</td>
<td>Haemophilus influenzae type B vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90648</td>
<td>Haemophilus influenza type B vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90649</td>
<td>Human Papillomavirus vaccine, types 6, 11, 16, 18 quadrivalent (4vHPV), 3 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90650</td>
<td>Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90651</td>
<td>Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonvalent (9vHPV), 2 or 3 dose schedule, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90653</td>
<td>Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90654</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90655</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90656</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, preservative free,.05 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90657</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90658</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90660</td>
<td>Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use</td>
<td></td>
<td></td>
<td>intranasal</td>
</tr>
<tr>
<td>90661</td>
<td>Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90670</td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90671</td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90672</td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90673</td>
<td>Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90662</td>
<td>Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90670</td>
<td>Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90671</td>
<td>Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90677</td>
<td>Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90675</td>
<td>Rabies vaccine, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90676</td>
<td>Rabies vaccine, for intradermal use</td>
<td></td>
<td></td>
<td>intradermal</td>
</tr>
<tr>
<td>90680</td>
<td>Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use</td>
<td></td>
<td></td>
<td>oral</td>
</tr>
<tr>
<td>90681</td>
<td>Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use</td>
<td></td>
<td></td>
<td>oral</td>
</tr>
<tr>
<td>90682</td>
<td>Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
<tr>
<td>90685</td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use</td>
<td></td>
<td></td>
<td>intramuscular</td>
</tr>
</tbody>
</table>
90686  Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90687  Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688  Influenza virus vaccine, quadrivalent (IIV4) split virus, 0.5 mL dosage, for intramuscular use
90694  Influenza virus vaccine, quadrivalent, (allIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use.
90690  Typhoid vaccine, live, oral
90691  Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use
90696  Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use
90698  Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type B, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use
90700  Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
90702  Diphtheria and tetanus toxoids absorbed (DT) when administered to individuals younger than 7 years, for intramuscular use
90707  Measles, Mumps and Rubella virus vaccine (MMR), live, for subcutaneous use
90710  Measles, Mumps, Rubella, and Varicella vaccine (MMRV), live, for subcutaneous use
90713  Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use
90714  Tetanus and diphtheria toxoids absorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use
90715  Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use
90716  Varicella virus vaccine (VAR), live, for subcutaneous use
90717  Yellow fever vaccine, live, for subcutaneous use
90723  Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, inactivated (DTaP-HepB-IPV), for intramuscular use
90732  Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
90644  Meningococcal conjugate vaccine, serogroups C&Y and Haemophilus influenza type b vaccine (Hib-MedCY), 4 dose schedule, when administered to children 6 weeks – 18 months of age, for intramuscular use
90733  Meningococcal polysaccharide vaccine, serogroups A,C,Y,W-135,quadrivalent (MPSV4),for subcutaneous use
90734  Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 quadrivalent (MCV4 or MenACWY), for intramuscular use
90620  Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B,(MenB-4C) 2 dose schedule, for intramuscular use
90621  Meningococcal recombinant lipoprotein vaccine, Serogroup B,(MenB-FHpb), 2 or 3 dose schedule, for intramuscular use
90736  Zoster (shingles) vaccine (HZV), live, for subcutaneous injection
90750  Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use
90738  Japanese encephalitis virus vaccine, inactivated, for intramuscular use
90739  Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use
Physician – Procedure Codes, Section 2 - Medicine, Drugs and Drug Administration

90740  Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
90743  Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
90744  Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule for intramuscular use
90746  Hepatitis B vaccine (HepB), adult dose, 3 dose schedule, for intramuscular use
90749  Unlisted vaccine/toxoid

90747  Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use
90748  Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use

DRUGS ADMINISTERED OTHER THAN ORAL METHOD
The following list of drugs can be injected either subcutaneous, intramuscular or intravenous. A listing of chemotherapy drugs can be found in the Chemotherapy Drug Section.

New York State Medicaid's policy for coverage of drugs administered by subcutaneous, intramuscular or intravenous methods in the physician's office is as follows: These drugs are covered for FDA approved indications and those recognized off-label indications listed in the drug compendia (the American Hospital Formulary Service Drug Information, United States Pharmacopeia-Drug Information, the DrugDex information system or Facts and Comparisons). In the absence of such a recognized indication, an approved Institutional Review Board (IRB) protocol would be required with documentation maintained in the patient's clinical file. Drugs are not covered for investigational or experimental use.

Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient.

For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice.

New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

NOTE: The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert acquisition cost per dose in amount charged field on claim form. For codes listed as BR in the Fee Schedule, also attach an itemized invoice to claim form.

THERAPEUTIC INJECTIONS (Maximum fee includes cost of materials)

J0121  Omadacycline, 1 mg
J0129  Abatacept, 10 mg
   (Administered under direct physician supervision, not for self-administration)
J0131  Acetaminophen, 10 mg
J0133  Acyclovir, 5 mg
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0135</td>
<td>Adalimumab, 20 mg</td>
</tr>
<tr>
<td>J0153</td>
<td>Adenosine, 1 mg</td>
</tr>
<tr>
<td></td>
<td>(Not to be used to report any adenosine phosphate compounds, instead use unlisted code)</td>
</tr>
<tr>
<td>J0171</td>
<td>Adrenalin, epinephrine, 0.1 mg</td>
</tr>
<tr>
<td>J0178</td>
<td>Aflibercept, 1 mg</td>
</tr>
<tr>
<td>J0179</td>
<td>Brolucizumab-dbll, 1 mg</td>
</tr>
<tr>
<td>J0180</td>
<td>Agalsidase beta, 1 mg</td>
</tr>
<tr>
<td>J0185</td>
<td>Aprepitant, 1 mg</td>
</tr>
<tr>
<td>J0202</td>
<td>Alemtuzumab, 1 mg</td>
</tr>
<tr>
<td>J0205</td>
<td>Alglucerase, per 10 units</td>
</tr>
<tr>
<td>J0207</td>
<td>Amifostine, 500 mg</td>
</tr>
<tr>
<td>J0210</td>
<td>Methylidopate HCl, up to 250 mg</td>
</tr>
<tr>
<td>J0215</td>
<td>Alefacept, 0.5 mg</td>
</tr>
<tr>
<td>J0219</td>
<td>Avalglucosidase alfa-ngpt, 4 mg</td>
</tr>
<tr>
<td>J0220</td>
<td>Alglucosidase alfa, not otherwise specified, 10 mg</td>
</tr>
<tr>
<td>J0221</td>
<td>Alglucosidase alfa, (lumizyme), 10 mg</td>
</tr>
<tr>
<td>J0222</td>
<td>Patisiran, 0.1 mg</td>
</tr>
<tr>
<td>J0223</td>
<td>Givosiran, 0.5 mg</td>
</tr>
<tr>
<td>J0224</td>
<td>Lumasiran, 0.5 mg</td>
</tr>
<tr>
<td>J0256</td>
<td>Alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg</td>
</tr>
<tr>
<td>J0257</td>
<td>Alpha 1 proteinase inhibitor (human), (glassia), 10 mg</td>
</tr>
<tr>
<td>J0270</td>
<td>Alprostadil, per 1.25 mcg</td>
</tr>
<tr>
<td></td>
<td>(Administered under direct physician supervision, not for self-administration)</td>
</tr>
<tr>
<td>J0275</td>
<td>Alprostadil urethral suppository</td>
</tr>
<tr>
<td></td>
<td>(Administered under direct physician supervision, not for self-administration)</td>
</tr>
<tr>
<td>J0278</td>
<td>Amikacin sulfate, 100 mg</td>
</tr>
<tr>
<td>J0280</td>
<td>Aminophylline, up to 250 mg</td>
</tr>
<tr>
<td>J0285</td>
<td>Amphotericin B, 50 mg</td>
</tr>
<tr>
<td>J0287</td>
<td>Amphotericin B lipid complex, 10 mg</td>
</tr>
<tr>
<td>J0288</td>
<td>Amphotericin B cholesteryl sulfate complex, 10 mg</td>
</tr>
<tr>
<td>J0289</td>
<td>Amphotericin B liposome, 10 mg</td>
</tr>
<tr>
<td>J0290</td>
<td>Ampicillin sodium, 500 mg</td>
</tr>
<tr>
<td>J0291</td>
<td>Plazomicin, 5 mg</td>
</tr>
<tr>
<td>J0295</td>
<td>Ampicillin sodium/sulbactam sodium, per 1.5 g</td>
</tr>
<tr>
<td>J0300</td>
<td>Amobarbital, up to 125 mg</td>
</tr>
<tr>
<td>J0348</td>
<td>Anidulafungin, 1 mg</td>
</tr>
<tr>
<td>J0360</td>
<td>Hydralazine HCl, up to 20 mg</td>
</tr>
<tr>
<td>J0364</td>
<td>Apomorphine hydrochloride, 1 mg</td>
</tr>
<tr>
<td>J0380</td>
<td>Metaraminol bitartrate, per 10 mg</td>
</tr>
<tr>
<td>J0390</td>
<td>Chloroquine HCl, up to 250 mg</td>
</tr>
<tr>
<td>J0400</td>
<td>Aripiprazole, intramuscular, 0.25 mg</td>
</tr>
<tr>
<td>J0401</td>
<td>Aripiprazole, extended release, intramuscular, 1 mg</td>
</tr>
<tr>
<td>J0456</td>
<td>Azithromycin, 500 mg</td>
</tr>
<tr>
<td>J0461</td>
<td>Atropine sulfate, 0.01 mg</td>
</tr>
<tr>
<td>J0470</td>
<td>Dimercaprol, per 100 mg</td>
</tr>
<tr>
<td>Code</td>
<td>Medication</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>J0475</td>
<td>Baclofen, 10 mg</td>
</tr>
<tr>
<td>J0485</td>
<td>Belatacept, 1 mg</td>
</tr>
<tr>
<td>J0490</td>
<td>Belimumab, 10 mg</td>
</tr>
<tr>
<td>J0491</td>
<td>Anifrolumab-fnia, 1 mg</td>
</tr>
<tr>
<td>J0500</td>
<td>Dicyclomine HCl, up to 20 mg</td>
</tr>
<tr>
<td>J0515</td>
<td>Benztropine mesylate, per 1 mg</td>
</tr>
<tr>
<td>J0517</td>
<td>Benralizumab, 1 mg</td>
</tr>
<tr>
<td>J0520</td>
<td>Bethanechol chloride, Mytonachol or Urecholine, up to 5 mg</td>
</tr>
<tr>
<td>J0558</td>
<td>Penicillin G benzathine and penicillin G procaine, 100,000 units</td>
</tr>
<tr>
<td>J0561</td>
<td>Penicillin G benzathine, 100,000 units</td>
</tr>
<tr>
<td>J0565</td>
<td>Bezlotoxumab, 10 mg</td>
</tr>
<tr>
<td>J0567</td>
<td>Cerliponase alfa, 1 mg</td>
</tr>
<tr>
<td>J0570</td>
<td>Buprenorphine implant, 74.2 mg</td>
</tr>
<tr>
<td>J0584</td>
<td>Burosumab-twza, 1mg</td>
</tr>
<tr>
<td>J0585</td>
<td>Onabotulinumtoxina A, 1 unit</td>
</tr>
<tr>
<td>J0586</td>
<td>Abobotulinumtoxina A, 5 units</td>
</tr>
<tr>
<td>J0587</td>
<td>Rimabotulinumtoxin B, 100 units</td>
</tr>
<tr>
<td>J0588</td>
<td>Incobotulinumtoxin A, 1 unit</td>
</tr>
<tr>
<td>J0593</td>
<td>Lanadelumab-flyo, 1 mg</td>
</tr>
<tr>
<td>J0594</td>
<td>Busulfan, 1 mg</td>
</tr>
<tr>
<td>J0598</td>
<td>C1 esterase inhibitor (human), cinryze, 10 units</td>
</tr>
<tr>
<td>J0599</td>
<td>C1 esterase inhibitor (human), (haegarda), 10 units</td>
</tr>
<tr>
<td>J0600</td>
<td>Edetate calcium disodium, up to 1000 mg</td>
</tr>
<tr>
<td>J0610</td>
<td>Calcium gluconate, per 10 ml</td>
</tr>
<tr>
<td>J0620</td>
<td>Calcium glycerophosphate and calcium lactate, per 10 ml</td>
</tr>
<tr>
<td>J0630</td>
<td>Calcitonin salmon, up to 400 units</td>
</tr>
<tr>
<td>J0636</td>
<td>Calcitriol, 0.1 mcg</td>
</tr>
<tr>
<td>J0637</td>
<td>Caspofungin acetate, 5 mg</td>
</tr>
<tr>
<td>J0638</td>
<td>Canakinumab, 1 mg</td>
</tr>
<tr>
<td>J0640</td>
<td>Leucovorin calcium, per 50 mg</td>
</tr>
<tr>
<td>J0641</td>
<td>Levoleucovorin NOS, 0.5 mg</td>
</tr>
<tr>
<td>J0642</td>
<td>Levoleucovorin (khapzory), 0.5 mg</td>
</tr>
<tr>
<td>J0690</td>
<td>Cefezolin sodium, 500 mg</td>
</tr>
<tr>
<td>J0692</td>
<td>Cefepime hydrochloride, 500 mg</td>
</tr>
<tr>
<td>J0694</td>
<td>Cefoxitin sodium, 1 gm</td>
</tr>
<tr>
<td>J0696</td>
<td>Ceftriaxone sodium, per 250 mg</td>
</tr>
<tr>
<td>J0697</td>
<td>Sterile cefuroxime sodium, per 750 mg</td>
</tr>
<tr>
<td>J0698</td>
<td>Cefotaxime sodium, per 1 gm</td>
</tr>
<tr>
<td>J0702</td>
<td>Betamethasone acetate 3 mg and betamethasone sodium phosphate 3mg</td>
</tr>
<tr>
<td>J0710</td>
<td>Cephapirin sodium, up to 1 gm</td>
</tr>
<tr>
<td>J0712</td>
<td>Ceftaroline fosamil, 10 mg</td>
</tr>
<tr>
<td>J0713</td>
<td>Cefazidime, per 500 mg</td>
</tr>
<tr>
<td>J0715</td>
<td>Ceftizoxime sodium, per 500 mg</td>
</tr>
<tr>
<td>J0717</td>
<td>Certolizumab pegol, 1 mg</td>
</tr>
</tbody>
</table>

(Administered under direct physician supervision, not for self-administration)
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0720</td>
<td>Chloramphenicol sodium succinate, up to 1 gm</td>
</tr>
<tr>
<td>J0725</td>
<td>Chorionic gonadotropin, per 1,000 USP units</td>
</tr>
<tr>
<td>J0739</td>
<td>Cabotegravir 1 mg</td>
</tr>
<tr>
<td>J0740</td>
<td>Cidofovir, 375 mg</td>
</tr>
<tr>
<td>J0741</td>
<td>Cabotegravir and rilpivirine, 2mg/3mg</td>
</tr>
<tr>
<td>J0743</td>
<td>Cilastatin sodium; imipenem, per 250 mg</td>
</tr>
<tr>
<td>J0744</td>
<td>Ciprofloxacin for intravenous infusion, 200 mg</td>
</tr>
<tr>
<td>J0745</td>
<td>Codeine phosphate, per 30 mg</td>
</tr>
<tr>
<td>J0770</td>
<td>Colistimethate sodium, up to 150 mg</td>
</tr>
<tr>
<td>J0775</td>
<td>Collagenase, clostridium histolyticum, 0.01 mg</td>
</tr>
<tr>
<td>J0780</td>
<td>Prochlorperazine, up to 10 mg</td>
</tr>
<tr>
<td>J0791</td>
<td>Crizanlizumab-tmca, 5mg</td>
</tr>
<tr>
<td>J0795</td>
<td>Corticorelin ovine triflate, 1 mcg</td>
</tr>
<tr>
<td>J0834</td>
<td>Cosyntropin 0.25 mg</td>
</tr>
<tr>
<td>J0875</td>
<td>Dalbavancin, 5 mg</td>
</tr>
<tr>
<td>J0881</td>
<td>Darbepoetin alfa, 1 mcg (Non-ESRD use)</td>
</tr>
<tr>
<td>J0885</td>
<td>Epoetin alfa, (Non-ESRD use), 1000 units</td>
</tr>
<tr>
<td>J0888</td>
<td>Epoetin beta, 1 mcg (Non-ESRD use)</td>
</tr>
<tr>
<td>J0894</td>
<td>Decitabine, 1 mg</td>
</tr>
<tr>
<td>J0895</td>
<td>Deferoxamine mesylate, 500 mg</td>
</tr>
<tr>
<td>J0896</td>
<td>Luspatercept-aamt, 0.25 mg</td>
</tr>
<tr>
<td>J0897</td>
<td>Denosumab, 1mg</td>
</tr>
<tr>
<td>J0945</td>
<td>Brompheniramine maleate, per 10 mg</td>
</tr>
<tr>
<td>J1000</td>
<td>Depo-estradiol cypionate, up to 5 mg</td>
</tr>
<tr>
<td>J1020</td>
<td>Methylprednisolone acetate, 20 mg</td>
</tr>
<tr>
<td>J1030</td>
<td>Methylprednisolone acetate, 40 mg</td>
</tr>
<tr>
<td>J1040</td>
<td>Methylprednisolone acetate, 80 mg</td>
</tr>
<tr>
<td>J1050</td>
<td>Medroxyprogesterone acetate, 1 mg</td>
</tr>
<tr>
<td>J1071</td>
<td>Testosterone cypionate, 1 mg</td>
</tr>
<tr>
<td>J1094</td>
<td>Dexamethasone acetate, 1 mg</td>
</tr>
<tr>
<td>J1096</td>
<td>Dexamethasone, lacrimal ophthalmic insert, 0.1 mg</td>
</tr>
<tr>
<td>J1097</td>
<td>Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml, ophthalmic irrigation solution, 1 ml</td>
</tr>
<tr>
<td>J1100</td>
<td>Dexamethasone sodium phosphate, 1 mg</td>
</tr>
<tr>
<td>J1110</td>
<td>Dihydroergotamine mesylate, per 1 mg</td>
</tr>
<tr>
<td>J1120</td>
<td>Acetazolamide sodium, up to 500 mg</td>
</tr>
<tr>
<td>J1160</td>
<td>Digoxin, up to 0.5 mg</td>
</tr>
<tr>
<td>J1165</td>
<td>Phenytoin sodium, per 50 mg</td>
</tr>
<tr>
<td>J1170</td>
<td>Hydromorphone, up to 4 mg</td>
</tr>
<tr>
<td>J1180</td>
<td>Dyphylline, up to 500 mg</td>
</tr>
<tr>
<td>J1190</td>
<td>Dexrazoxane HCl, per 250 mg</td>
</tr>
<tr>
<td>J1200</td>
<td>Diphenhydramine HCL, up to 50 mg</td>
</tr>
<tr>
<td>J1201</td>
<td>Cetirizine hydrochloride, 0.5 mg</td>
</tr>
<tr>
<td>J1205</td>
<td>Chlorothiazide sodium, per 500 mg</td>
</tr>
<tr>
<td>J1212</td>
<td>DMSO, dimethyl sulfoxide, 50%, 50 ml</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>J1230</td>
<td>Methadone HCl, up to 10 mg</td>
</tr>
<tr>
<td>J1240</td>
<td>Dimenhydrinate, up to 50 mg</td>
</tr>
<tr>
<td>J1260</td>
<td>Dolasetron mesylate, 10 mg</td>
</tr>
<tr>
<td>J1267</td>
<td>Doripenem, 10 mg</td>
</tr>
<tr>
<td>J1300</td>
<td>Eculizumab, 10 mg</td>
</tr>
<tr>
<td>J1301</td>
<td>Edaravone, 1 mg</td>
</tr>
<tr>
<td>J1303</td>
<td>Ravulizumab-cwvz, 10 mg</td>
</tr>
<tr>
<td>J1305</td>
<td>Evinacumab-dgnb, 5mg</td>
</tr>
<tr>
<td>J1306</td>
<td>Inclisiran, 1 mg</td>
</tr>
<tr>
<td>J1320</td>
<td>Amitriptyline HCl, up to 20 mg</td>
</tr>
<tr>
<td>J1322</td>
<td>Elosulfase alfa, 1mg</td>
</tr>
<tr>
<td>J1330</td>
<td>Ergonovine maleate, up to 0.2 mg</td>
</tr>
<tr>
<td>J1335</td>
<td>Ertapenem sodium, 500 mg</td>
</tr>
<tr>
<td>J1364</td>
<td>Erythromycin lactobionate, per 500 mg</td>
</tr>
<tr>
<td>J1380</td>
<td>Estradiol valerate, up to 10 mg</td>
</tr>
<tr>
<td>J1410</td>
<td>Estrogen conjugated, per 25 mg</td>
</tr>
<tr>
<td>J1426</td>
<td>Casimersen, 10 mg</td>
</tr>
<tr>
<td>J1427</td>
<td>Viltolarsen, 10 mg</td>
</tr>
<tr>
<td>J1428</td>
<td>Eteplirsen, 10 mg</td>
</tr>
<tr>
<td>J1429</td>
<td>Golodirsen, 10 mg</td>
</tr>
<tr>
<td>J1435</td>
<td>Estrone, per 1 mg</td>
</tr>
<tr>
<td>J1436</td>
<td>Etidronate disodium, per 300 mg</td>
</tr>
<tr>
<td>J1437</td>
<td>Ferric derisomaltose, 10 mg</td>
</tr>
<tr>
<td>J1438</td>
<td>Etaercept, 25 mg</td>
</tr>
<tr>
<td></td>
<td>(Administered under direct physician supervision, not self-administered)</td>
</tr>
<tr>
<td>J1439</td>
<td>Ferric Carboxymaltose, 1 mg</td>
</tr>
<tr>
<td>J1442</td>
<td>Filgrastim (G-CSF), excludes biosimilars, 1 microgram</td>
</tr>
<tr>
<td>J1447</td>
<td>Tbo-Filgrastim, 1 microgram</td>
</tr>
<tr>
<td>J1448</td>
<td>Trilaciclib, 1mg</td>
</tr>
<tr>
<td>J1450</td>
<td>Fluconazole, 200 mg</td>
</tr>
<tr>
<td>J1452</td>
<td>Fomivirsen sodium, intraocular, 1.65 mg</td>
</tr>
<tr>
<td>J1453</td>
<td>Fosaprepitant Injection, 1 mg</td>
</tr>
<tr>
<td>J1454</td>
<td>Fosnetupitant 235 mg and palonestron 0.25 mg</td>
</tr>
<tr>
<td>J1455</td>
<td>Foscarnet sodium, per 1000 mg</td>
</tr>
<tr>
<td>J1458</td>
<td>Galsulfase, 1 mg</td>
</tr>
<tr>
<td>J1459</td>
<td>Immune globulin (Privigen), intravenous, non lyophilized (e.g. liquid), 500 mg</td>
</tr>
<tr>
<td>J1460</td>
<td>Gamma globulin, intramuscular, 1 cc</td>
</tr>
<tr>
<td>J1551</td>
<td>Immune globulin (cutaquig), 100 mg</td>
</tr>
<tr>
<td>J1554</td>
<td>Immune globulin (Asceniv), 500 mg</td>
</tr>
<tr>
<td>J1555</td>
<td>Immune globulin (Cuvitru), 100 mg</td>
</tr>
<tr>
<td>J1556</td>
<td>Immune globulin (Bivigam), 500 mg</td>
</tr>
<tr>
<td>J1557</td>
<td>Immune globulin, (gammmaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg</td>
</tr>
<tr>
<td>J1558</td>
<td>Immune globulin (xembify), 100 mg</td>
</tr>
<tr>
<td>J1560</td>
<td>Gamma globulin, intramuscular, over 10 cc</td>
</tr>
<tr>
<td>J1561</td>
<td>Immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g. liquid), 500 mg</td>
</tr>
</tbody>
</table>
J1562 Immune globulin (Vivaglobin), 100 mg
J1566 Immune globulin, intravenous, lyophilized (e.g. powder), not otherwise specified, 500 mg
J1568 Immune globulin, (Octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg
J1569 Immune globulin, (Gammagard Liquid), non-lyophilized, (e.g. liquid), 500 mg
J1570 Ganciclovir sodium, 500 mg
J1572 Immune globulin, (flebogamma/flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), 500 mg
J1573 Hepatitis B immune globulin (HepaGam B), intravenous, 0.5 ml
J1575 Immune Globulin/Hyaluronidase (HYQVIA), 100 mg
J1580 Garamycin, gentamicin, up to 80 mg
J1595 Glatiramer acetate, 20 mg
J1599 Immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified, 500 mg
J1600 Gold sodium thiomalate, up to 50 mg
J1602 Golimumab, 1mg, for intravenous use
J1610 Glucagon HCl, per 1 mg
J1620 Gonadorelin HCl, per 100 mcg
J1626 Granisetron HCl, 100 mcg
J1627 Granisetron, extended release, 0.1 mg
J1628 Guselkumab, 1 mg
J1630 Haloperidol, up to 5 mg
J1631 Haloperidol decanoate, per 50 mg
J1642 Heparin sodium, (heparin lock flush), per 10 units
J1644 Heparin sodium, per 1000 units
J1645 Dalteparin sodium, per 2500 IU
J1652 Fondaparinux sodium, 0.5 mg
J1655 Tinzaparin sodium, 1000 IU
J1710 Hydrocortisone sodium phosphate, up to 50 mg
J1720 Hydrocortisone sodium succinate, up to 100 mg
J1726 Hydroxyprogesterone caproate,(makena), 10 mg
J1729 Hydroxyprogesterone caproate, not otherwise specified, 10 mg
J1730 Diazoxide, up to 300 mg
J1738 Meloxicam, 1mg
J1740 Ibuprofen, 100 mg
J1743 Idursulfase, 1 mg
J1745 Infliximab, 10 mg
J1746 Ibalizumab-uiyk, 10 mg
J1750 Iron dextran, 50mg
J1756 Iron sucrose, 1 mg
J1786 Imiglucerase, 10 units
J1790 Droperidol, up to 5 mg
J1800 Propranolol HCl, up to 1 mg
J1815 Insulin, per 5 units
J1817 Insulin (i.e., insulin pump) per 50 units
(Administered under direct physician supervision, not for self-administration)
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1823</td>
<td>Inebilizumab-cdon, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J1826</td>
<td>Interferon beta-1a, 30 mcg</td>
<td></td>
</tr>
<tr>
<td>J1830</td>
<td>Interferon beta-1b, 0.25 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Administered under direct physician supervision, not for self-administration)</td>
<td></td>
</tr>
<tr>
<td>J1840</td>
<td>Kanamycin sulfate, up to 500 mg</td>
<td></td>
</tr>
<tr>
<td>J1850</td>
<td>Kanamycin sulfate, up to 75 mg</td>
<td></td>
</tr>
<tr>
<td>J1885</td>
<td>Ketorolac tromethamine, per 15 mg</td>
<td></td>
</tr>
<tr>
<td>J1890</td>
<td>Cephalothin sodium, up to 1 gm</td>
<td></td>
</tr>
<tr>
<td>J1930</td>
<td>Lanreotide, 1mg</td>
<td></td>
</tr>
<tr>
<td>J1931</td>
<td>Laronidase, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J1940</td>
<td>Furosemide, up to 20 mg</td>
<td></td>
</tr>
<tr>
<td>J1943</td>
<td>Aripiprazole lauroxil (Initio), 1 mg</td>
<td></td>
</tr>
<tr>
<td>J1944</td>
<td>Aripiprazole lauroxil, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J1950</td>
<td>Leuprolide acetate (for depot suspension), per 3.75 mg</td>
<td></td>
</tr>
<tr>
<td>J1951</td>
<td>Leuprolide acetate for depot suspension (fensolvi), per .25 mg</td>
<td></td>
</tr>
<tr>
<td>J1952</td>
<td>Leuprolide injectable, camcevi, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J1955</td>
<td>Levocarnitine, per 1 gm</td>
<td></td>
</tr>
<tr>
<td>J1956</td>
<td>Levofloxacin, 250 mg</td>
<td></td>
</tr>
<tr>
<td>J1960</td>
<td>Levorphanol tartrate, up to 2 mg</td>
<td></td>
</tr>
<tr>
<td>J1980</td>
<td>Hyoscyamine sulfate, up to 0.25 mg</td>
<td></td>
</tr>
<tr>
<td>J1990</td>
<td>Chlordiazepoxide HCl, up to 100 mg</td>
<td></td>
</tr>
<tr>
<td>J2001</td>
<td>Lidocaine HCl for intravenous infusion, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2010</td>
<td>Lincomycin HCl, up to 300 mg</td>
<td></td>
</tr>
<tr>
<td>J2020</td>
<td>Linezolid, 200 mg</td>
<td></td>
</tr>
<tr>
<td>J2060</td>
<td>Lorazepam, 2 mg</td>
<td></td>
</tr>
<tr>
<td>J2150</td>
<td>Mannitol, 25% in 50 ml</td>
<td></td>
</tr>
<tr>
<td>J2175</td>
<td>Meperidine HCl, per 100 mg</td>
<td></td>
</tr>
<tr>
<td>J2180</td>
<td>Meperidine and promethazine HCL, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2182</td>
<td>Mepolizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2185</td>
<td>Meropenem, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J2210</td>
<td>Methylergonovine maleate, up to 0.2 mg</td>
<td></td>
</tr>
<tr>
<td>J2248</td>
<td>Micafungin sodium, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2260</td>
<td>Milrinone lactate, per 5 mg</td>
<td></td>
</tr>
<tr>
<td>J2270</td>
<td>Morphine sulfate, up to 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2274</td>
<td>Morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2278</td>
<td>Ziconotide, 1 mcg</td>
<td></td>
</tr>
<tr>
<td>J2280</td>
<td>Moxifloxacin, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J2310</td>
<td>Naloxone hydrochloride, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2320</td>
<td>Nandrolone decanoate, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2323</td>
<td>Natalizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2326</td>
<td>Nusinersen, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J2350</td>
<td>Ocrelizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2353</td>
<td>Octreotide, depot form for intramuscular injection, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2355</td>
<td>Oprelvekin, 5 mg</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>J2356</td>
<td>Tezepelumab-ekko, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2357</td>
<td>Omalizumab, 5 mg</td>
<td></td>
</tr>
<tr>
<td>J2358</td>
<td>Olanzapine, long-acting, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2360</td>
<td>Orphenadrine citrate, up to 60 mg</td>
<td></td>
</tr>
<tr>
<td>J2370</td>
<td>Phenylephrine HCl, up to 1 ml</td>
<td></td>
</tr>
<tr>
<td>J2405</td>
<td>Ondansetron HCl, per 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2406</td>
<td>Oritavancin (kimyrsa), 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2407</td>
<td>Oritavancin, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2410</td>
<td>Oxymorphone HCl, up to 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2425</td>
<td>Palifermin, 50 mcg</td>
<td></td>
</tr>
<tr>
<td>J2426</td>
<td>Paliperidone palmitate extended release, 1mg</td>
<td></td>
</tr>
<tr>
<td>J2430</td>
<td>Pamidronate disodium, per 30 mg</td>
<td></td>
</tr>
<tr>
<td>J2440</td>
<td>Papaverine HCl, up to 60 mg</td>
<td></td>
</tr>
<tr>
<td>J2460</td>
<td>Oxytetracycline HCl, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2469</td>
<td>Palonosetron HCl, 25 mcg</td>
<td></td>
</tr>
<tr>
<td>J2502</td>
<td>Pasireotide long acting, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2503</td>
<td>Pegaptanib sodium, 0.3 mg</td>
<td></td>
</tr>
<tr>
<td>J2504</td>
<td>Pegademase bovine, 25 IU</td>
<td></td>
</tr>
<tr>
<td>J2506</td>
<td>Pegfilgrastim, excludes biosimilar, 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2507</td>
<td>Pegloticase, 1mg</td>
<td></td>
</tr>
<tr>
<td>J2510</td>
<td>Penicillin G procaine, aqueous, up to 600,000 units</td>
<td></td>
</tr>
<tr>
<td>J2513</td>
<td>Pentastarch, 10% solution, 100 ml</td>
<td></td>
</tr>
<tr>
<td>J2515</td>
<td>Pentobarbital sodium, per 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2540</td>
<td>Penicillin G potassium, up to 600,000 units</td>
<td></td>
</tr>
<tr>
<td>J2543</td>
<td>Piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)</td>
<td></td>
</tr>
<tr>
<td>J2545</td>
<td>Pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg</td>
<td></td>
</tr>
<tr>
<td>J2550</td>
<td>Promethazine HCl, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2560</td>
<td>Phenobarbital sodium, up to 120 mg</td>
<td></td>
</tr>
<tr>
<td>J2562</td>
<td>Plerixafor, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2590</td>
<td>Oxytocin, up to 10 units</td>
<td></td>
</tr>
<tr>
<td>J2597</td>
<td>Desmopressin acetate, per 1 mcg</td>
<td></td>
</tr>
<tr>
<td>J2650</td>
<td>Prednisolone acetate, up to 1 ml</td>
<td></td>
</tr>
<tr>
<td>J2670</td>
<td>Tolazoline HCl, up to 25 mg</td>
<td></td>
</tr>
<tr>
<td>J2675</td>
<td>Progesterone, per 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2680</td>
<td>Fluphenazine decanoate, up to 25 mg</td>
<td></td>
</tr>
<tr>
<td>J2690</td>
<td>Procainamide HCl, up to 1 gm</td>
<td></td>
</tr>
<tr>
<td>J2700</td>
<td>Oxacillin sodium, up to 250 mg</td>
<td></td>
</tr>
<tr>
<td>J2710</td>
<td>Neostigmine methylsulfate, up to 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2720</td>
<td>Protamine sulfate, per 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2730</td>
<td>Pralidoxime chloride, up to 1 gm</td>
<td></td>
</tr>
<tr>
<td>J2760</td>
<td>Phentolamine mesylate, up to 5 mg</td>
<td></td>
</tr>
<tr>
<td>J2765</td>
<td>Metoclopramide HCl, up to 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2778</td>
<td>Ranibizumab, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J2779</td>
<td>Ranibizumab, via intravitreal implant (susvimo), 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>J2780</td>
<td>Ranitidine HCl, 25 mg</td>
<td></td>
</tr>
<tr>
<td>J2783</td>
<td>Rasburicase, 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2786</td>
<td>Reslizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2793</td>
<td>Rilonacept, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2794</td>
<td>Risperidone, (Risperdal consta), 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2796</td>
<td>Romiplostim, 10 micrograms</td>
<td></td>
</tr>
<tr>
<td>J2797</td>
<td>Rolapitant, 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2798</td>
<td>Risperidone (perseris), 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2800</td>
<td>Methocarbamol, up to 10 ml</td>
<td></td>
</tr>
<tr>
<td>J2820</td>
<td>Sargramostim (GM-CSF), 50 mcg</td>
<td></td>
</tr>
<tr>
<td>J2840</td>
<td>Sebelipase alfa, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2860</td>
<td>Siltuximab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J2910</td>
<td>Aurothioglucose, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J2916</td>
<td>Sodium ferric gluconate complex in sucrose injection, 12.5 mg</td>
<td></td>
</tr>
<tr>
<td>J2920</td>
<td>Methylprednisolone sodium succinate, up to 40 mg</td>
<td></td>
</tr>
<tr>
<td>J2930</td>
<td>Methylprednisolone sodium succinate, up to 125 mg</td>
<td></td>
</tr>
<tr>
<td>J2940</td>
<td>Somatrem, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2941</td>
<td>Somatropin, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2995</td>
<td>Streptokinase, per 250,000 IU</td>
<td></td>
</tr>
<tr>
<td>J2997</td>
<td>Alteplase recombinant, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J2998</td>
<td>Plasminogen, human-tvmh, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3000</td>
<td>Streptomycin, up to 1 gm</td>
<td></td>
</tr>
<tr>
<td>J3030</td>
<td>Sumatriptan succinate, 6 mg</td>
<td></td>
</tr>
<tr>
<td>J3031</td>
<td>Fremanezumab-vfrm, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3032</td>
<td>Eptinezumab-jjmr, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3060</td>
<td>Taliglucerace alfa (Elelyso), 10 units</td>
<td></td>
</tr>
<tr>
<td>J3070</td>
<td>Pentazocine, 30 mg</td>
<td></td>
</tr>
<tr>
<td>J3090</td>
<td>Tedizolid phosphate, 1mg</td>
<td></td>
</tr>
<tr>
<td>J3095</td>
<td>Televancin, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J3105</td>
<td>Terbutaline sulfate, up to 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3111</td>
<td>Romozosumab-aqqg, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3121</td>
<td>Testosterone enanthate, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3145</td>
<td>Testosterone undecanoate, 1mg</td>
<td></td>
</tr>
<tr>
<td>J3230</td>
<td>Chlorpromazine HCl, up to 50 mg</td>
<td></td>
</tr>
<tr>
<td>J3240</td>
<td>Thyrotropin alpha, 0.9 mg. provided in 1.1 mg vial</td>
<td></td>
</tr>
<tr>
<td>J3241</td>
<td>Teprotumumab-trbw, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J3243</td>
<td>Tigecycline, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3245</td>
<td>Tildrakizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3250</td>
<td>Trimethobenzamide HCl, up to 200 mg</td>
<td></td>
</tr>
<tr>
<td>J3260</td>
<td>Tobramycin sulfate, up to 80 mg</td>
<td></td>
</tr>
<tr>
<td>J3262</td>
<td>Tocilizumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3265</td>
<td>Torsemide, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J3280</td>
<td>Thiethylperazine maleate, up to 10 mg</td>
<td></td>
</tr>
<tr>
<td>J3285</td>
<td>Treprostinil, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J3299</td>
<td>Triamcinolone acetonide (xipere), 1 mg</td>
<td></td>
</tr>
</tbody>
</table>
J3300  Triamcinolone acetonide, preservative free, 1mg
J3301  Triamcinolone acetonide, not otherwise specified, 10 mg
J3302  Triamcinolone diacetate, per 5 mg
J3303  Triamcinolone hexacetonide, per 5 mg
J3304  Triamcinolone acetonide, preservative free, extended-release, 1 mg
J3305  Triamterexate glucuronate, per 25 mg
J3310  Perphenazine, up to 5 mg
J3315  Triptorelin pamoate, 3.75 mg
J3316  Triptorelin, extended-release, 3.75 mg
J3320  Spectinomycin dihydrochloride, up to 2 gm
J3357  Ustekinumab, for subcutaneous injection, 1 mg
J3358  Ustekinumab, for intravenous injection, 1 mg
J3360  Diazepam, up to 5 mg
J3364  Urokinase, 5,000 IU vial
J3370  Vancomycin HCl, 500 mg
J3380  Vedolizumab, 1 mg
J3385  Velaglucerase alfa, 100 units
J3396  Verteporfin, 0.1 mg
J3397  Vestronidase alfa-vjbk, 1 mg
J3398  Voretigene neparvovec-rzyl, 1 billion vector genomes
J3399  Onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
J3400  Triflupromazine HCl, up to 20 mg
J3410  Hydroxyzine HCl, up to 25 mg
J3411  Thiamine HCl, 100 mg
J3415  Pyridoxine HCl, 100 mg
J3420  Vitamin B-12 cyanocobalamin, up to 1000 mcg
J3430  Phytonadione, (vitamin K), per 1 mg
J3465  Voriconazole, 10 mg
J3470  Hyaluronidase, up to 150 units
J3475  Magnesium sulfate, per 500 mg
J3480  Potassium chloride, per 2 meq
J3489  Zoledronic acid, 1 mg
J3490  Unclassified drugs
J3520  Edetate disodium, per 150 mg
J3590  Unclassified Biologicals
J3591  Unclassified Drug or Biological used for ESRD on dialysis

**MISCELLANEOUS DRUGS AND SOLUTIONS**

Codes followed by an ^ do not require an NDC to be provided when billed.

A4216^ Sterile water, saline and/or dextrose (diluent), 10 ml
A4218^ Sterile saline or water, metered dose dispenser, 10 ml
J7030  Infusion, normal saline solution (or water), 1000 cc
J7040  Infusion, normal saline solution (or water), sterile (500 ml = 1 unit)
J7042  5% dextrose/normal saline (500 ml = 1 unit)
J7050  Infusion, normal saline solution (or water), 250 cc
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7060</td>
<td>5% dextrose/water (500 ml = 1 unit)</td>
</tr>
<tr>
<td>J7070</td>
<td>Infusion, D5W, 1000 cc</td>
</tr>
<tr>
<td>J7100</td>
<td>Infusion, dextran 40, 500 ml</td>
</tr>
<tr>
<td>J7110</td>
<td>Infusion, dextran 75, 500 ml</td>
</tr>
<tr>
<td>J7120</td>
<td>Ringers lactate infusion, up to 1000 cc</td>
</tr>
<tr>
<td>J7121</td>
<td>5% Dextrose in lactated ringers infusion, up to 1000 cc</td>
</tr>
<tr>
<td>J7131</td>
<td>Hypertonic saline solution, 1 ml\</td>
</tr>
<tr>
<td>J7168</td>
<td>Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity</td>
</tr>
<tr>
<td>J7169</td>
<td>Coagulation Factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg</td>
</tr>
<tr>
<td>J7294</td>
<td>Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hour</td>
</tr>
<tr>
<td>J7295</td>
<td>Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each</td>
</tr>
<tr>
<td>J7296</td>
<td>Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg</td>
</tr>
<tr>
<td>J7297</td>
<td>Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 3 year duration</td>
</tr>
<tr>
<td>J7298</td>
<td>Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5 year duration</td>
</tr>
<tr>
<td>J7300</td>
<td>Intrauterine copper contraceptive</td>
</tr>
<tr>
<td>J7301</td>
<td>Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg</td>
</tr>
<tr>
<td>J7304</td>
<td>Contraceptive supply, hormone containing patch, each</td>
</tr>
<tr>
<td>J7306</td>
<td>Levonorgestrel (contraceptive) implant system, including implants and supplies</td>
</tr>
<tr>
<td>J7307</td>
<td>Etonogestrel (contraceptive) implant system, including implant and supplies</td>
</tr>
<tr>
<td>J7308</td>
<td>Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg)</td>
</tr>
<tr>
<td>J7311</td>
<td>Fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg</td>
</tr>
<tr>
<td>J7312</td>
<td>Dexamethasone, intravitreal implant, 0.1 mg</td>
</tr>
<tr>
<td>J7313</td>
<td>Fluocinolone acetonide, intravitreal implant, (Iluvien) 0.01 mg</td>
</tr>
<tr>
<td>J7314</td>
<td>Fluocinolone acetonide, intravitreal implant, (Yutiq) 0.01 mg</td>
</tr>
<tr>
<td>J7316</td>
<td>Ocriplasmin (Jetrea), 0.125 mg</td>
</tr>
<tr>
<td>J7321^</td>
<td>Hyaluronan or derivative, Hyalgan or Supartz, or visco-3, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7323^</td>
<td>Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7324^</td>
<td>Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7325^</td>
<td>Hyaluronan or derivative, Synvisc or Synvisc-One, intra-articular</td>
</tr>
<tr>
<td>J7326^</td>
<td>Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose</td>
</tr>
<tr>
<td>J7336</td>
<td>Capsaicin 8% patch, per square centimeter</td>
</tr>
<tr>
<td>J7342</td>
<td>Ciprofloxacin otic suspension, 6 mg</td>
</tr>
<tr>
<td>J7345</td>
<td>Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg</td>
</tr>
<tr>
<td>J7351</td>
<td>Bimatoprost, intracameral implant, 1 microgram</td>
</tr>
<tr>
<td>J7402</td>
<td>Mometasone furoate sinus implant, (sinuva), 10 micrograms</td>
</tr>
<tr>
<td>J7501</td>
<td>Azathioprine, parenteral (eg Imuran), 100 mg</td>
</tr>
<tr>
<td>J7504</td>
<td>Lymphocyte immune globulin, antithymocyte globulin equine, parenteral, 250 mg</td>
</tr>
<tr>
<td>J7527</td>
<td>Everolimus, oral, 0.25 mg</td>
</tr>
<tr>
<td>J7606</td>
<td>Formoterol Fumarate, inhalation solution, non-compounded, administered through DME, unit dose form, 20 mcg</td>
</tr>
<tr>
<td>J7611</td>
<td>Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1mg</td>
</tr>
<tr>
<td>J7612</td>
<td>Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg</td>
</tr>
</tbody>
</table>
J7613  Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
J7614  Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME. Unit dose. 0.5 mg
J7620  Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME
J7627  Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
J7628  Bitolterol mesylate, inhalation solution, compounded product, administered through DME, concentrated form, per mg
J7631  Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
J7640  Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 mcg
J7644  Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
J7648  Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
J7649  Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
J7658  Isoproterenol HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
J7668  Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 10 mg
J7669  Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
J7674  Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
J7682  Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, 300 mg
J7999  Compounded drug, not otherwise classified
J8501  Aprepitant, oral, 5 mg
J8540  Dexamethasone, oral, 0.25 mg
J8650  Nabilone, oral, 1 mg
L8603^  Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies
Q0138  Ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use)
Q4101^  Apligraf, per square centimeter
Q4102^  Oasis wound matrix, per square centimeter
Q4103^  Oasis burn matrix, per square centimeter
Q4106^  Dermagraft, per square centimeter
Q4108^  Integra matrix, per square centimeter
Q4110^  Primatrix, per square centimeter
Q4111^  GammaGraft, per square centimeter
Q4121^  Theraskin, per square centimeter
Q5101  Filgrastim-snndz, biosimilar, (zarxio), 1 microgram
Q5103 Infliximab-dyyb, biosimilar,(inflectra), 10 mg
Q5104 Infliximab-abda, biosimilar, (renflexis), 10 mg
Q5108 Pegfilgrastim-jmdb, biosimilar, 0.5 mg
Q5111 Pegfilgrastim-cbqv, biosimilar, 0.5 mg
Q9991 Buprenorphine extended-release, less than or equal to 100 mg
Q9992 Buprenorphine extended-release, greater than 100 mg
S0190 Mifepristone, oral, 200 mg
(When administered for medically necessary non-surgical abortion)
S0191 Misoprostol, oral, 200 mcg
(When administered for medically necessary non-surgical abortion)
S9435 Medical foods for inborn errors of metabolism
(Reimbursement limited to Inborn Metabolic Disease Centers or Medical Directors of Inborn Metabolic Disease Centers)

HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS and INFUSIONS, and CHEMOTHERAPY and OTHER HIGHLY COMPLEX DRUG or HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

If a significant separately identifiable Evaluation and Management service is performed, the appropriate E/M service code should be reported using modifier ‘25’ in addition to 96360-96549. For same day E/M service a different diagnosis is not required.

If performed to facilitate the infusion or injection, the following services are included and are not reported separately:

a. Use of local anesthesia
b. IV start
c. Access to indwelling IV, subcutaneous catheter or port
d. Flush at conclusion of infusion
e. Standard tubing, syringes, and supplies

When multiple drugs are administered, report the service(s) and the specific materials or drugs for each.

When administering multiple infusions, injections or combinations, only one “initial” service code should be reported, unless protocol requires that two separate IV sites must be used. If an injection or infusion is of a subsequent or concurrent nature, even if it is the first such service within that group of services, then a subsequent or concurrent code from the appropriate section should be reported (eg, the first IV push given subsequent to an initial one-hour infusion is reported using a subsequent IV push code).

When these codes are reported by the physician, the “initial” code that best describes the key or primary reason for the encounter should always be reported irrespective of the order in which the infusions or injections occur. When reporting codes for which infusion time is a factor, use the actual time over which the infusion is administered. Intravenous or intra-arterial push is defined as: (a) an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient, or (b) an infusion of 15 minutes or less.

HYDRATION
Codes 96360-96361 are intended to report a hydration IV infusion to consist of a pre-packaged fluid and electrolytes (e.g., normal saline, D5-1/2 normal saline+30mEq KCL/liter), but are not used to report infusion of drugs or other substances. Hydration IV infusions typically require direct physician supervision for purposes of consent, safety oversight, or intraservice supervision of staff. Typically such infusions require little special handling to prepare or dispose of, and staff that administer these do not typically require advanced practice training. After initial set-up, infusion typically entails little patient risk and thus little monitoring. These codes are not intended to be reported by the physician in the facility setting.

96360  Intravenous infusion, hydration; initial, 31 minutes to 1 hour
(Do not report 96360 if performed as a concurrent infusion service)
(Do not report intravenous infusion for hydration of 30 minutes or less)

96361 each additional hour
(List separately in addition to primary procedure)
(Use 96361 in conjunction with 96360)
(Report 96361 for hydration infusion intervals of greater than 30 minutes beyond 1 hour increments)
(Report 96361 to identify hydration if provided as a secondary or subsequent service after a different initial service [96360, 96365, 96409, 96413] is administered through the same IV access)

THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS
(EXCLUDES CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION)
A therapeutic, prophylactic, or diagnostic IV infusion or injection (other than hydration) is for the administration of substances/drugs. When fluids are used to administer the drug(s), the administration of the fluid is considered incidental hydration and is not separately reportable. These services typically require direct physician supervision for any or all purposes of patient assessment, provision of consent, safety oversight, and intra-service supervision of staff. Typically, such infusions require special consideration to prepare, dose or dispose of, require practice training and competency for staff who administer the infusions, and require periodic patient assessment with vital sign monitoring during the infusion. These codes are not intended to be reported by the physician in the facility setting.
(Do not report 96365-96371 with codes for which IV push or infusion is an inherent part of the procedure [e.g., administration of contrast material for a diagnostic imaging study])

96365  Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 each additional hour
(List separately in addition to primary procedure)
(Report 96366 in conjunction with 96365, 96367)
(Report 96366 for additional hour[s] of sequential infusion)
(Report 96366 for infusion intervals of greater than 30 minutes beyond 1 hour increments)

96367 additional sequential infusion of a new drug/substance, up to 1 hour
(List separately in addition to primary procedure)
(Report 96367 in conjunction with 96365, 96409, 96413 to identify the infusion of a new drug/substance provided as a secondary or subsequent service after a different initial service is administered through the same IV access)
(Report 96367 only once per sequential infusion of same infusate mix)

96368 concurrent infusion
(List separately in addition to primary procedure)
(Report 96368 only once per encounter)
(Report 96368 in conjunction with 96365, 96366, 96413, 96415, 96416)

96369 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)

96370 each additional hour
(List separately in addition to primary procedure)
(Use 96370 in conjunction with 96369)
(Use 96370 for infusion intervals of greater than 30 minutes beyond 1 hour increments)

96371 additional pump set-up with establishment of new subcutaneous infusion site(s)
(List separately in addition to primary procedure)
(Use 96371 in conjunction with 96369)
(Use 96369, 96371 only once per encounter)

96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular (Bill on one claim line for multiple injections)

**CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION**

Procedures 96405-96549 are independent of the patient’s office visit. Either may occur independently from the other on any given day, or they may occur sequentially on the same day. Intravenous chemotherapy injections are administered by a physician, a nurse practitioner or by a qualified assistant under supervision of the physician or nurse practitioner. Preparation of chemotherapy agent(s) is included in the service for administration of the agent.

Regional (isolation) chemotherapy perfusion should be reported using the codes for arterial infusion (96420-96425). Placement of the intra-arterial cathether should be reported using the appropriate code from the Cardiovascular Surgery section. Placement of arterial and venous cannula(s) for extracorporeal circulation via a membrane oxygenator perfusion pump should be reported using code 38623. Code 36823 includes dose calculation and administration of the chemotherapy agent by injection into the perfusate. Do not report code(s) 96409-96425 in conjunction with code 36823. Report separate codes for each parenteral method of administration employed when chemotherapy is administered by different techniques. The administration of medications (eg, antibiotics, steroidal agents, antiemetics, narcotics, analgesics) administered independently or sequentially as supportive management of chemotherapy administration should be separately reported using 96360, 96361, 96365 as appropriate.

**INJECTION AND INTRAVENOUS INFUSION CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION**

Intravenous or intra-arterial push is defined as: a) an injection in which the healthcare professional who administers the substance/drug is continuously present to administer the injection and observe the patient, or b) an infusion of 15 minutes or less.

96405 Chemotherapy administration, intralesional; up to and including 7 lesions
96406 intralesional, more than 7 lesions
96409 intravenous; push technique, single or initial substance/drug
96413 Chemotherapy administration, intravenous infusion technique, up to one hour, single or initial substance/drug
   (Report 96361 to identify hydration if administered as a secondary or subsequent service in association with 96413 through the same IV access)
   (Report 96366, 96367, to identify therapeutic, prophylactic, or diagnostic drug infusion or injection, if administered as a secondary or subsequent service in association with 96413 through the same IV access)
96415 each additional hour
   (List separately in addition to primary procedure)
   (Use 96415 in conjunction with 96413)
   (Report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour increments)
96416 initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump

**INTRA-ARTERIAL CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION**

96420 Chemotherapy administration, intra-arterial; push technique
96422 infusion technique, up to one hour
96423 infusion technique, each additional hour
   (List separately in addition to primary procedure)
   (Use 96423 in conjunction with code 96422)
   (Report 96423 for infusion intervals of greater than 30 minutes beyond 1-hour increments)
96425 infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump

**OTHER INJECTION AND INFUSION SERVICES**

96440 Chemotherapy administration into pleural cavity, requiring and including thoracentesis
96446 Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
96450 Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture
96521 Refilling and maintenance of portable pump
96522 Refilling and maintenance of implantable pump or reservoir for drug delivery systemic (eg, intravenous, intra-arterial)
   (Access of pump port is included in filling of implantable pump)
   Codes 96521-96523 may be reported when these devices are used for therapeutic drugs other than chemotherapy.
96542 Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents
96549 Unlisted chemotherapy procedure
J9999 Not otherwise classified, antineoplastic drugs

**CHEMOTHERAPY DRUGS**
(Maximum fee is for chemotherapy drug only and does not include the administration procedures as listed above)

**NOTE:** The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert actual acquisition cost per dose in amount charged field on claim form. For codes listed BR/Report required, also attach itemized invoice to claim form.

Reimbursement for drugs furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

**Codes followed by an ^ do not require an NDC to be provided when billed.**

<table>
<thead>
<tr>
<th>Code</th>
<th>Drug Name</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9000</td>
<td>Doxorubicin HCl, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9015</td>
<td>Aldesleukin, per single use vial</td>
<td></td>
</tr>
<tr>
<td>J9017</td>
<td>Arsenic trioxide, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9019</td>
<td>Asparaginase (Erwinaze), 1,000 IU</td>
<td></td>
</tr>
<tr>
<td>J9020</td>
<td>Asparaginase, not otherwise specified, 10,000 units</td>
<td></td>
</tr>
<tr>
<td>J9021</td>
<td>Asparaginase, recombinant, (rylaze), 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J9022</td>
<td>Atezolizumab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9023</td>
<td>Avelumab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9025</td>
<td>Azacitidine, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9027</td>
<td>Clofarabine, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9030</td>
<td>BCG live (intravesical) instillation, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9032</td>
<td>Belinostat, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9033</td>
<td>Bendamustine injection HCL (Treanda), 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9034</td>
<td>Bendamustine injection HCL (Bendeka), 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9035</td>
<td>Bevacizumab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9036</td>
<td>Bendamustine HCL, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9037</td>
<td>Belantamab mafodontin-blmf, 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J9039</td>
<td>Blinatumomab, 1 microgram</td>
<td></td>
</tr>
<tr>
<td>J9040</td>
<td>Bleomycin sulfate, 15 units</td>
<td></td>
</tr>
<tr>
<td>J9041</td>
<td>Bortezomib (velcade), 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J9042</td>
<td>Brentuximab vedotin, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9043</td>
<td>Cabazitaxel, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9044</td>
<td>Bortezomib, not otherwise specified, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J9045</td>
<td>Carboplatin, 50 mg</td>
<td></td>
</tr>
<tr>
<td>J9047</td>
<td>Carfilzomib (Kyprolis), 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9050</td>
<td>Carmustine, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J9055</td>
<td>Cetuximab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9057</td>
<td>Copanlisib, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9060</td>
<td>Cisplatin, powder or solution, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9061</td>
<td>Amivantamab-vmjw, 2 mg</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>J9065</td>
<td>Cladribine, per 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9070</td>
<td>Cyclophosphamide, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J9071</td>
<td>Cyclophosphamide, (auromedics), 5 mg</td>
<td></td>
</tr>
<tr>
<td>J9098</td>
<td>Cytarabine liposome, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9100</td>
<td>Cytarabine, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J9118</td>
<td>Calaspargase pegol-mknl, 10 units</td>
<td></td>
</tr>
<tr>
<td>J9119</td>
<td>Cemiplimab-nwlc, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9120</td>
<td>Dactinomycin, 0.5 mg</td>
<td></td>
</tr>
<tr>
<td>J9130</td>
<td>Dacarbazine, 100 mg</td>
<td></td>
</tr>
<tr>
<td>J9144</td>
<td>Daratumumab, 10 mg and hyaluronidase-fihj</td>
<td></td>
</tr>
<tr>
<td>J9145</td>
<td>Daratumumab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9150</td>
<td>Daunorubicin HCl, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9151</td>
<td>Daunorubicin citrate, liposomal formulation, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9153</td>
<td>Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine</td>
<td></td>
</tr>
<tr>
<td>J9155</td>
<td>Degarelix, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9160</td>
<td>Denileukin diftitox, 300 mcg</td>
<td></td>
</tr>
<tr>
<td>J9165</td>
<td>Diethylstilbestrol diphosphate, 250 mg</td>
<td></td>
</tr>
<tr>
<td>J9171</td>
<td>Docetaxel, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9173</td>
<td>Durvalumab, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9175</td>
<td>Elliott’s B solution, 1 ml</td>
<td></td>
</tr>
<tr>
<td>J9176</td>
<td>Elotuzumab, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9177</td>
<td>Enfortumab vedotin-ejfv 0.25mg</td>
<td></td>
</tr>
<tr>
<td>J9178</td>
<td>Epirubicin HCl, 2 mg</td>
<td></td>
</tr>
<tr>
<td>J9179</td>
<td>Eribulin mesylate, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J9181</td>
<td>Etoposide, 10 mg</td>
<td></td>
</tr>
<tr>
<td>J9185</td>
<td>Fludarabine phosphate, 50 mg</td>
<td></td>
</tr>
<tr>
<td>J9190</td>
<td>Fluorouracil, 500 mg</td>
<td></td>
</tr>
<tr>
<td>J9198</td>
<td>Gemcitabine hydrochloride, (infugem), 100 mg</td>
<td></td>
</tr>
<tr>
<td>J9200</td>
<td>Floxuridine, 500 mg</td>
<td></td>
</tr>
<tr>
<td>J9201</td>
<td>Gemcitabine HCl, NOS, 200 mg</td>
<td></td>
</tr>
<tr>
<td>J9202</td>
<td>Goserelin acetate implant per 3.6 mg</td>
<td></td>
</tr>
<tr>
<td>J9203</td>
<td>Gemtuzumab ozogamicin, 0.1 mg</td>
<td></td>
</tr>
<tr>
<td>J9204</td>
<td>Mogamulizumab-kpkc, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9205</td>
<td>Irinotecan liposome, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9206</td>
<td>Irinotecan, 20 mg</td>
<td></td>
</tr>
<tr>
<td>J9207</td>
<td>Ixabepilone, injection, 1mg</td>
<td></td>
</tr>
<tr>
<td>J9208</td>
<td>Ifosfamide, 1 g</td>
<td></td>
</tr>
<tr>
<td>J9209</td>
<td>Mesna, 200 mg</td>
<td></td>
</tr>
<tr>
<td>J9210</td>
<td>Emapalumab-lxsg, 1 mg</td>
<td></td>
</tr>
<tr>
<td>J9211</td>
<td>Idarubicin HCl, 5 mg</td>
<td></td>
</tr>
<tr>
<td>J9212</td>
<td>Interferon alfacon-1, recombinant, 1 mcg</td>
<td></td>
</tr>
<tr>
<td>J9213</td>
<td>Interferon, alfa-2a, recombinant, 3 million units</td>
<td></td>
</tr>
<tr>
<td>J9214</td>
<td>Interferon, alfa-2b, recombinant, 1 million units</td>
<td></td>
</tr>
<tr>
<td>J9215</td>
<td>Interferon, alfa-N3, (human leukocyte derived), 250,000 IU</td>
<td></td>
</tr>
</tbody>
</table>
J9216  Interferon, gamma 1-B, 3 million units
J9217  Leuprolide acetate (for depot suspension), 7.5 mg
J9218  Leuprolide acetate, per 1 mg
J9219^  Leuprolide acetate implant, 65 mg
J9223  Lurbinectedin, 0.1 mg
J9225  Histrelin implant (Vantas), 50 mg
J9226  Histrelin implant (Supprelin LA), 50 mg
J9227  Isatuximab-irfc, 10 mg
J9228  Ipilimumab, 1 mg
J9229  Inotuzumab ozogamicin, 0.1 mg
J9230  Mechlorethamine HCl (nitrogen mustard), 10 mg
J9245  Melphalan HCl, 50 mg
J9246  Melphalan (evomela), 1 mg
J9250  Methotrexate sodium, 5 mg
J9260  Methotrexate sodium, 50 mg
J9261  Nelarabine, 50 mg
J9262  Omacetaxine mepesuccinate (Synibro), 0.01 mg
J9263  Oxaliplatin, 0.5 mg
J9264  Paclitaxel protein-bound particles, 1 mg
J9266  Pegasparagase, per single dose vial
J9267  Paclitaxel, 1 mg
J9268  Pentostatin, per 10 mg
J9269  Tagraxofusp-erzs, 10 mcg
J9270  Plicamycin, 2.5 mg
J9271  Pembrolizumab, 1 mg
J9272  Dostarlimab-gxly, 10 mg
J9273  Tisotumub vedotin-tftv, 1 mg
J9280  Injection, Mitomycin, 5 mg
J9281  Mitomycin pyelocalyceal instillation, 1 mg
J9285  Olaratumab, 10 mg
J9293  Mitoxantrone HCl, per 5 mg
J9295  Necitumumab, 1 mg
J9299  Nivolumab, 1 mg
J9301  Obinutuzumab, 1 mg
J9302  Ofatumumab, 10 mg
J9303  Panitumumab, 10 mg
J9304  Pemetrexed (pemfexy), 10 mg
J9305  Pemetrexed, 10 mg
J9306  Pertuzumab (Perjeta), 1 mg
J9307  Pralatrexate, 1 mg
J9308  Ramucirumab, 5 mg
J9309  Polatuzumab vedotin-piiq, 1 mg
J9311  Rituximab 10 mg and hyaluronidase
J9312  Rituximab, 10 mg
J9313  Moxetumomab pasudotox-tdfk, 0.01 mg
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9316</td>
<td>Pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg</td>
</tr>
<tr>
<td>J9317</td>
<td>Sacituzumab govitecan-hziy, 2.5 mg</td>
</tr>
<tr>
<td>J9318</td>
<td>Romidepsin, non-lyophilized, 0.1 mg</td>
</tr>
<tr>
<td>J9319</td>
<td>Romidepsin, lyophilized, 0.1 mg</td>
</tr>
<tr>
<td>J9320</td>
<td>Streptozocin, 1 g</td>
</tr>
<tr>
<td>J9325</td>
<td>Talimogene laherparepvec, per 1 million plaque forming units</td>
</tr>
<tr>
<td>J9330</td>
<td>Temsirolimus, injection, 1 mg</td>
</tr>
<tr>
<td>J9331</td>
<td>Sirolimus protein-bound particles, 1 mg</td>
</tr>
<tr>
<td>J9332</td>
<td>Efgartigimod alfa-fcab, 2mg</td>
</tr>
<tr>
<td>J9340</td>
<td>Thiotepa, 15 mg</td>
</tr>
<tr>
<td>J9348</td>
<td>Naxitamab-gqqk, 1 mg</td>
</tr>
<tr>
<td>J9349</td>
<td>Tafasitamab-CXIX, 2 mg</td>
</tr>
<tr>
<td>J9351</td>
<td>Topotecan, 0.1 mg</td>
</tr>
<tr>
<td>J9352</td>
<td>Trabectedin, 0.1 mg</td>
</tr>
<tr>
<td>J9353</td>
<td>Margetuximab-cmkb, 5 mg</td>
</tr>
<tr>
<td>J9354</td>
<td>Ado-trastuzumab emtansine (Kadcyla), 1 mg</td>
</tr>
<tr>
<td>J9355</td>
<td>Trastuzumab, excludes biosimilar, 10 mg</td>
</tr>
<tr>
<td>J9356</td>
<td>Trastuzumab, 10 mg and hyaluronidase-oysk</td>
</tr>
<tr>
<td>J9357</td>
<td>Valrubicin, intravesical, 200 mg</td>
</tr>
<tr>
<td>J9358</td>
<td>Fam-trastuzumab deruxtecan-nxki, 1mg</td>
</tr>
<tr>
<td>J9359</td>
<td>Loncastuximab tesirine-lpyl, 0.075 mg</td>
</tr>
<tr>
<td>J9360</td>
<td>Vinblastine sulfate, 1 mg</td>
</tr>
<tr>
<td>J9370</td>
<td>Vincristine sulfate, 1 mg</td>
</tr>
<tr>
<td>J9371</td>
<td>Vincristine sulfate liposome (Marqibo), 1 mg</td>
</tr>
<tr>
<td>J9390</td>
<td>Vinorelbine tartrate, 10 mg</td>
</tr>
<tr>
<td>J9395</td>
<td>Fulvestrant, 25 mg</td>
</tr>
<tr>
<td>J9400</td>
<td>Ziv-aflibercept (Zaltrap), 1 mg</td>
</tr>
<tr>
<td>J9600</td>
<td>Porfimer sodium, 75 mg</td>
</tr>
<tr>
<td>J9999</td>
<td>Not otherwise classified, antineoplastic drugs</td>
</tr>
<tr>
<td>Q0174</td>
<td>Thiethylperazine maleate, 10 mg, oral</td>
</tr>
<tr>
<td>Q0177</td>
<td>Hydroxyzine pamoate, 25 mg</td>
</tr>
<tr>
<td>Q2017</td>
<td>Teniposide, 50 mg</td>
</tr>
<tr>
<td>Q2043</td>
<td>Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion</td>
</tr>
<tr>
<td>Q2050</td>
<td>Doxorubicin hydrochloride liposomal, 10 mg</td>
</tr>
<tr>
<td>Q5107</td>
<td>Bevacizumab-awwb; 10 mg</td>
</tr>
<tr>
<td>Q5112</td>
<td>Trastuzumab-dttb; 10 mg</td>
</tr>
<tr>
<td>Q5113</td>
<td>Trastuzumab-pkrb; 10 mg</td>
</tr>
<tr>
<td>Q5114</td>
<td>Trastuzumab-dkst; 10 mg</td>
</tr>
<tr>
<td>Q5115</td>
<td>Rituximab-abbs, 10 mg</td>
</tr>
<tr>
<td>Q5116</td>
<td>Trastuzumab-qyyp; 10 mg</td>
</tr>
<tr>
<td>Q5117</td>
<td>Trastuzumab-anns; 10 mg</td>
</tr>
<tr>
<td>Q5118</td>
<td>Bevacizumab-bvzr; 10 mg</td>
</tr>
<tr>
<td>Q5119</td>
<td>Rituximab-pvvr; 10 mg</td>
</tr>
<tr>
<td>Q5120</td>
<td>Pegfilgrastim-bmez; 0.5 mg</td>
</tr>
</tbody>
</table>
Q5121  Infliximab-axxq; 10 mg
Q5121  Rituximab-arrx, biosimilar, (riabni), 10 mg
PSYCHIATRY

Codes 90785-90899 are for face-to-face services provided by a Psychiatrist. Hospital care by the attending physician in treating a psychiatric inpatient or partial hospitalization may be initial or subsequent in nature (see 99221-99233) and may include exchanges with nursing and ancillary personnel. Hospital care services involve a variety of responsibilities unique to the medical management of inpatients, such as physician hospital orders, interpretation of laboratory or other medical diagnostic studies and observations. Some patients receive hospital evaluation and management services only and others receive evaluation and management services and other procedures. If other procedures such as electroconvulsive therapy are rendered, by the physician, in addition to hospital evaluation and management services, these should be listed separately (ie, hospital care service plus electroconvulsive therapy).

Other evaluation and management services, such as office medical services or other patient encounters, may be described as listed in the section on Evaluation and Management, if appropriate. The Evaluation and Management services should not be reported separately, when reporting codes 90833, 90836, 90838.

(When billing for procedure codes 90832 through 90837, the total time billed to New York State Medicaid should reflect the face-to-face contact time with the patient. Reimbursement for all work performed before and after the face-to-face encounter (eg, analysis of tests, reviewing records, etc.) is included in the maximum reimbursable amount for the face-to-face encounter.) More information on the definition of time, specifically the definition of face-to-face contact time can be found under General Information and Rules in the Medicine Section.

INTERACTIVE COMPLETITY

90785 Interactive complexity
(List separately in addition to primary procedure)
(Use 90785 in conjunction with codes for diagnostic psychiatric evaluation (90791, 90792), psychotherapy (90832, 90834, 90837) psychotherapy when performed with an evaluation and management service (90833, 90836, 90838, 99202-99251, 99304 – 99337, 99341 – 99350), and group psychotherapy (90853))
(Do not report 90785 in conjunctions with 90839, 90840, or in conjunction with E/M services when no psychotherapy service is also reported)

90791 Psychiatric diagnostic examination
90792 Psychiatric diagnostic examination with medical services
(Use 90785 in conjunction with 90791, 90792 when the diagnostic evaluation includes interactive complexity services)
(Do not report 90791 or 90792 in conjunction with 99202-99337, 99341-99350, 99366-99368, 99401-99444)
Psychotherapy is the treatment for mental illness and behavioral disturbances in which the clinician establishes a professional contract with the patient and, through definitive therapeutic communication, attempts to alleviate the emotional disturbances, reverse or change maladaptive patterns of behavior, and encourage personality growth and development. The codes for reporting psychotherapy are divided into two broad categories: Interactive Psychotherapy; and Insight Oriented, Behavior Modifying and/or Supportive Psychotherapy.

Interactive psychotherapy is typically furnished to children. It involves the use of physical aids and non-verbal communication to overcome barriers to therapeutic interaction between the clinician and a patient who has not yet developed, or has lost, either the expressive language communication skills to explain his/her symptoms and response to treatment, or the receptive communication skills to understand the clinician if he/she were to use ordinary adult language for communication.

Insight oriented, behavior modifying and/or supportive psychotherapy refers to the development of insight or affective understanding, the use of behavior modification techniques, the use of supportive interactions, the use of cognitive discussion of reality, or any combination of the above to provide therapeutic change.

Some patients receive psychotherapy only and other receive psychotherapy and medical evaluation and management services. These evaluation and management services involve a variety of responsibilities unique to the medical management of psychiatric patients, such as medical diagnostic evaluation (eg, evaluation of co-morbid medical conditions, drug interactions, and physical examinations), drug management when indicated, physician orders, interpretation of laboratory or other medical diagnostic studies and observations.

In reporting psychotherapy, the appropriate code is chosen on the basis of the type of psychotherapy (interactive using non-verbal techniques versus insight oriented, behavior modifying and/or supportive using verbal techniques), the place of service (office versus inpatient), the face-to-face time spent with the patient during psychotherapy, and whether evaluation and management services are furnished on the same date of service as psychotherapy.

To report medical evaluation and management services furnished on a day when psychotherapy is not provided, select the appropriate code from the Evaluation and Management Services Guidelines.
OFFICE INSIGHT ORIENTED, BEHAVIOR MODIFYING AND/OR SUPPORTIVE PSYCHOTHERAPY

90832  Psychotherapy, 30 minutes with patient
90833  Psychotherapy, 30 minutes with patient when performed with an evaluation and management service
   (List separately in addition to primary procedure)
   (Use 90833 in conjunction with 99202-99255, 99304-99337, 99341-99350)
90834  Psychotherapy, 45 minutes with patient
90836  Psychotherapy, 45 minutes with patient when performed with an evaluation and management service
   (List separately in addition to primary procedure)
   (Use 90836 in conjunction with 99202-99255, 99304-99337, 99341-99350)
90837  Psychotherapy, 60 minutes with patient
90838  Psychotherapy, 60 minutes with patient when performed with an evaluation and management service
   (List separately in addition to primary procedure)
   (Use 90838 in conjunction with 99202-99255, 99304-99337, 99341-99350)
   (Use the appropriate prolonged services code (99354-99357) for the psychotherapy services 68 minutes or longer)

OTHER PSYCHOTHERAPY

90846  Family psychotherapy (without the patient present) 50 minutes
90847  Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes
90849  Multiple family group psychotherapy
   (1 1/2 hours, per person; maximum 8 persons per group)
90853  Group psychotherapy (other than of a multiple-family group)
   (1 1/2 hours, per person; maximum 8 persons per group)

OTHER PSYCHIATRIC SERVICES OR PROCEDURES

90863  Pharmacologic management, including prescription and review of medication, when performed with psychotherapy services
   (List separately in addition to primary procedure)
   (Use 90863 in conjunction with 90832, 90834, 90837)
   (For pharmacologic management with psychotherapy services performed by a physician or other qualified health care professional who may report evaluation and management codes, use the appropriate evaluation and management codes 99202-99255, 99281-99285, 99304-99337, 99341-99359 and the appropriate psychotherapy with the evaluation and management service 90833, 90836, 90838)
90870  Electroconvulsive therapy (includes necessary monitoring)
90899  Unlisted psychiatric service or procedure

PSYCHIATRIC SOCIAL WORKER VISITS

For dates of service on or after July 1, 2002, report services provided by a Certified Social Worker (CSW) under the direct supervision of an employing psychiatrist, using the following procedure codes
and maximum reimbursable amounts: 90832 ($13.50), 90834 ($27.00), 90846 ($7.20), 90847 ($7.20), 90849 ($7.20), 90853 ($7.20), 90837 ($7.20).

See modifier –AJ. (For services provided prior to July 1, 2002, continue to use procedure codes W0092-W0095.)

**DIALYSIS**

(Professional dialysis fees for procedures 90935-90947 are intended for the attending physician’s personal services related to the dialysis procedures performed)

See SURGERY Section for corresponding surgical procedures.

Codes 90967-90970 are reported when outpatient ESRD related services are not performed consecutively during an entire full month.

Evaluation and management services unrelated to ESRD services that cannot be performed during the dialysis session may be reported separately.

For ESRD related services and dialysis procedure(s) performed during a period of hospitalization:

Separately report appropriate Hospital Evaluation and Management Services code(s) for the hospitalized period if service(s) is unrelated to ESRD services. Report 90945 or 90947 for each inpatient dialysis procedure.

**HEMODIALYSIS**

Codes 90935, 90937 are reported to describe the hemodialysis procedure with all evaluation and management services related to the patient’s renal disease on the day of the hemodialysis procedure. These codes are used for inpatient ESRD and non-ESRD procedures or for outpatient non-ESRD dialysis services. Code 90935 is reported if only one evaluation of the patient is required related to the hemodialysis procedure. Code 90937 is reported when patient re-evaluation(s) is required during a hemodialysis procedure. Use the modifier -25 with Evaluation and Management codes for separately identifiable services unrelated to the dialysis procedure or renal failure which cannot be rendered during the dialysis session.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90935</td>
<td>Hemodialysis procedure with single evaluation by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>90937</td>
<td>Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription</td>
</tr>
</tbody>
</table>

**MISCELLANEOUS DIALYSIS PROCEDURE**

Codes 90945, 90947 describe dialysis procedures other than hemodialysis (eg, peritoneal dialysis, hemofiltration or continuous renal replacement therapies), and all evaluation and management services related to the patient’s renal disease on the day of the procedure. Code 90945 is reported if only one evaluation of the patient is required related to that procedure. Code 90947 is reported when patient re-evaluation(s) is required during a procedure.

Utilize modifier -25 with Evaluation and Management codes for separately identifiable services unrelated to the procedure or renal failure which cannot be rendered during the dialysis session.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90945</td>
<td>Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single evaluation by a physician or other qualified health care professional</td>
</tr>
<tr>
<td>90947</td>
<td>Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated evaluation by a physician or...</td>
</tr>
</tbody>
</table>
other qualified health care professional, with or without substantial revision of dialysis prescription

**END-STAGE RENAL DISEASE SERVICES**

Codes 90951-90962 are reported ONCE per month to distinguish age-specific services related to the patient’s end-stage renal disease (ESRD) performed in an outpatient setting with three levels of service based on the number of face-to-face visits. ESRD-related physician services include establishment of a dialyzing cycle, outpatient evaluation and management of the dialysis visits, telephone calls, and patient management during the dialysis provided during a full month. These codes are not used if hospitalization occurred during the month. In the circumstances where the patient has had a complete assessment visit during the month and services are provided over a period of less than a month, 90951-90962 may be used according to the number of visits performed.

Codes 90963-90966 are reported once per month for a full month of service to distinguish age-specific services for end-stage renal disease (ESRD) services for home dialysis patients. For ESRD and non-ESRD dialysis services performed in an inpatient setting, and for non-ESRD dialysis services performed in an outpatient setting, see 90935-90937 and 90945-90947.

Evaluation and management services unrelated to ESRD services that cannot be performed during the dialysis session may be reported separately.

Codes 90967-90970 are reported to distinguish age-specific services for end-stage renal disease (ESRD) services for less than a full month of service, per day, for services provided under the following circumstances: home dialysis patients less than a full month, transient patients, partial month where there was one or more face-to-face visits without the complete assessment, the patient was hospitalized before a complete assessment was furnished, dialysis was stopped due to recovery or death, or the patient received a kidney transplant. For reporting purposes, each month is considered 30 days.

Codes 90967-90970 are used to report ESRD related services on a per day basis, one claim line is used prorating the number of days within the month X the fee listed, the total number of days should be entered in the “Days or Units” field. The codes can be used preceding and/or following the period of hospitalization. The date of service should be the last date within the month that services were provided.

**EXAMPLE:** A four year old receiving continuous peritoneal dialysis has sixteen days of daily outpatient care, preceding or following a period of hospitalization. Report code on one line indicating 16 in the days/units field.

90951 End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional

90952 with 2-3 face-to-face visits by a physician or other qualified health care professional per month

90953 with 1 face-to-face visit by a physician or other qualified health care professional per month

90954 End-stage renal disease (ESRD) related services monthly, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month
90955 with 2-3 face-to-face visits by a physician or other qualified health care professional per month

90956 with 1 face-to-face visit by a physician or other qualified health care professional per month

90957 End-stage renal disease (ESRD) related services monthly, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face visits by a physician or other qualified health care professional per month

90958 with 2-3 face-to-face visits by a physician or other qualified health care professional per month

90959 with 1 face-to-face visit by a physician or other qualified health care professional per month

90960 End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month

90961 with 2-3 face-to-face visits by a physician or other qualified health care professional per month

90962 with 1 face-to-face visit by a physician or other qualified health care professional per month

(Codes 90951-90962 are reported one time, once a month)

90963 End stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents

90964 End stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents

90965 End stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents

90966 End stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older

(Codes 90963-90966 are reported one time, once a month)

90967 End stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age

90968 for patients 2-11 years of age

90969 for patients 12-19 years of age

90970 for patients 20 years of age and older

(Codes 90967-90970 are reported on one line, prorating the number of days within the month X the fee listed. The total number of days should be entered in the “Days or Units” field. The date of service will be the last date within the month that services were provided)

OTHER DIAYLSIS PROCEDURES

90999 Unlisted dialysis procedure, inpatient or outpatient
GASTROENTEROLOGY

91010 Esophageal motility (manometric study of the esophagus and/or gastroesophageal junction) study with interpretation and report;
91013 with stimulation or perfusion (eg, stimulant, acid or alkali perfusion)
(List separately in addition to primary procedure)
(Use 91013 in conjunction with 91010)
(Do not report 91013 more than once per session)
91020 Gastric motility (manometric) studies
91022 Duodenal motility (manometric) study
91030 Esophagus, acid perfusion (Bernstein) test for esophagitis
91034 Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation
91035 Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation
(91034, 91035 are for patients with esophageal reflux who have already undergone endoscopy and manometry/motility studies, or for those patients who are unable to undergo conventional tests or in whom conventional tests have proven inconclusive. These test are not covered for screening for Barrett's Esophagus)
91037 Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation
91038 prolonged (greater than 1 hour, up to 24 hours)
91040 Esophageal balloon distension provocation study
91065 Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance; bacterial overgrowth, or oro-cecal gastrointestinal transit)
91110 Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with interpretation and report
(Visualization of the colon is not reported separately)
91111 Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report
(Do not report 91111 in conjunction with 91110)
91112 Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report
(Do not report 91112 in conjunction with 91020, 91022, 91117)
91117 Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report
(Do not report 91117 in conjunction with 91120, 91122)
91120 Rectal sensation, tone, and compliance test (ie, response to graded balloon distention)
91122 Anorectal manometry
(Do not report 91220, 91122 in conjunction with 91117)
91200 Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report
91299 Unlisted diagnostic gastroenterology procedure

OPHTHALMOLOGY

OPHTHALMOLOGICAL DIAGNOSTIC AND TREATMENT SERVICES

REPORTING
See MEDICINE General Information and Rules and special ophthalmology notations below. To report Evaluation and Management services, wherever performed, use descriptors from the Evaluation and Management Services for Specialists in Ophthalmology listing (99201 et seq). To report hospital and emergency department medical services, use the descriptors from the Evaluation and Management Services for Specialists in Ophthalmology listing (99221 et seq) unless specific ophthalmological descriptors (92002 et seq) are more appropriate.

**DEFINITIONS:**

**INTERMEDIATE OPHTHALMOLOGICAL SERVICES** describes an evaluation of a new or existing condition complicated with a new diagnostic or management problem not necessarily relating to the primary diagnosis, including history, general medical observation, external ocular and adnexal examination and other diagnostic procedures as indicated; may include the use of mydriasis for ophthalmoscopy. Intermediate services in a new patient do not usually include determination of the refractive state but do so in an established patient (92012) who is under continuing active treatment (e.g., review of history, external examination, ophthalmoscopy, biomicroscopy for an acute complicated condition (e.g., iritis) not requiring comprehensive ophthalmological services or review of interval history, external examination, ophthalmoscopy, biomicroscopy and tonometry in established patient with known cataract not requiring comprehensive ophthalmological services).

**COMPREHENSIVE OPHTHALMOLOGICAL SERVICES** describes a general evaluation of the complete visual system. The comprehensive services constitute a single service entity but need not be performed at one session. The service includes history, general medical observation, external and ophthalmoscopic examination, gross visual fields and basic sensorimotor examination. It often includes, as indicated: biomicroscopy, examination with cycloplegia or mydriasis, tonometry, and includes determination of the refractive state, unless the condition of the media precludes this or it is otherwise contraindicated, as in presence of trauma or severe inflammation. It always includes initiation of diagnostic and treatment programs. Intermediate and comprehensive ophthalmological services constitute integrated services in which medical decision making cannot be separated from the examining techniques used. Itemization of service components, such as slit lamp examination, keratometry, routine ophthalmoscopy, retinoscopy, tonometry, or motor evaluation is not applicable.

(eg, the comprehensive services required for diagnosis and treatment of a patient with symptoms indicating possible disease of the visual system, such as glaucoma, cataract or retinal disease, or to rule out disease of the visual system, new or established patient) “Initiation of diagnostic and treatment program” includes the prescription of medication, lenses and other therapy and arranging for special ophthalmological diagnostic or treatment services, consultations, laboratory procedures and radiological services.

**SPECIAL OPHTHALMOLOGICAL SERVICES** describes services in which a special evaluation of part of the visual system is made, which goes beyond the services usually included under general ophthalmological services, or in which special treatment is given. Special ophthalmological services may be reported in addition to the general ophthalmological services or evaluation and management services. (eg, fluorescein angioscopy or quantitative visual field examination should be separately reported)
Prescription of lenses may be deferred to a subsequent visit, but in any circumstance is not reported separately. (“Prescription of lenses” does not include anatomical facial measurements for or writing of laboratory specifications for spectacles; for spectacle services, see 92340 et seq).

**DETERMINATION OF THE REFRACTIVE STATE**: is the quantitative procedure that yields the refractive data necessary to determine the best visual acuity with lenses and to prescribe lenses. It is not a separate medical procedure, or service entity, but is an integral part of the general ophthalmological services, carried out with reference to other diagnostic procedures. The evaluation of the need for and the prescription of lenses is never based on the refractive state alone. Determination of the refractive state is not reported separately.

Medical diagnostic evaluation by the physician is an integral part of all Ophthalmological services. Technical procedures (which may or may not be performed by the physician personally) are often part of the service, but should not be mistaken to constitute the service itself.

Intermediate and comprehensive ophthalmological services constitute integrated services in which medical diagnostic evaluation cannot be separated from the examining techniques used. Itemization of service components, such as slit lamp examination, keratometry, ophthalmoscopy, retinoscopy, determination of refractive state, tonometry, motor evaluation, etc. is not applicable.

**PRESCRIBING OF POLYCARBONATE LENS(ES)**: The prescriber must maintain documentation in the recipient’s clinical file of the recipient’s systemic ailments and ocular pathology which relate to the medical need for one or more polycarbonate lens(es).

**GENERAL OPHTHALMOLOGICAL SERVICES**

The designation of new or established patient does not preclude the use of a specific level of service. For Evaluation and Management services see 99201 et seq. Solely for the purposes of distinguishing between new and established patients, professional services are those face-to-face services rendered by a physician and reported by a specific CPT code(s).

**NEW PATIENT**

A new patient is one who has not received any professional services from the physician within the past three years.

- 92002 Ophthalmological services: medical examination and evaluation with initiation of diagnostic and treatment program; intermediate, new patient (with/without refraction)
- 92004 comprehensive, new patient (with/without refraction)

**ESTABLISHED PATIENT**

An established patient is one who has received professional services from the physician within the past three years and whose medical and administrative records are available to the physician.

- 92012 Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient (with/without refraction)
- 92014 comprehensive, established patient (with/without refraction)
### SPECIAL OPHTHALMOLOGICAL SERVICES

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>92018</td>
<td>Ophthalmological examination and evaluation, under general anesthesia, with or without manipulation of globe for passive range of motion or other manipulation to facilitate diagnostic examination; complete limited</td>
</tr>
<tr>
<td>92019</td>
<td>Gonioscopy (separate procedure)</td>
</tr>
<tr>
<td>92020</td>
<td>Computerized corneal topography, unilateral or bilateral, with interpretation and report (Do not report 92025 in conjunction with 65710-65755) (92025 is not used for manual keratoscopy, which is part of a single system evaluation and management or ophthalmological service)</td>
</tr>
<tr>
<td>92025</td>
<td>Sensorimotor examination with multiple measurements of ocular deviation (eg, restrictive or paretic muscle with diplopia) with interpretation and report (separate procedure)</td>
</tr>
<tr>
<td>92060</td>
<td>Orthoptic training</td>
</tr>
<tr>
<td>92071</td>
<td>Fitting of contact lens for treatment of ocular surface disease (Do not report 92071 in conjunction with 92072)</td>
</tr>
<tr>
<td>92072</td>
<td>Fitting of contact lens for management of keratoconus, initial fitting (Do not report 92072 in conjunction with 92071)</td>
</tr>
<tr>
<td>92081</td>
<td>Visual field examination, unilateral or bilateral, with interpretation and report; limited examination (eg, tangent screen, Autoplot, arc perimeter, or single stimulus level automated test, such as Octopus 3 or 7 equivalent)</td>
</tr>
<tr>
<td>92082</td>
<td>intermediate examination (eg, at least 2 isopters on Goldmann perimeter, or semiquantitative, automated suprathreshold screening program, Humphrey suprathreshold automatic diagnostic test, Octopus program 33)</td>
</tr>
<tr>
<td>92083</td>
<td>extended examination, (eg, Goldmann visual fields with a least 3 isopters plotted and static determination within the central 30 degrees, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) (Gross visual field testing (eg, confrontation testing) is a part of general ophthalmological services and is not reported separately)</td>
</tr>
<tr>
<td>92100</td>
<td>Serial tonometry (separate procedure) with multiple measurements of intraocular pressure over an extended time period with interpretation and report, same day (eg, diurnal curve or medical treatment of acute elevation of intraocular pressure)</td>
</tr>
<tr>
<td>92132</td>
<td>Scanning computerized ophthalmic diagnostic imaging, anterior segment, with interpretation and report, unilateral or bilateral</td>
</tr>
<tr>
<td>92133</td>
<td>Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve</td>
</tr>
<tr>
<td>92134</td>
<td>retina (Do not report 92133 and 92134 at the same patient encounter) (For scanning computerized ophthalmic diagnostic imaging of the optic nerve and retina, see 92133, 92134)</td>
</tr>
<tr>
<td>92136</td>
<td>Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation (one or both eyes) (LT, RT modifiers valid)</td>
</tr>
</tbody>
</table>

### OPHTHALMOSCOPY
Routine ophthalmoscopy is part of general and special ophthalmologic services whenever indicated. It is a non-itemized service and is not reported separately.

92201 Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral

92202 with drawing of optic nerve or macula (eg, for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or bilateral

92230 Fluorescein angioscopy with interpretation and report (LT, RT modifiers valid)

92235 Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral

92240 Indocyanine-green angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral

92242 Fluorescein angiography and indocyanine-green angiography (includes multiframe imaging) performed at the same patient encounter with interpretation and report, unilateral or bilateral

92250 Fundus photography with interpretation and report (one or both eyes) (LT, RT modifiers valid)

92260 Ophthalmodynamometry (one or both eyes) (LT, RT modifiers valid)

**OTHER SPECIALIZED SERVICES**

Color vision testing with pseudoisochromatic plates is not reported separately. It is included in the appropriate general or ophthalmologic service.

92265 Needle oculo electromyography, one or more extraocular muscles, one or both eyes, with interpretation and report (LT, RT modifiers valid)

92270 Electro-oculography with interpretation and report

92273 Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld (ERG)

92274 multifocal (mfERG)

92286 Anterior segment imaging with interpretation and report; with specular microscopy and endothelial cell analysis

92287 with fluorescein angiography

**CONTACT LENS SERVICES**

The prescription of contact lens includes specification of optical and physical characteristics (such as power, size, curvature, flexibility, gas-permeability). It is not a part of the general ophthalmological services. The fitting of contact lens includes instruction and training of the wearer and incidental revision of the lens during the training period.

Contact lenses may be supplied for the treatment of ocular pathology. A written recommendation or prescription by an ophthalmologist or optometrist is always required for contact lenses. The ophthalmologist or optometrist may also fit and dispense contact lenses.

The prescriber must maintain the following documentation in the recipient’s clinical file:

- A description of the ocular pathology or medical necessity which provides justification for the recipient’s need for contact lenses;
- The best corrected vision both with and without eyeglasses;
- The best corrected vision both with and without contact lenses;
- The refractive error; and
• The date of the last complete eye exam.

92310  Prescription of optical and physical characteristics of and fitting of contact lens, (includes materials) with medical supervision of adaptation (for ocular pathology); corneal lens, both eyes, except for aphakia
   (Reimbursement for one eye is limited to $150.00)
   (Reimbursement for both eyes requires BR)
   92311  corneal lens for aphakia, one eye (LT or RT modifier valid)
   92312  corneal lens for aphakia, both eyes
   92313  corneoscleral lens (one or both eyes) (LT, RT modifiers valid)
   92326  Replacement of contact lens (one or both eyes) (LT, RT modifiers valid)

**OCULAR PROSTHETICS, ARTIFICIAL EYE SERVICES**

V2623  Prosthetic eye, plastic, custom (Includes fitting and supply of ocular prosthesis and clinical supervision of adaptation)
V2624  Polishing/resurfacing of ocular prosthesis
V2625  Enlargement of ocular prosthesis
V2626  Reduction of ocular prosthesis
V2627  Scleral cover shell
   (When prescribed as an artificial support to a shrunken and sightless eye or as barrier in treatment of severe dry eye)
   (Includes supply of shell, fitting and clinical supervision of adaptation)

**SPECTACLE SERVICES (INCLUDING PROSTHESIS FOR APHAKIA)**

Prescription of spectacles, when required, is an integral part of general ophthalmological services and is not reported separately. It includes specification of lens type (monofocal, bifocal, other), lens power, axis prism, absorptive factor, impact resistance and other factors.

Fitting of spectacles is a separate service; when provided by the physician, it is reported as indicated by 92340-92358.

Fitting includes measurement of anatomical facial characteristics, the writing of laboratory specifications, and the final adjustment of the spectacles to the visual axes and anatomical topography. Presence of physician is not required.

Supply of materials is a separate service component; it is not part of the service of fitting spectacles.

92340  Fitting of spectacles, except for aphakia; monofocal
92341     bifocal
92342     multifocal, other than bifocal
92352  Fitting of spectacle prosthesis for aphakia; monofocal
92353     multifocal
92354  Fitting of spectacle mounted low vision aid; single element system
92355     telescopic or other compound lens system
92358  Prosthesis service for aphakia, temporary (disposable or loan, including materials) (one or both eyes)

**SUPPLY OF MATERIALS**

Supply of contact lenses and prosthetics is included in codes 92310-V2627.

99070  Supply of spectacles, except prosthesis for aphakia and low vision aids
Supply of low vision aids (A low vision aid is any lens or device used to aid or improve visual function in a person whose vision cannot be normalized by conventional spectacle correction, includes reading additions up to 4 D.)
Supply of permanent prosthesis for aphakia; spectacles.

OTHER PROCEDURES
92499  Unlisted ophthalmological service or procedure

SPECIAL OTORHINOLARYNGOLOGIC SERVICES
Diagnostic or treatment procedures usually included in a comprehensive otorhinolaryngologic evaluation or office visit, are reported as an integrated medical service, using appropriate descriptors from the 99201 series. Itemization of component procedures, (eg, otoscopy, rhinoscopy, tuning fork test) does not apply.
Special otorhinolaryngologic services are those diagnostic and treatment services not usually included in a comprehensive otorhinolaryngologic evaluation or office visit. These services are reported separately, using codes 92502-92700.
All services include medical diagnostic evaluation. Technical procedures (which may or may not be performed by the physician personally) are often part of the service, but should not be mistaken to constitute the service itself.
92502  Otolaryngologic examination under general anesthesia
92511  Nasopharyngoscopy with endoscope (separate procedure)
92521  Evaluation of speech fluency (eg, stuttering, cluttering)
92522  Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria);
92523  with evaluation of speech sound production with evaluation of language comprehension and expression (eg, receptive and expressive language)
92524  Behavioral and qualitative analysis of voice and resonance

VESTIBULAR FUNCTION TESTS, WITH RECORDING (EG, ENG, PENG), AND MEDICAL DIAGNOSTIC EVALUATION
92537  Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations)
92538  monothermal (ie, one irrigation in each ear for a total of two irrigations)
92540  Basic vestibular evaluation, includes spontaneous nystagmus test with eccentric gaze fixation nystagmus, with recording, positional nystagmus test, minimum of 4 positions, with recording, optokinetic nystagmus test, bidirectional foveal and peripheral stimulation, with recording, and oscillating tracking test, with recording (Do not report 92540 in conjunction with 92541, 92542, 92544, or 92545)
92541  Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording
92542  Positional nystagmus test, minimum of 4 positions, with recording
92544  Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording
92545  Oscillating tracking test, with recording
92546  Sinusoidal vertical axis rotational testing
92517  Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP)
92518  ocular (oVEMP)
92519  cervical (cVEMP) and ocular (oVEMP)
AUDILOGIC FUNCTION TESTS WITH MEDICAL DIAGNOSTIC EVALUATION

The audiometric tests listed below imply the use of calibrated electronic equipment. Other hearing tests (such as whispered voice, tuning fork) are considered part of the general otorhinolaryngologic services and are not reported separately. All services include testing of both ears.

92550  Tymanometry and reflex threshold measurements  
(Do not report 92550 in conjunction with 92567, 92568)
92551  Screening test, pure tone, air only
92552  Pure tone audiometry(threshold); air only
         air and bone
92553  Speech audiometry threshold
92555  with speech recognition
92556  Comprehensive audiometry threshold evaluation and speech recognition 
        (92553 and 92556 combined)
92557  Tone decay test
92565  Stenger test, pure tone
92567  Tymanometry (impedance testing)
92568  Acoustic reflex testing; threshold
92570  Acoustic immittance testing, includes tympanometry (impedance testing), acoustic reflex 
        threshold testing, and acoustic reflex decay testing  
        (Do not report 92570 in conjunction with 92567, 92568)
92571  Filtered speech test
92650  Auditory evoked potentials; screening of auditory potential with broadband stimuli, automated 
        analysis
92651  for hearing status determination, broadband stimuli, with interpretation and report
92652  for threshold estimation at multiple frequencies, with interpretation and report
92653  neurodiagnostic, with interpretation and report
92587  Distortion product evoked otoacoustic emissions; limited evaluation (to confirm the presence 
        or absence of hearing disorder, 3-6 frequencies) or transient evoked otoacoustic emissions, 
        with interpretation and report
92588  comprehensive diagnostic evaluation (quantitative analysis of outer hair cell function by 
        cochlear mapping, minimum of 12 frequencies), with interpretation and report

EVALUATIVE AND THERAPEUTIC SERVICES

Codes 92601 and 92603 describe post-operative analysis and fitting of previously placed external devices, connection to the cochlear implant, and programming of the stimulator. Codes 92602 and 92604 describe subsequent sessions for measurements and adjustment of the external transmitter and re-programming of the internal stimulator.

92601  Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with 
        programming
92602  subsequent reprogramming  
        (Do not report 92602 in addition to 92601)
92603  Diagnostic analysis of cochlear implant, age 7 years or older; with programming 
92604  subsequent reprogramming  
        (Do not report 92604 in addition to 92603)
92597  Evaluation for use and/or fitting of voice prosthetic device to supplement oral speech
92607 Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour
92608 each additional 30 minutes
   (List separately in addition to primary procedure)
   (Use 92608 in conjunction with 92607)
92609# Therapeutic services for the use of speech-generating device, including programming and modification
92610 Evaluation of oral and pharyngeal swallowing function
92611 Motion fluoroscopic evaluation of swallowing function by cine or video recording
92612 Flexible endoscopic evaluation of swallowing by cine or video recording
92613 interpretation and report only
92614 Flexible endoscopic evaluation, laryngeal sensory testing by cine or video recording
92615 interpretation and report only
92616 Flexible endoscopic evaluation of swallowing and laryngeal sensory testing by cine or video recording
92617 interpretation and report only

SPECIAL DIAGNOSIS PROCEDURES
92640# Diagnostic analysis with programming of auditory brainstem implant, per hour

OTHER PROCEDURES
92700 Unlisted otolaryngological service or procedure

CARDIOVASCULAR

OTHER THERAPEUTIC SERVICES AND PROCEDURES
92950 Cardiopulmonary resuscitation (eg, in cardiac arrest)
   (each 15 minute unit of time)
   (See also critical care services, 99291, 99292)
92953 Temporary transcutaneous pacing
92960 Cardioversion, elective, electrical conversion of arrhythmia; external
   (each 15 minute unit of time)
92961 internal (separate procedure)
92970 Cardioassist-method of circulatory assist; internal
92971 external
92986 Percutaneous balloon valvuloplasty; aortic valve
92987 mitral valve
92990 pulmonary valve
92997 Percutaneous transluminal pulmonary artery balloon angioplasty; single vessel
92998 each additional vessel
   (List separately in addition to primary procedure)
   (Use 92998 in conjunction with 92997)

CORONARY THERAPEUTIC SERVICES AND PROCEDURES
92920 Percutaneous transluminal coronary angioplasty; single major coronary artery or branch
92921 each additional branch of a major coronary artery
   (List separately in addition to primary procedure)
92924 Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch
(Use 92921 in conjunction with 92920, 92924, 92928, 92933, 92937, 92941, 92943)

92925 each additional branch of a major coronary artery
(List separately in addition to primary procedure)
(Use 92925 in conjunction with 92924, 92928, 92933, 92937, 92941, 92943)

92928 Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch

92929 each additional branch of a major coronary artery
(List separately in addition to primary procedure)
(Use 92925 in conjunction with 92924, 92928, 92933, 92937, 92941, 92943)

92933 Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch

92934 each additional branch of a major coronary artery
(List separately in addition to primary procedure)
(Use 92934 in conjunction with 92933, 92937, 92941, 92943)

92937 Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel

92938 each additional branch subtended by the bypass graft
(List separately in addition to primary procedure)
(Use 92938 in conjunction with 92937)

92941 Percutaneous transluminal revascularization of acute total/ subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel

92943 Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel

92944 each additional coronary artery, coronary artery branch, or bypass graft
(List separately in addition to primary procedure)
(Use 92944 in conjunction with 92944, 92928, 92933, 92937, 92941, 92943)

92973 Percutaneous transluminal coronary thrombectomy mechanical
(List separately in addition to primary procedure)
(Use 92973 in conjunction with codes 92928, 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92975, 93454-93461)
(Do not report 92973 for aspiration thrombectomy)

92974 Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy
(List separately in addition to primary procedure)
(Use 92974 in conjunction with codes 92928, 92920)

92975 Thrombolysis, coronary; by intracoronary infusion, including selective coronary angiography

92977 by intravenous infusion
92978  Endoluminal imaging of (coronary vessel or graft) using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (List separately in addition to primary procedure)

92979  each additional vessel (List separately in addition to primary procedure)
(Use 92979 in conjunction with code 92978)
(Intravascular ultrasound services include all transducer manipulations and repositioning within the specific vessel being examined, both before and after therapeutic intervention (eg, stent placement))

**CARDIOGRAPHY**

93000  Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93010  interpretation and report only
93015  Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; with supervision, interpretation and report
93016  supervision only without interpretation and report
93018  interpretation and report only
93024  Ergonovine provocation test
93025  Microvolt T-wave alternans for assessment of ventricular arrhythmias
93040  Rhythm ECG, one to three leads; with interpretation and report
93050  Arterial pressure waveform analysis for assessment of central arterial waveform pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive (Do not report 93050 in conjunction with diagnostic or interventional intra-arterial procedures)

**CARDIOVASCULAR MONITORING SYSTEM**

93224  External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional
93227  review and interpretation by a physician or other qualified health care professional
93244  External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation
93248  External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation
93228  External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional.
93229  technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional.
93268  External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; includes transmission, review and interpretation by a physician or other qualified health care professional

93272  review and interpretation by a physician or other qualified health care professional

93278  Signal-averaged electrocardiography (SAECG), with or without ECG
(For interpretation and report only, see modifier -26)

**CARDIOVASCULAR DEVICE MONITORING-IMPLANTABLE AND WEARABLE DEVICES**

93279  Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead pacemaker system or leadless pacemaker system in one cardiac chamber

93280  dual lead pacemaker system

93281  multiple lead pacemaker system

93282  single lead transvenous implantable defibrillator system

93283  dual lead transvenous implantable defibrillator system

93284  multiple lead transvenous implantable defibrillator system

93285  implantable subcutaneous lead defibrillator system

93286  subcutaneous cardiac rhythm monitor system

93287  Peri-procedural device evaluation (in person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review and report by a physician or other qualified health care professional; single, dual, or multiple lead pacemaker system, or leadless pacemaker system
(Report 93286 once before and once after surgery, procedure, or test, when device evaluation and programming is performed before and after surgery, procedure, or test)

93288  single, dual, or multiple lead transvenous implantable defibrillator system
(Report 93287 once before and once after surgery, procedure, or test, when device evaluation and programming is performed before and after surgery, procedure, or test)

93289  Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system, or leadless pacemaker system

93287  single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements

93261  implantable subcutaneous lead defibrillator system

93290  implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors
(Do not report 93290 in conjunction with 93297, 93299)

93291  subcutaneous cardiac rhythm monitor system, including heart rhythm derived data analysis
(Do not report 93291 in conjunction with 93282, 93288-93290, 93298,93299)

93292  wearable defibrillator system
(Do not report 93292 in conjunction with 93294)
93293  Transtelephonic rhythm strip pacemaker evaluation(s) single, dual, or multiple lead pacemaker system, includes recording with and without magnet application with analysis, review and report(s) by a physician or other qualified health care professional, up to 90 days (Report 93293 only once per 90 days)

93294  Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional (Report 93294 only once per 90 days)

93295  single, dual, or multiple lead implantable defibrillator system with analysis, review(s) and report(s) by a physician or other qualified health care professional (Report 93295 only once per 90 days)

93297  Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified (Report 93297 only once per 30 days)

93298  subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional (Report 93298 only once per 30 days)

**ECHOCARDIOGRAPHY**

For procedure codes 93303-93355, See Radiology Section General Instructions and General Information and Rules. When more than one radiology procedure is performed during the same patient encounter, reimbursement shall be limited to the greater fee plus 60% of the lesser fees. (Echocardiography includes obtaining ultrasonic signals from the heart and great arteries, with two-dimensional image and/or Doppler ultrasonic signal documentation, interpretation and report. When interpretation is performed separately, use modifier -26.)

93303  Transthoracic echocardiography for congenital cardiac anomalies; complete

93304  follow-up or limited study

93306  Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography

93307  Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography

93308  follow-up or limited study

93312  Echocardiography, transesophageal, real time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report

93313  placement of transesophageal probe only

93314  image acquisition, interpretation and report only

93315  Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report

93316  placement of transesophageal probe only

93317  image acquisition, interpretation and report only
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93318</td>
<td>Echocardiography, transesophageal (TEE) for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis</td>
</tr>
<tr>
<td>93319</td>
<td>3D echocardiographic imaging and postprocessing during transesophageal echocardiography, or during transthoracic echocardiography for congenital cardiac anomalies, for the assessment of cardiac structure(s) (eg, cardiac chambers and valves, left atrial appendage, interatrial septum, interventricular septum) and function, when performed (List separately in addition to code for echocardiographic imaging)</td>
</tr>
<tr>
<td>93320</td>
<td>Doppler echocardiography, pulsed wave and/or continuous wave with spectral display; complete (List separately in addition to codes for echocardiographic imaging)</td>
</tr>
<tr>
<td>93321</td>
<td>follow-up or limited study (List separately in addition to codes for echocardiographic imaging) (Use 93320, 93321 separately in conjunction with 93303, 93304, 93312, 93314, 93315, 93317, 93350, 93351)</td>
</tr>
<tr>
<td>93325</td>
<td>Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) (Use 93325 in conjunction with 76825-76828, 93303, 93304, 93312, 93314, 93315, 93317, 93350, 93351)</td>
</tr>
<tr>
<td>93350</td>
<td>Echocardiography, transthoracic, real time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report (The appropriate stress testing code(s) from the 93015-93018 series should be reported in addition to 93350 to capture the exercise stress portion of the study)</td>
</tr>
<tr>
<td>93351</td>
<td>including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional (Do not report 93351 in conjunction with 93015-93018, 93350)</td>
</tr>
<tr>
<td>93355</td>
<td>Echocardiography, transesophageal (TEE) for guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (eg, TAVR, transcatheter pulmonary valve replacement, mitral valve repair, paravalvular regurgitation repair, left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural), real-time image acquisition and documentation, guidance with quantitative measurements, probe manipulation, interpretation, and report, including diagnostic transesophageal echocardiography and, when performed, administration of ultrasound contrast, Doppler, color flow, and 3D</td>
</tr>
</tbody>
</table>

**CARDIAC CATHETERIZATION**

Cardiac catheterization is a diagnostic medical procedure which includes introduction, positioning and repositioning, when necessary, of catheter(s), within the vascular system, recording of intracardiac and/or intravascular pressure(s), and final evaluation and report of procedure. There are two code families for cardiac catheterization: one for congenital heart disease and one for all other conditions. Anomalous coronary arteries, patent foramen vale, mitral valve prolapse, and bicuspid aortic valve are to be reported with 93451-93464, 93566-93568.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93451</td>
<td>Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed</td>
</tr>
</tbody>
</table>
93452 Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed
(Do not report 93452 in conjunction with 93453, 93458-93461)

93453 Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation when performed
(Do not report 93453 in conjunction with 93451, 93452, 93456-93461)

93454 Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation;
with catheter placement(s) in bypass graft(s) (internal mammary, free arterial venous grafts) including intraprocedural injection(s) for bypass graft angiography
with right heart catheterization
with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization
with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography
with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography

93456 Left heart catheterization by transseptal puncture through intact septum or by transapical puncture
(List separately in addition to primary procedure)

93457 Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent), including assessing hemodynamic measurements before, during, after, and repeat pharmacologic agent administration, when performed
(List separately in addition to primary procedure)
(Report 93463 only once per catheterization procedure)
(Do not report 93463 for pharmacologic agent administration in conjunction with coronary interventional procedure codes 92975, 92977, 92928, 92920, 92924)

93458 Physiologic exercise study (eg, bicycle or arm ergometry) including assessing hemodynamic measurements before and after
(List separately in addition to primary procedure)
(Use 93464 in conjunction with 33477, 93451-93453, 93456-93461, 93593, 93594, 93595, 93596, 93597)
(Report 93464 only once per catheterization procedure)

93459 Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes

93460 Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization
(List separately in addition to primary procedure)
93564 for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed
(List separately in addition to primary procedure)
93565 for selective left ventricular or left atrial angiography
(List separately in addition to primary procedure)
(Do not report 93563-93565 in conjunction with 93452-93461)
(Use 93565 in conjunction with 33741, 33745, 93582, 93593, 93594, 93595, 93596, 93597)
93566 for selective right ventricular or right atrial angiography
(List separately in addition to primary procedure)
93567 for supravalvular aortography
(List separately in addition to primary procedure)
93568 for pulmonary angiography
(List separately in addition to primary procedure)
(Use 93568 in conjunction with 33741, 33745, 93451, 93453, 93456, 93457, 93460, 63461, 93580, 93581, 93582, 93593, 93594, 93595, 93596, 93597)
93571 Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel
(List separately in addition to primary procedure)
93572 each additional vessel
(List separately in addition to primary procedure)
(Intravascular distal coronary blood flow velocity measurements include all Doppler transducer manipulations and repositioning within the specific vessel being examined, during coronary angioplasty or therapeutic intervention [eg, angioplasty])

REPAIR OF STRUCTURAL HEART DEFECT
93580 Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant
93581 Percutaneous transcatheter closure of a congenital ventricular septal defect with implant
93582 Percutaneous transcatheter closure of patent ductus arteriosus
93583 Percutaneous transcatheter septal reduction therapy (eg, alcohol septal ablation) including temporary pacemaker insertion when performed

TRANSCATHETER CLOSURE OF PARAVALVULAR LEAK
Codes 93590, 93591, 93592 are used to report transcatheter closure of paravalvular leak (PVL). Codes 93590 and 93591 include, when performed, percutaneous access, placing the access sheath(s), advancing the delivery system to the paravalvular leak, positioning the closure device, repositioning the closure device as needed, and deploying the device.
Codes 93590 and 93591 include, when performed, fluoroscopy (76000), angiography, radiological supervision and interpretation services performed to guide the PVL closure (eg, guiding the device placement and documenting completion of the intervention),
Code 93590 includes transseptal puncture, and left heart catheterization/left ventriculography (93452, 93453, 93458, 93459, 93460, 93461, 93565, 93595, 93596, 93597). Transapical left heart catheterization (93462) may be reported separately, when performed. 

Code 93591 includes, when performed, supravalvular aortography (93567), left heart catheterization/left ventriculography (93452, 93453, 93458, 93459, 93460, 93461, 93565, 93595, 93596, 93597). Transapical left heart catheterization (93462) may be reported separately, when performed.

Diagnostic right heart catheterization codes (93451,93456 93457, 93593, 93594, 93598) and diagnostic coronary angiography codes (93454, 93455, 93456, 93457,93563, 93564) may be reported with 93590, 93591, representing separate and distinct services from PVL closure, if:
1. No prior study is available and a full diagnostic study is performed, or
2. A prior study is available, but as documented in the medical record:
   a. there is inadequate visualization of the anatomy and/or pathology, or
   b. the patient’s condition with respect to the clinical indication has changed since the prior study, or
   c. there is a clinical change during the procedure that requires a new evaluation.

Other cardiac catheterization services may be reported separately, when performed for diagnostic purposes not intrinsic to PVL closure.

For same session/same day diagnostic cardiac catheterization services report the appropriate diagnostic cardiac catheterization code(s) appended with modifier 59 indicating separate and distinct procedural service from PVL closure.

93590 Percutaneous transcatheter closure of paravalvular leak; initial occlusion device, mitral valve
93591 initial occlusion device, aortic valve
93592 each additional occlusion device (List separately in addition to code for primary Procedure

CARDIAC CATHETERIZATION FOR CONGENITAL HEART DEFECTS

Cardiac catheterization for the evaluation of congenital heart defect(s) is reported with 93593, 93594, 93595,93596, 93597, 93598. Cardiac catheterization services for anomalous coronary arteries arising from the aorta or off of other coronary arteries, patent foramen ovale, mitral valve prolapse, and bicuspid aortic valve, in the absence of other congenital heart defects, are reported with 93451-93464, 93566, 93567, 93568. However, when these conditions exist in conjunction with other congenital heart defects, 93593, 93594, 93595, 93596, 93597 may be reported. Evaluation of anomalous coronary arteries arising from pulmonary arterial system is reported with the cardiac catheterization for congenital heart defects codes.

93593 Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone; normal native connections
93594 abnormal native connections
93595 Left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone; normal or abnormal native connections
93596 Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone(s); normal native connections
93597 abnormal native connections
93598  Cardiac output measurement(s) thermodilution or other indicator dilution method, performed during cardiac catheterization for the evaluation of congenital heart defects (List separately in addition to code for primary procedure)

**INTRACARDIAL ELECTROPHYSIOLOGICAL PROCEDURES/STUDIES**

Intracardiac electrophysiologic studies (EPS) are an invasive diagnostic medical procedure which include the insertion and repositioning of electrode catheters, recording of electrograms before and during pacing or programmed stimulation of multiple locations in the heart, analysis of recorded information, and report of the procedure.

Electrophysiologic studies are most often performed with two or more electrode catheters. In many circumstances, patients with arrhythmias are evaluated and treated at the same encounter. In this situation, a diagnostic *electrophysiologic study* is performed, induced tachycardia(s) are *mapped*, and on the basis of the diagnostic and mapping information, the tissue is *ablated*. Electrophysiologic study(s), mapping, and ablation represent distinctly different procedures, requiring individual reporting whether performed on the same or subsequent dates.

**DEFINITIONS:**

**ARRHYTHMIA INDUCTION**: In most electrophysiologic studies, an attempt is made to induce arrhythmia(s) from single or multiple sites within the heart. Arrhythmia induction is achieved by performing pacing at different rates, programmed stimulation (introduction of critically timed electrical impulses), and other techniques. Because arrhythmia induction occurs via the same catheter(s) inserted for the electrophysiologic study(s), catheter insertion and temporary pacemaker codes are not additionally reported. Codes 93600-93603, 93610-93612 and 93618 are used to describe unusual situations where there may be recording, pacing or an attempt at arrhythmia induction from only one site in the heart.

Code 93619 describes only evaluation of the sinus node, atrioventricular node and His-Purkinje conduction system, without arrhythmia induction. Codes 93620-93624 and 93640-93642 all include recording, pacing and attempted arrhythmia induction from one or more site(s) in the heart.

**MAPPING**: Mapping is a distinct procedure performed in addition to a diagnostic electrophysiologic procedure and should be separately reported using code 93609. When a tachycardia is induced, the site of tachycardia origination or its electrical path through the heart is often defined by mapping. Mapping creates a multidimensional depiction of a tachycardia by recording multiple electrograms obtained sequentially or simultaneously from multiple catheter sites in the heart. Depending upon the technique, certain types of mapping catheters may be repositioned from point-to-point within the heart, allowing sequential recording from the various sites to construct maps. Other types of mapping catheters allow mapping without a point-to-point technique by the allowing simultaneous recording from many electrodes on the same catheter and computer-assisted three dimensional reconstruction of the tachycardia activation sequence.

**ABLATION**: Once the part of the heart involved in the tachycardia is localized, the tachycardia may be treated by ablation (the delivery of a radiofrequency energy to the area to selectively destroy cardiac tissue). Ablation procedures (93653-93657) may be performed: independently on a date subsequent to a diagnostic electrophysiologic study and mapping; or, at the time a diagnostic electrophysiologic study, tachycardia(s) induction and mapping is performed. When an electrophysiologic study, mapping, and ablation are performed on the same date, each procedure should be separately reported. In reporting catheter ablation, code 93633 and/or 93657 should be reported once to describe ablation of cardiac arrhythmias, regardless of the number of arrhythmias ablated.

93600  Bundle of His recording
93602  Intra-atrial recording
93603  Right ventricular recording
93609 Intraventricular and/or intra-atrial mapping of tachycardia site(s) with catheter manipulation to record from multiple sites to identify origin of tachycardia (List separately in addition to primary procedure) (Use 93609 in conjunction with codes 93620, 93653, 93657) (Do not report 93609 in addition to 93613)

93610 Intra-atrial pacing

93612 Intraventricular pacing (Do not report 93612 in conjunction with codes 93620-93622)

93613 Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to primary procedure) (Use 93613 in conjunction with codes 93620, 93653, 93657) (Do not report 93613 in addition to 93609)

93615 Esophageal recording of atrial electrogram with or without ventricular electrogram(s); with pacing

93616 Induction of arrhythmia by electrical pacing

93619 Comprehensive electrophysiologic evaluation with right atrial pacing and recording, right ventricular pacing and recording, HIS bundle recording, including insertion and repositioning of multiple electrode catheters, without induction or attempted induction of arrhythmia (Do not report 93619 in conjunction with 93600, 93602, 93610, 93612, 93618, or 93620-93622)

93620 Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with right atrial pacing and recording, right ventricular pacing and recording, HIS bundle recording

93621 with left atrial pacing and recordings from coronary sinus or left atrium (List separately in addition to primary procedure)

93622 with left ventricular pacing and recordings (List separately in addition to primary procedure)

93623 Programmed stimulation and pacing after intravenous drug infusion (List separately in addition to primary procedure)

93624 Electrophysiologic follow-up study with pacing and recording to test effectiveness of therapy, including induction or attempted induction of arrhythmia

93631 Intra-operative epicardial and endocardial pacing and mapping to localize the site of tachycardia or zone of slow conduction for surgical correction

93640 Electrophysiologic evaluation of single or dual chamber pacing cardioverter-defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement; with testing of single or dual chamber pacing cardioverter-defibrillator pulse generator

93642 Electrophysiologic evaluation of single or dual chamber transvenous pacing cardioverter-defibrillator (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)

93644 Electrophysiologic evaluation of subcutaneous implantable defibrillator (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming of reprogramming of sensing or therapeutic parameters) (Do not report 96344 in conjunction with 33270 at the time of subcutaneous implantable defibrillator device insertion)
93650 Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement

93653 Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including intracardiac electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when performed; with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry (Do not report 93653 in conjunction with 93600-93603, 93610, 93612, 93618-93620, 93642, 93654, 93656)

93654 with treatment of ventricular tachycardia or focus of ventricular ectopy including left ventricular pacing and recording, when performed (Do not report 93654 in conjunction with 93279-93284, 93286-93289, 93600-93603, 93609, 93610, 93612, 93613, 93618-93620, 93622, 93642, 93653, 93656)

93655 Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to primary procedure) (Use 93655 in conjunction with 93653, 93654, 93656)

93656 Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac electrophysiologic 3-dimensional mapping, intracardiac echocardiography including imaging supervision and interpretation, induction or attempted induction of an arrhythmia including left or right atrial pacing/recording, right ventricular pacing/recording, and His bundle recording, when performed (Do not report 93656 in conjunction with 92379-93284, 93286-93289, 93462, 93600, 93602, 93603, 93610, 93612, 93618, 93619, 93620, 93621, 93653, 93654)

93657 Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to primary procedure) (Use 93657 in conjunction with 93656)

93660 Evaluation of cardiovascular function with tilt table evaluation, with continuous ECG monitoring and intermittent blood pressure monitoring, with or without pharmacological intervention

93662 Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to primary procedure) (Do not report 92961 in addition to code 93662)

**NONINVASIVE PHYSIOLOGIC STUDIES AND PROCEDURES**

93701 Bioimpedance, thoracic; electrical

93724 Electronic analysis of antitachycardia pacemaker system (includes electrocardiographic recording, programming of device, induction and termination of tachycardia via implanted pacemaker, and interpretation of recordings)
93745 Initial set-up and programming by a physician or other qualified health care professional of wearable cardioverter-defibrillator includes initial programming of system, establishing baseline electronic ECG, transmission of data to data repository, patient instruction in wearing system and patient reporting of problems or events (Do not report 93745 in conjunction with 93282, 93292)

93750 Interrogation of ventricular assist device (VAD), in person, with physician or qualified health care professional analysis of device parameters (eg, drivelines, alarms, power surges), review of device function (eg, flow and volume status, septum status, recovery), with programming, if performed, and report (Do not report 93750 in conjunction with 33975, 33976, 33977, 33981-33983)

93784 Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; including recording, scanning analysis, interpretation and report

93790 review with interpretation and report

OTHER PROCEDURES
93797 Physician or other qualified health care professional services for outpatient cardiac rehabilitation; without continuous ecg monitoring (per session)

93798 with continuous ECG monitoring (per session)

93799 Unlisted cardiovascular service or procedure

NONINVASIVE VASCULAR DIAGNOSTIC STUDIES
For procedure codes 93880-93990, see Radiology Section General Instructions and General Information and Rules.
Vascular studies include patient care required to perform the studies, supervision of the studies and interpretation of study results with copies for patient records of hard copy output with analysis of all data, including bidirectional vascular flow or imaging when provided.
The use of a simple hand-held or other Doppler device that does not produce hard copy output or that produces a record that does not permit analysis of bidirectional vascular flow, is considered to be part of the physical examination of the vascular system and is not separately reported.
Duplex scan (eg, 93880, 93882): Describes an ultrasonic scanning procedure for characterizing the pattern and direction of blood flow in arteries or veins with the production of real time images integrating B-mode two-dimensional vascular structure with spectral and/or color flow Doppler mapping or imaging.
Non-invasive physiologic studies are performed using equipment separate and distinct from the duplex scanner. Codes 93922, 93923 and 93924 describe the evaluation of non-imaging physiologic recordings of pressures, Doppler analysis of bidirectional blood flow, plethysmography, and/or oxygen tension measurements appropriate for the anatomic area studied

CEREBROVASCULAR ARTERIAL STUDIES
93880 Duplex scan of extracranial arteries; complete bilateral study
93882 unilateral or limited study
93886 Transcranial Doppler study of the intracranial arteries; complete study
93888 limited study
93890 Transcranial Doppler study of the intracranial arteries; vasoreactivity study
emboli detection without intravenous microbubble injection
emboli detection with intravenous microbubble injection

EXTREMITY ARTERIAL STUDIES (INCLUDING DIGITS)
93922 Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with transcutaneous oxygen tension measurements at 1-2 levels)
93923 Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more level(s), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)
93924 Noninvasive physiologic studies of lower extremity arteries, at rest and following treadmill stress testing, (ie, bidirectional Doppler waveform or volume plethysmography recording and analysis at rest with ankle/brachial indices immediately after and at timed intervals following performance of a standardized protocol on a motorized treadmill plus recording of time of onset of claudication or other symptoms, maximal walking time, and time to recovery) complete bilateral study
(Do not report 93924 in conjunction with 93922, 93923)
93925 Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study
93926 unilateral or limited study
93930 Duplex scan of upper extremity arteries or arterial bypass grafts; complete bilateral study
93931 unilateral or limited study

EXTREMITY VENOUS STUDIES (INCLUDING DIGITS)
93970 Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study
93971 unilateral or limited study

VISCERAL AND PENILE VASCULAR STUDIES
93975 Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study
93976 limited study
93978 Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study
93979 unilateral or limited study
93980 Duplex scan of arterial inflow and venous outflow of penile vessels; complete study
93981 unilateral or limited study

EXTREMITY ARTERIAL VENOUS STUDIES
93985  Duplex scan of arterial flow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete bilateral study
93986  complete unilateral study
93990  Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)

OTHER NONINVASIVE VASCULAR DIAGNOSTIC STUDIES
93998  Unlisted noninvasive vascular diagnostic study

PULMONARY

PULMONARY DIAGNOSTIC TESTING, REHABILITATION, AND THERAPIES
Codes 94010-94799 include laboratory procedure(s), interpretation and physician's services (except surgical and anesthesia services as listed in their sections), unless otherwise stated. If a separate identifiable Evaluation and Management service is performed, the appropriate E/M service code should be reported in addition to 94010-94799.
94010  Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
94011  Measurement of spirometric forced expiratory flows in an infant or child through 2 years of age
94012  Measurement of spirometric forced expiratory flows, before and after bronchodilator, in an infant or child through 2 years of age
94013  Measurement of lung volumes (ie, functional residual capacity [FRC], forced vital capacity [FVC], and expiratory reserve volume [ERV] in an infant or child through 2 years of age
94014  Patient-initiated spirometric recording per 30-day period of time; includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and review and interpretation by a physician or other qualified health care professional
94016  review and interpretation only by a physician or other qualified health care professional
94060  Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
94070  Bronchospasm provocation evaluation, multiple spirometric determinations as in 94010, with administered agents (eg antigen(s), cold air, methacholine)
94200  Maximum breathing capacity, maximal voluntary ventilation
94375  Respiratory flow volume loop
94610  Intrapulmonary surfactant administration by a physician or other qualified health care professional through endotracheal tube
94617  Exercise test for bronchospasm, including pre- and post-spirometry and pulse oximetry; with electrocardiographic recording(s)
94619  without electrocardiographic recordings.
94618  Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed
94621  Cardiopulmonary exercise testing including measurements of minute ventilation, CO2 production, O2 uptake and electrocardiographic recordings
94625 Physician or other qualified health care professional services for outpatient pulmonary rehabilitation; without continuous oximetry monitoring (per session)
94626 with continuous oximetry monitoring (per session)
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (eg, with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device)
94642 Aerosol inhalation of pentamidine for pneumocystis carinii pneumonia treatment for prophylaxis
94644 Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour
(For services of less than 1 hour, use 94640)
94645 each additional hour
(List separately in addition to primary procedure)
(Use 94645 in conjunction with 94644)
94664 Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device
(94664 can be reported one time only per day of service)
94680 Oxygen uptake, expired gas analysis; rest and exercise, direct, simple
94681 including C02 output, percentage oxygen extracted
94690 rest, indirect (separate procedure)
94726 Plethysmography for determination of lung volumes and, when performed, airway resistance
(Do not report 94726 in conjunction with 94727, 94728)
94727 Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes
(Do not report 94727 in conjunction with 94726)
94728 Airway resistance by impulse oscillometry
(Do not report 94728 in conjunction with 94010, 94060, 94070, 94375, 94726)
94729 Diffusing capacity (eg, carbon monoxide, membrane)
(List separately in addition to primary procedure)
(Report 94729 in conjunction with 94010, 94060, 94070, 94375, 94726-94728)
94772 Circadian respiratory pattern recording (pediatric pneumogram), 12 to 24 hour continuous recording, infant (includes interpretation and report)
(Separate procedure codes for electromyograms, EEG, ECG, and recordings of respiration are excluded when 94772 is reported)
94777 Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; review, interpretation and preparation of report only by a physician or other qualified health care professional
94799 Unlisted pulmonary service or procedure

ALLERGY AND CLINICAL IMMUNOLOGY
DEFINITIONS:
ALLERGY SENSITIVITY TESTS: the performance and evaluation of selective cutaneous and mucous membrane tests in correlation with the history, physical examination, and other observations of the patient. The number of tests performed should be judicious and dependent upon the history, physical findings, and clinical judgment. All patients should not necessarily receive the same tests or the same number of sensitivity tests. Maximum fees include observation and interpretation of the tests by a
Physician. In routine office practice, any of the following items may be billed in addition to the appropriate visit codes.

**IMMUNOTHERAPY (Desensitization, Hyposensitization):** The parenteral administration of allergenic extracts as antigens at periodic intervals, usually on an increasing dosage scale to a dosage which is maintained as maintenance therapy. Indications for immunotherapy are determined by appropriate diagnostic procedures coordinated with clinical judgment and knowledge of the natural history of allergic diseases.

For professional services for allergen immunotherapy not including provision of allergenic extracts, see appropriate Evaluation and Management code.

**ALLERGY TESTING**

95004  Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests

95017  Allergy testing, any combination of percutaneous (scratch, puncture, prick) and Intracutaneous (intradermal), sequential and incremental, with venoms, immediate type reaction, including test interpretation and report, specify number of tests

95018  Allergy testing, any combination of percutaneous (scratch, puncture, prick) and Intracutaneous (intradermal), sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests

95024  Intracutaneous (intradermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests

95028  Intracutaneous (intradermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests

95044  Patch or application test(s) (up to 10 tests) (Specify number of tests)

95060  Ophthalmic mucous membrane tests

95065  Direct nasal mucous membrane test

**SENSITIVITY TESTING**

(Maximum fees include reading of test)

86485  Skin test, candida

86486  Unlisted antigen, each

86490  Coccidioidomycosis

86510  Histoplasmosis

86580  Tuberculosis, intradermal

**ALLERGEN IMMUNOTHERAPY**

Codes 95115-95180 include the professional services necessary for allergen immunotherapy. Office Evaluation and Management codes may be used in addition to allergen immunotherapy if, and only if, other identifiable services are provided at that time.

95115  Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection

95117  2 or more injections

95144  Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials)

95145  Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom
95146  2 single stinging insect venoms
95147  3 single stinging insect venoms
95148  4 single stinging insect venoms
95149  5 single stinging insect venoms
95165  Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; (to be administered by or under the supervision of another physician) single or multiple antigens, multiple dose vial(s),
      (Specify number of DOSES)
95170  whole body extract of biting insect of other arthropod (specify number of doses)
95180  Rapid desensitization procedure, each hour (eg, insulin, penicillin, equine serum)

**ENDOCRINOLOGY**

95250  Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified healthcare professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording

95251  analysis, interpretation and report

**NEUROLOGY AND NEUROMUSCULAR PROCEDURES**

Neurologic services are typically consultative, and any of the levels of consultation (99241-99255) may be appropriate. In addition, services and skills outlined under Evaluation and Management levels of service appropriate to neurologic illnesses should be coded similarly.

All services listed below (95805-95829) include recording, interpretation by a physician and report. For interpretation only, use modifier -26.

**SLEEP TESTING**

Orders for sleep testing are limited to physician specialists in pulmonology, otolaryngology and neurology. Documentation to support the medical necessity of sleep testing must be maintained in the ordering physician's clinical file. Sleep studies and polysomnography refer to the continuous and simultaneous monitoring and recording of various physiological and pathophysiological parameters of sleep for six or more hours with physician review, interpretation and report.

The studies are performed to diagnose a variety of sleep disorders and to evaluate a patient's response to therapies such as nasal continuous positive airway pressure (NCPAP). Polysomnography is distinguished from sleep studies by the inclusion of sleep staging which is defined to include a 1-4 lead electroencephalogram (EEG), electro-oculogram (EOG), and a submental electromyogram (EMG).

Additional parameters of sleep include: 1) ECG; 2) airflow; 3) ventilation and respiratory effort; 4) gas exchange by oximetry, transcutaneous monitoring, or end tidal gas analysis; 5) extremity muscle activity, motor activity-movement; 6) extended EEG monitoring; 7) penile tumescence; 8) gastroesophageal reflux; 9) continuous blood pressure monitoring; 10) snoring; 11) body positions; etc.

For a study to be reported as polysomnography, sleep must be recorded and staged.

95805  Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness
95807  Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate and oxygen saturation, attended by a technologist
95808  Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist
95810  age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
95811  age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist
95782  younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
95783  younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist

**ROUTINE ELECTROENCEPHALOGRAPHY (EEG)**
EEG codes 95812-95822 include hyperventilation and/or photic stimulation when appropriate. Routine EEG codes 95816-95822 include 20 to 40 minutes of recording. Extended EEG codes 95812-95813 include reporting times longer than 40 minutes.
95812  Electroencephalogram (EEG) extended monitoring; 41-60 minutes
95813  61-119 minutes
95816  Electroencephalogram (EEG); including recording awake and drowsy
95819  including recording awake and asleep
95822  recording in coma or sleep only
95824  cerebral death evaluation only
95829  Electrocopticogram at surgery (separate procedure)
95830  Insertion by physician or other qualified health care professional of sphenoidal electrodes for electroencephalographic (EEG) recording

**MUSCLE AND RANGE OF MOTION TESTING**
95851  Range of motion measurements and report (separate procedure); each extremity (excluding hand) or each trunk section (spine)
95852  hand, with or without comparison with normal side
95857  Cholinesterase inhibitor challenge test for myasthenia gravis

**ELECTROMYOGRAPHY AND NERVE CONDUCTION TESTS**
Needle electromyographic procedures include the interpretation of electrical waveforms measured by equipment that produces both visible and audible components of electrical signals recorded from the muscle(s) studied by the needle electrode.
95860  Needle electromyography; one extremity with or without related paraspinal areas
95861  two extremities with or without related paraspinal areas
95863  three extremities with or without related paraspinal areas
95864  four extremities with or without related paraspinal areas
95865  larynx
   (Do not report modifier 50 in conjunction with 95865)
95866  hemidiaphragm
95867  cranial nerve supplied muscle(s), unilateral
95868  cranial nerve supplied muscle(s), bilateral
95869  thoracic paraspinal muscles (excluding T1 or T12)
95870  limited study of muscles in one extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters
95872  Needle electromyography, using single fiber electrode, with quantitative measurement of jitter, blocking and/or fiber density, any/all sites of each muscle studied
95885  Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited
   (List separately in addition to primary procedure)
95886  complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels
   (List separately in addition to primary procedure)
95887  Needle electromyography, non-extremity (cranial nerve supplied or axial) muscle(s) done with nerve conduction, amplitude and latency/velocity study
   (List separately in addition to primary procedure)

**ISCHEMIC MUSCLE TESTING AND GUIDANCE FOR CHEMODENERVATION**
95875  Ischemic limb exercise test with serial specimen(s) acquisition for muscle(s) metabolite(s)

**NERVE CONDUCTION TESTS**
95905  Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report
   (Report 95905 only once per limb studied)
   (Do not report 95905 in conjunction with 95907-95913)
95907  Nerve conduction studies; 1-2 studies
95908  3-4 studies
95909  5-6 studies
95910  7-8 studies
95911  9-10 studies
95912  11-12 studies
95913  13 or more studies

**INTRAOPERATIVE NEUROPHYSIOLOGY**
95940  Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes
   (List separately in addition to primary procedure)
   (Use 95940 in conjunction with the study preformed)

**AUTONOMIC FUNCTION TESTS**
95921  Testing of autonomic nervous system function; cardiovagal innervation (parasympathetic function), including two or more of the following: heart rate response to deep breathing with recorded R-R interval, Valsalva ratio, and 30:15 ratio
95922  vasomotor adrenergic innervation (sympathetic adrenergic function), including beat-to-beat blood pressure and R-R interval changes during Valsalva maneuver and at least five minutes of passive tilt
95923  sudomotor, including one or more of the following: quantitative sudomotor axon reflex test (QSART), silastic sweat imprint, thermoregulatory sweat test, and changes in sympathetic skin potential
95924  combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt
(Do not report 95924 in conjunction with 95921 or 95922)

**EVOKE POTENTIALS AND REFLEX TESTS**

95925  Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs
95926  in lower limbs
95938  Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs
95927  in the trunk or head
95928  Central motor evoked potential study (transcranial motor stimulation); upper limbs
95929  lower limbs
95939  Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs
95930  Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report
95933  Orbicularis oculi (blink) reflex, by electrodiagnostic testing
95937  Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any one method

**SPECIAL EEG TESTS**

95954  Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, thiopental activation test)
95955  Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery)
95958  Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring
95961  Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or identify vital brain structures; initial hour of attendance by a physician or other qualified health care professional
95962  each additional hour of attendance by a physician or other qualified health care professional
   (List separately in addition to primary procedure)
   (Use 95962 in conjunction with code 95961)
95965  Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (eg, epileptic cerebral cortex localization)
95966  for evoked magnetic fields, single modality (eg, sensory, motor, language, or visual cortex localization)
95967  for evoked magnetic fields, each additional modality (eg, sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)
Physician – Procedure Codes, Section 2- Medicine, Drugs and Drug Administration

95700  Electroencephalogram (EEG), continuous recording, with video when performed, setup, patient education, and takedown when performed, administered in person by EEG technologist, minimum of 8 channels

95705  Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; unmonitored

95706  with intermittent monitoring and maintenance

95707  with continuous, real-time monitoring and maintenance

95708  Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored

95709  with intermittent monitoring and maintenance

95710  with continuous, real-time monitoring and maintenance

95711  Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; unmonitored

95712  with intermittent monitoring and maintenance

95713  with continuous, real-time monitoring and maintenance

95714  Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored

95715  with intermittent monitoring and maintenance

95716  with continuous, real-time monitoring and maintenance

**MONITORING**

95717  Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; without video

95718  with video (VEEG)

95719  Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; without video

95720  with video (VEEG)

95721  Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, without video

95722  greater than 36 hours, up to 60 hours of EEG recording, with video (VEEG)

95723  greater than 60 hours, up to 84 hours of EEG recording, without video

95724  greater than 60 hours, up to 84 hours of EEG recording, with video (VEEG)

95725  greater than 84 hours of EEG recording, without video

95726  greater than 84 hours of EEG recording, with video (VEEG)

**NEUROSTIMULATORS, ANALYSIS-PROGRAMMING**

95970  Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified
health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming

95971 with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional

95972 with complex spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional

95976 with simple cranial nerve neurostimulator pulse generator/transmitter programming by a physician or other qualified health care professional

95977 with complex cranial nerve neurostimulator pulse generator/transmitter programming by a physician or other qualified health care professional

95983 with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional

95984 with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)

95980 Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming

95981 subsequent, without reprogramming

95982 subsequent, with reprogramming

OTHER PROCEDURES

95991 Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed; requiring skill of a physician or other qualified health care professional

95999 Unlisted neurological or neuromuscular diagnostic procedure

MOTION ANALYSIS

Codes describe services performed as part of a major therapeutic or diagnosis decision making process. Motion analysis is performed in a dedicated motion analysis laboratory (ie, a facility capable of performing videotaping from the front, back and both sides, computerized 3-D kinematics, 3-D kinetics and dynamic electromyography).

96002 Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles

96003 Dynamic fine wire electromyography, during walking or other functional activities, 1 muscle (Do not report 96002, 96003 in conjunction with 95860-95864, 95869-95872)

FUNCTIONAL BRAIN MAPPING

96020 Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or other qualified health care professional (ie, psychologist), with review of test results and report
(Evaluation and Management services codes should not be reported on the same day as 96020)

**CENTRAL NERVOUS SYSTEM ASSESSMENTS/TESTS (E.G., NEURO-COGNITIVE, MENTAL STATUS, SPEECH TESTING)**

The following codes are used to report the services provided during testing of the cognitive function of the central nervous system functions.

96105  Assessment of aphasia (includes assessment of expressive and receptive speech and language function, language comprehension, speech production ability, reading, spelling, writing, eg, by Boston Diagnostic Aphasia Examination) with interpretation and report, per hour

96110  Developmental screening (eg, developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument

96112  Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour

96113  each additional 30 minutes (List separately in addition to code for primary procedure)

96116  Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; first hour

96121  each additional hour (List separately in addition to code for primary procedure)

96130  Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour

96131  each additional hour (List separately in addition to code for primary procedure)

96132  Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour

96133  each additional hour (List separately in addition to code for primary procedure)

96136  Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes

96137  each additional 30 minutes (List separately in addition to code for primary procedure)

96138  Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes

96139  each additional 30 minutes (List separately in addition to code for primary procedure)

**PHOTODYNAMIC THERAPY**

96570  Photodynamic therapy by endoscopic application of light to ablate abnormal tissue via activation of photosensitive drug(s), first 30 minutes
(List separately in addition to code for endoscopy or bronchoscopy procedures of lung and esophagus)

96571 each additional 15 minutes
(List separately in addition to code for endoscopy or bronchoscopy procedures of lung and esophagus)

96573 Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day

96574 Debridement of premalignant hyperkeratotic lesion(s) (ie, targeted curettage, abrasion) followed with photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care professional, per day

SPECIAL DERMATOLOGICAL PROCEDURES
Dermatologic services are typically consultative, and any of the levels of consultation (99241-99255) may be appropriate. In addition, services and skills outlined under Evaluation and Management levels of service appropriate to dermatologic illnesses should be coded similarly.

96910 Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B (For diagnosis of Cutaneous T-Cell Lymphoma)

96920 Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm
96921 250 sq cm to 500 sq cm
96922 over 500 sq cm
96999 Unlisted special dermatological service or procedure

OSTEOPATHIC MANIPULATIVE TREATMENT
Osteopathic manipulative treatment is a form of manual treatment applied by a physician to eliminate or alleviate somatic dysfunction and related disorders. This treatment may be accomplished by a variety of techniques.

Body regions referred to are: head region; cervical region; thoracic region; lumbar region; sacral region; pelvic region; lower extremities; upper extremities; rib cage region; abdomen and viscera region.

98925 Osteopathic manipulative treatment (OMT); one to two body regions involved
98926 three to four body regions involved
98927 five to six body regions involved
98928 seven to eight body regions involved
98929 nine to ten body regions involved

SPECIAL SERVICES
MISCELLANEOUS SERVICES
96040 Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family
97542# Wheelchair management (eg, assessment, fitting, training), each 15 minutes (up to a maximum of 2 hours)
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>98960</td>
<td>Education and training for patient self-management by a qualified, nonphysician health care professional using a standardized curriculum, face-to-face with the patient (could include caregiver/family) each 30 minutes; individual patient</td>
</tr>
<tr>
<td>98961</td>
<td>2-4 patients</td>
</tr>
<tr>
<td>98962</td>
<td>5-8 patients</td>
</tr>
<tr>
<td>99050</td>
<td>Services provided in the office at times other than regularly scheduled office hours, or days when the office is normally closed (eg, holidays, Saturday or Sunday), in addition to basic service</td>
</tr>
<tr>
<td>99051</td>
<td>Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service</td>
</tr>
<tr>
<td>99070</td>
<td>Supplies and materials, provided by the physician over and above those usually included with the office visit or other services rendered (List drugs, trays, supplies, or materials provided)</td>
</tr>
<tr>
<td>99091</td>
<td>Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified healthcare professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time, each 30 days</td>
</tr>
<tr>
<td>G0108</td>
<td>Diabetes outpatient self-management training services, individual, per 30 minutes</td>
</tr>
<tr>
<td>G0109</td>
<td>Group session (2 or more), per 30 minutes</td>
</tr>
<tr>
<td>G0372</td>
<td>Physician service required to establish and document the need for a power mobility device (Use in addition to primary Evaluation and Management code)</td>
</tr>
<tr>
<td>G0406</td>
<td>Follow-up inpatient consultation, limited, physicians typically spend 15 minutes communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0407</td>
<td>Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0408</td>
<td>Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0425</td>
<td>Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0426</td>
<td>Initial inpatient telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0427</td>
<td>Initial inpatient telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth.</td>
</tr>
<tr>
<td>G0459</td>
<td>Inpatient telehealth pharmacologic management, including prescription, use, and review of medication with no more than minimal medical psychotherapy. Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation</td>
</tr>
<tr>
<td>G8431</td>
<td>Screening for clinical depression is documented as being positive and a follow-up plan is documented</td>
</tr>
<tr>
<td>G8510</td>
<td>Screening for clinical depression is documented as being negative, a follow-up plan is not required</td>
</tr>
<tr>
<td>H0049</td>
<td>Alcohol and/or drug screening</td>
</tr>
</tbody>
</table>
H0050 Alcohol and/or drug services, brief intervention, per 15 minutes
Q3014 Telehealth originating site facility fee
S0013 Esketamine, nasal spray, 1 mg
S2083 Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline (included in an E/M visit after the 90 day post-operative period, if no E/M visit billed code can be billed separately)
S9445 Patient education, not otherwise classified, non-physician provider, individual, per session. (The initial lactation counseling session should be a minimum of 45 minutes. Follow up session(s) should be a minimum of 30 minutes. Three sessions within 12-month period immediately following delivery.)
S9446 Patient education, not otherwise classified, non-physician provider, group, per session. (Up to a maximum of eight participants in a group session. 60 minute minimum session length. One prenatal and one postpartum class per recipient per pregnancy.)

New York State Medicaid will provide reimbursement for separate and distinct breastfeeding services provided by International Board Certified Lactation Consultants (IBCLCs) credentialed by the International Board of Lactation Consultant Examiners (IBLCE).

Modifier "AF" (specialty physician), along with the appropriate "S" code, must be reported on a claim when the physician is the provider of service. For additional information on eligible provider types and coverage/billing guidelines see: http://www.health.ny.gov/health_care/medicaid/program/update/2013/2013-03.htm#fee

T1013 Sign language or oral interpretive services, per 15 minutes
T2022 Case Management, per month (Physician Specialty: 333 billing for Collaborative Care ONLY.)

OTHER SPECIAL SERVICES

99116 Anesthesia complicated by utilization of total body hypothermia (List separately in addition to primary procedure)

MODERATE (CONSCIOUS) SEDATION

Moderate (also known as conscious) sedation is a drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain cardiovascular function or a patent airway, and spontaneous ventilation is adequate.

Moderate sedation codes are not used to report administration of medications for pain control minimal sedation (anxiolysis), deep sedation, or monitored anesthesia care (00100-01999).

99151 Moderate sedation services provided by the same physician or other qualified healthcare professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient’s level of consciousness and physiological status; initial 15 minutes of intraservice time, patient younger than 5 years of age

99152 initial 15 minutes of intraservice time, patient age 5 years or older

99153 each additional 15 minutes of intraservice time (List separately in addition to code for primary procedure)

99155 Moderate sedation services provided by a physician or other qualified healthcare professional other than the physician or other qualified healthcare professional performing
the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age
99156    initial 15 minutes of intraservice time, patient age 5 years or older
99157    each additional 15 minutes of intraservice time (List separately in addition to code for primary procedure)

**OTHER SERVICES AND PROCEDURES**

99170    Anogenital examination magnified, in childhood for suspected trauma, including image recording when performed.
99183    Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session
99184    Initiation of selective head or total body hypothermia in the critically ill neonate, includes appropriate patient selection by review of clinical, imaging and laboratory data, confirmation of esophageal temperature probe location, evaluation of amplitude EEG, supervision of controlled hypothermia, and assessment of patient tolerance of cooling (Do not report 99184 more than once per hospital stay)
99188    Application of topical fluoride varnish by a physician or other qualified health care professional
99190    Assembly and operation of pump with oxygenator or heat exchanger (with or without ECG and/or pressure monitoring); each hour
    99191    45 minutes
    99192    30 minutes
99195    Phlebotomy, therapeutic (separate procedure)
99199    Unlisted special service, procedure